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Structure-Function Studies of Conserved  
Sequence Motifs of Cytochrome b5 Reductase 
Louis J. Crowley 
ABSTRACT 
 
 NADH:Cytochrome b5 Reductase (cb5r) catalyzes the two electron reduction of 
the iron center of the heme cofactor found within cytochrome b5 (cb5) utilizing reducing 
equivalents of the nicotinamide adenine dinucleotide (NADH) coenzyme.  Cb5r is 
characterized by two domains necessary for proper enzyme function: a flavin-binding 
domain and a pyridine nucleotide-binding domain.  Within these domains are highly 
conserved “motifs” necessary for the proper binding and orientation of both the NADH 
coenzyme and the FAD cofactor. 
 To address the importance of these conserved motifs site-directed mutagenesis 
was utilized to generate a series of variants upon residues found within the motifs to 
allow for the full characterizations.  Second, naturally occurring recessive congenital 
methemoglobinemia (RCM) mutants that are found within or in close proximity to these 
highly conserved motifs were analyzed utilizing site-directed mutagenesis.   
 The flavin-binding motif “91RxYSTxxSN97” was characterized by the generation of 
variants T94H, T94G, T94P, P95I, V96S, and S97N.  In addition to this, the naturally 
occurring double mutant P92H/E255- was fully characterized to establish a role of the 
P92 residue giving rise to RCM.    
 xv
 The role of the “124GRxxST127” was determined by the introduction of a positive 
charge, charge reversal, and conserved amino acid mutations through site-directed 
mutagenesis of the G124, K125, and M126 residues.  Based on the data presented here, 
each of the residues of the GRxxST motif are directly involved in maintaining the proper 
binding and orientation of the cb5r flavin prosthetic group.   
 Analysis of the NADH-binding motif “273CGxxx-M278” was accomplished 
through the characterization of the type II RCM variant M272- and the type I RCM 
variant P275L.  This demonstrates that the deletion of the M272 residue causes a frame 
shift leading to the inability of the NADH substrate to bind.  The introduction of the 
P275L variant showed that substrate affinity was diminished, yet   turnover was 
comparable to wild-type cytochrome b5 reductase, indicating that although P275 is 
required for proper substrate binding it is not essential for overall catalytic function. 
 Finally, analysis of the naturally occurring double mutant G75S/V252M provided 
the first insight into a methemoglobinemia variant that possessed mutations in both the 
FAD-binding and NADH-binding domains.   
 1
 
 
 
 
 
 
 
 
1.  INTRODUCTION 
 
Cytochrome b5 Reductase 
NADH: Cytochrome b5 reductase (cb5r,  EC 1.6.6.2) is a member of the 
flavoprotein transhydrogenases [1] which catalyze the transfer of reducing equivalents 
between the two electron carrying nicotinamide dinucleotides and one electron carriers.  
Other members of this family include ferrodoxin:NADP+ reductase (FNR) [2], plant and 
fungal NAD(P)H: nitrate reductases [3], NADPH: cytochrome P450 reductase [4], 
NADPH: sulphite reductase, phthalate dioxygenase reductase [5], nitric oxide synthase 
[6], and various other flavoproteins.  The enzymes found within this flavoprotein family 
have been demonstrated to comprise both flavin-binding domains and pyridine 
nucleotide-binding domains.  The overall function of cytochrome b5 reductase is to serve 
as an electron donor for cytochrome b5 through a hydride ion transfer from the reduced 
coenzyme, NADH, to the non-covalently bound cytochrome b5 reductase flavin adenine 
dinucelotide (FAD) cofactor. 
Cytochrome b5 reductase is encoded by the DIA1 gene (Figure 1), located on the 
human chromosome 22q13-qter [7, 8]  and transcribes two isoforms of cb5r produced by 
the use of alternative promoters [9, 10].  Each isoform is localized to separate regions of 
the cell and thus, performs separate functions.  The first isoform is the microsomal 
isozyme which comprises the majority of transcribed cb5r and is generated through the 
1a 1b 2 3 4 5 6 7 8 9 3’5’
1a 2 3 4 5 6 7 8 9 3’
2 3 4 5 6 7 8 9 3’5’
5’
A.
B.
C.
Membrane-bound cb5r (ubiquitous)
Soluble cb5r (erythrocyte)  
 
Figure 1.  Structure of the Human DIA1 Gene that Encodes Cytochrome b5 
Reductase.  The DIA1 gene (A) is composed of exons 1-9 [11].  There are two alternate 
transcription start sites, 1a and 1b, which yield the two isoforms of cb5r.  (B) represents 
the membrane-bound cb5r isoform containing exon 1a-9, but not 1b, and consists of 300 
amino acids (GAQLÆCFVF), including the myristoylation signature in exon 1a. (C) 
represents the soluble cb5r isoform containing exons 2-9, but not exon 1, and consisting 
of the 275 amino acids that comprise the diaphorase domain (LFQRÆCFVF). 
 
transcription of all 9 exons of the DIA1 gene.  The microsomal isozyme comprises 300 
amino acids residues with a molecular weight of ~34 kDa, and contains a myristoylated 
25 amino acid N-terminal hydrophobic region that serves as the membrane anchoring 
domain [12-14].  This membrane bound isozyme is localized to the cytosolic face of the 
endoplasmic reticulum as well as the mitochondrial, nuclear, and plasma membranes of 
somatic cells.  The electron transfer process between the microsomal cb5r and 
cytochrome b5 are required for a variety of metabolic transformations that include: steroid 
biosynthesis [15], desaturation and elongation of fatty acids, cholesterol biosynthesis [16, 
17], and P450-dependent reactions [18].  More recently, it has also been shown to be part 
of the microsomal cytochrome b5 reductase-cytochrome b5 pathway directly involved in 
the reductive detoxification of arylhydroxylamine carcinogens in human liver [19]. 
In the second isoform, only exons 2-9 are transcribed from the DIA1 gene 
producing a 275 amino acid residue soluble form of cb5r.  Soluble cytochrome b5 
 2
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reductase is comprised of an N-terminal FAD-binding domain and a C-terminal NADH-
binding domain [20, 21].  The NAD-binding domain forms a three-layered α-β-α fold, 
which is common for pyridine dinucleotide-binding regions, while the FAD-binding 
domain has an antiparallel β-barrel topology.  This isozyme is a flavoprotein with a 
molecular mass of ~31 kDa is primarily found within the circulating erythrocytes where 
it is involved in the reduction of methemoglobin to hemoglobin [22, 23] through an 
interaction with cytochrome b5.  
The mechanism of electron transfer for the soluble form of cb5r from the 
physiological substrate, NADH and the FAD cofactor of cb5r is shown in Figure 2.  In 
this schematic, two electrons are first transferred from NADH to FAD by hydride ion   
(H-) transfer.  The two-electron reduced enzyme-NAD+ complex (E-FADH—NAD+) sub 
sequentially transfers two electrons to two molecules of cytochrome b5 by the anionic red 
semiquinone form (E-FAD·- - NAD+), returns the reduced enzyme to its oxidized state 
[24].  The reduction of FAD by NADH has been determined to be the rate-limiting step 
in the electron transfer process catalyzed by cytochrome b5 reductase [25-27].  In the 
porcine variant of cytochrome b5 reductase, it was also determined that the anionic red 
semiquinone of FAD is stabilized by the binding of NAD+ [28, 29].  Further studies by 
Meyer et al. [30] confirmed that the binding of NAD+ is involved in the stabilization of 
the red semiquinone of cb5r and also showed that it modulates the electron transfer to 
cytochrome b5 [30], thus demonstrating the importance of the anionic red semiquinone 
form of cb5r (E-FAD·- - NAD+) in the catalytic process.  Recent studies by Iyanagi et al. 
[24] have generated a new scheme for the electron transfer sequence of cytochrome b5 
reductase involving the neutral blue semiquinone form and the oxidized  
NADH + 2cb5(Fe3+)
cb5rox (FAD)
NAD+ + H+ + 2cb5(Fe2+)
cb5rred (FADH2)A.
B. NADH
E-FAD E-FAD- -NAD+
H+e-
E-FAD-.NAD+
e- NAD+
(1)
 
 
Figure 2. Mechanism of Cytochrome b5 Reductase Mediated Cytochrome b5 
Reduction.  (A) represents the chemical reaction (equation 1) catalyzed by cb5r. (B) 
illustrates the mechanism of cb5r transfer where each electron (e-) reduces one molecule 
of cb5 [31]. 
 
 
 
 
 
 
E-FAD-NADH-NAD+ E-FAD-NADH E-FAD-NADH* E-FADH- - NAD+
NAD+ E-FAD NADH
H- transfer
NADH
E-FAD-NAD+ E-FAD●-- -NAD+ E-FADH● -NAD+
e- H+ e-
(i)
(ii) (iii)
(iv)(v)(vi)(vii)
(viii)
 
 
 
Figure 3.  New Model of the Reaction Sequence of Cytochrome b5 Reductase.  This 
new model represents the reaction sequence of cytochrome b5 reductase containing the 
neutral blue semi-quinone form and the oxidized enzyme-NADH-NAD+ ternary complex 
as intermediates [24]. 
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enzyme-NADH-NAD+ ternary complex (Figure 3).  This scheme involves the following 
seven-step process: (i) formation of the oxidized enzyme-NADH complex (E-FAD-
NADH), (ii) conversion of E-FAD-NADH to a form that has the ability to transfer a 
hydride ion (E-FAD-NADH), (iii) hydride (H-) transfer from NADH to FAD, (iv) the 
first one-electron transfer from the two-electron reduced enzyme complex (E-FADH -
NAD+), (v) rapid conversion of the neutral blue semiquinone form (E-FADH· -NAD+) to 
the anionic red semiquinone form (E-FAD· -NAD+), (vi) the second one-electron 
transfer from E-FAD· -NAD+, (vii) formation of the oxidized enzyme-NADH-NAD+ 
ternary complex (E-FAD-NADH-NAD+) by binding of NADH, and (viii) release of 
NAD+.   
Similar to the binding interaction between NADH and cytochrome b5 reductase, 
the binding interaction between cytochrome b5 reductase and its one electron acceptor, 
cytochrome b5, has also been extensively studied [26, 35-38, 112].  Cytochrome b5 is also 
transcribed as both a soluble and microsomal isozyme, comprised of 97 and 133 amino 
acid residues, respectively, by the CYB5 gene located on human chromosome 18q23 and 
has a molecular weight of ~11 kDa.  The electron acceptor of cytochrome b5 is the iron 
center of a single protoheme IX prosthetic group which also gives cb5 its characteristic 
red color.  Cytochrome b5 is an acidic molecule with 21 surface accessible carboxylic 
acid residues and possesses an isoelectric point (pI) of 4.90 [32], whereas the isoelectric 
point (pI) of cytochrome b5 reductase is 7.15, thus suggesting a role for charge 
complimentarity between cytochrome b5 reductase and cytochrome b5 complex 
formation.  This was confirmed through  studies by Salemme [33] utilizing a best-fit 
computer  program based on the crystallographic data for cytochrome b5, indicated that  
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Figure 4.  Structure of Cytochrome b5 Generated in silico.  The molecular model of 
cytochrome b5 displaying the negatively charged residues and exposed heme propionate 
group determined to be involved in the binding interaction with cytochrome b5 reductase 
was generated utilizing the molecular modeling software Web Lab Viewer Pro [34].  This 
model represents a surface representation of cb5 (1CYO ) where the acidic residues are 
red, basic residues are blue, and neutral residues are displayed as white clouds. 
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Figure 5.  Structure of Cytochrome b5 Reductase Generated in silico.  The molecular 
model of cytochrome b5 reductase displaying the positively charged residues K41, K125, 
K162, and K163that have been determined to be involved in the binding interaction with 
cytochrome b5  was generated utilizing the molecular modeling software Web Lab 
Viewer Pro [34].  This model represents a surface representation of cb5 reductase (1IB0 ) 
where the acidic residues are red, basic residues are blue, and neutral residues are 
displayed as white clouds. 
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electron transfer involved interactions through the charge pairing of the surface 
accessible carboxyl residues E-47, E-48, E-52, E-60, D-64 (shown in Figure 4) and the 
exposed heme propionate group of the active site. Further confirmation was established 
by Dailey and Strittmatter [35] utilizing selective carboxylate group modification to  
reveal that these same carboxyl groups, located in the active site of cytochrome b5, were 
involved in the electron transfer interaction between cytochrome b5 reductase, NADPH-
cytochrome-P450, and stearyl-CoA desaturase [35, 36].  In order to establish the charge 
pairing of cytochrome b5 reductase residues, Ozols and Strittmatter determined that the 
lysyl residues of cytochrome b5 reductase played a significant role in the interaction 
between cytochrome b5 and cytochrome b5 reductase.  Modification of only seven lysyl 
residues of cb5r resulted in a loss of catalytic activity utilizing cb5 as the final electron 
acceptor, whereas no change in catalytic activity was demonstrated through the 
modification of the lysyl residues on cytochrome b5.  Furthermore, through the selective 
acylation of several lysyl residues on cytochrome b5 reductase, cytochrome b5 reduction 
was inhibited [37].  Sequence analyses of protease-generated cross-linked peptides 
demonstrated that four essential lysine residues in cytochrome b5 reductase involved in 
forming charge pairs with the active site carboxyl groups of cytochrome b5 and included: 
K-163, K-41, K-125, and K-162 [38] (Figure 5).  
 
Crystal Structure of Cytochrome b5 Reductase  
High resolution crystal structures of the soluble, diaphorase domain of R. 
norvegicus cytochrome b5 reductase was recently solved in the absence (2.0 Å, PDB 
1I7P) and presence (2.3 Å, PDB 1IB0) of bound NAD+ [21] (Figure 6).  The structures 
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displayed a classical bi-domain arrangement, comprised of an amino terminal FAD-
binding lobe (amino acid residues I33-R142) and a carboxy-terminal NADH-binding lobe 
(amino acid residues K172-F300).  Residues G148-V171 comprise what has recently 
been termed the “linker” or “hinge” region.  This 28 amino acid residue segment forms a 
three-stranded, anti-parallel β-sheet that has been demonstrated to be of critical 
importance in determining the correct orientation and modulation of electron transfer 
between that of the FAD- and NADH-binding domain [39, 40]. 
The amino-terminal FAD-binding domain (Figure 7) is comprised of a seven-stranded 
antiparallel β-barrel, labeled as Fβ1-Fβ7, oriented towards the si-face of the flavin 
isoalloxazine ring and capped by a single α-helix found in the FAD-binding domain.  A 
majority of the interactions with the FAD- prosthetic group occur via the adenine 
dinucleotide moiety of the flavin and with a long loop of the FAD-binding domain which 
is comprised of amino acid residues K110-K125 forming a “lid” and is situated between 
Fβ6 and the α-helix.  The NADH- binding domain (Figure 8) is composed of a canonical 
Rossman fold [41] formed by 3 α/β/α layers arranged into a five-stranded parallel β-sheet 
that is oriented towards the re-face of the isoalloxazine ring of the FAD prosthetic group.  
The isoalloxazine ring is the only region of the FAD- cofactor that forms interactions via 
hydrogen bonds between the NADH-binding site and the isoalloxazine ring.  This occurs 
through the FAD-binding domain loop strands Fβ3 and Fβ4 (amino acid residues P92-
K110) and the NADH-binding domain Nβ1-NαA (amino acid residues T181-T184).  The 
“hinge” or “linker” region (Figure 9) is situated between the FAD-binding and NADH-
binding domains and is comprised of a three-stranded anti-parallel β-sheet structure 
designated as Hβ1-Hβ3.  Studies of this linker region by Davis et al. [40]  demonstrated  
  
 
 
Figure 6.  The Tertiary Structure of Rat Cytochrome b5 Reductase.  The 2.0Å 
resolution X-ray crystal structure derived from soluble recombinant rat liver cb5r (PDB 
1IB0) [21] is illustrated as a schematic model where the red portions represent α-helices, 
the yellow ribbons with directional arrows represent β-sheet structures, and the green 
tubes are indicative of random coils and flexible loop structures.  The FAD cofactor (left) 
and NAD+ (right) are shown in stick configurations with standard CPK coloration. 
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Figure 7.  The Structure of the FAD-Binding Domain of Cytochrome b5 Reductase.  
A view of the N-terminal FAD-binding domain of rat cb5r (PDB 1IB0) with FAD bound.  
The re-face of the isoalloxazine ring faces towards the right.  FAD is shown in stick 
configuration with standard CPK coloration.  The polypeptide backbone is shown in 
green with the single α-helix in red and β-sheets colored yellow and are labeled 
accordingly. 
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Figure 8.  The Structure of the NADH-Binding Domain of Cytochrome b5 
Reductase.  A view of the C-terminal NADH-binding domain of rat cb5r (PDB 1IB0) 
with NAD+ bound.   NAD+ is shown in stick configuration with standard CPK coloration.  
The polypeptide backbone is shown in green with the single α-helix in red and β-sheets 
colored yellow and are labeled accordingly. 
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Figure 9.  The Structure of the “Hinge” Region of Cytochrome b5 Reductase.  A 
view of the “Hinge” region of rat cb5r (PDB 1IB0) located between the FAD and NADH-
binding domains.  The polypeptide backbone is shown in green with the β-sheets colored 
yellow and are labeled accordingly. 
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that allows for efficient electron transfer to occur.  These studies also demonstrated that it 
is this “linker” region which is actively involved in properly orienting the FAD- and 
NADH-binding lobes of cb5r towards efficient electron transfer and suggested that any 
disruption within the conformation of the β-sheet architecture would lead to a significant 
decrease in catalysis.      
 
Recessive Congenital Methemoglobinemia    
 In 1943 Quenton Gibson of Queen’s University, Belfast, described the first 
hereditable trait that was associated with a specific enzyme deficiency [43].  In patients 
with a familial incidence of idiopathic cyanosis, Hitzenberger later established a 
diagnosis of congenital, familial methemoglobinemia [42].  Based on this diagnosis, 
Gibson determined that the inability of circulating erythrocytes to reduce the pools of 
methemoglobin would give rise to familial idiopathic methemoglobinemia [43].  In 1948, 
Gibson further elucidated the pathway involved in the actual reduction of methemoglobin 
which directly involved the enzyme methemoglobin reductase [44], now referred to as 
NADH: cytochrome b5 reductase (cb5r). 
 Methemoglobin is the derived form of hemoglobin in which the iron center of the 
heme prosthetic group is in its oxidized state.  In the ferric heme state the iron center is 
unable to efficiently bind oxygen and the oxygen affinity of the accompanying ferrous 
hemes in the hemoglobin tetramer is decreased, thereby impairing oxygen delivery.  
Methemoglobin is constantly generated physiologically due to the deoxygenation of the 
molecule, however, endogenous enzymatic hemoglobin reduction pathways maintain 
methemoglobin levels at or below 3% of total hemoglobin.  Inability to efficiently reduce 
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the levels of methemoglobin gives rise to the disease termed methemoglobinemia.  The 
primary pathway that converts methemoglobin to hemoglobin involves the reduced form 
of NADH: cytochrome b5 reductase.  In this pathway, reducing equivalents are 
transferred from the pyridine dinucleotide, NADH to the FAD- prosthetic group of cb5r, 
followed by the reduction of two molecule of cytochrome b5.  In circulating erythrocytes, 
cytochrome b5 directly transfers one electron to the iron center of the heme prosthetic 
group in methemoglobin thereby reducing it to hemoglobin. 
 The most common cause of recessive congenital methemoglobinemia (RCM) 
directly results from a deficiency of cytochrome b5 reductase.  Individuals with RCM 
have an inability to effectively reduce methemoglobin which is constantly being formed 
through the deoxygenation of hemoglobin in circulating erythrocytes.  Defects in the 
expression of cytochrome b5 reductase give rise to two forms of methemoglobinemia 
known as type I and type II which are classified based on the patient pathophysiology.   
In type I, the prevalent symptom is mild cyanosis which results in headaches, 
fatigue and shortness of breath during exercise and is restricted to the soluble isozyme of 
cb5r found in circulating erythrocytes.  This form of methemoglobinemia is inherited in 
an autosomal recessive pattern and is found worldwide, however, it has been determined 
to be endemic in certain populations such as the Athabascan Alaskans, Navajo Indians, 
and Yakutsk natives of Siberia.  Compound heterozygotes or homozygotes that express 
type I RCM have methemoglobin concentrations ranging from 10 to 40% and are 
relatively asymptomatic where cyanosis is the only symptom.  Life expectancy is not 
affected in these patients. 
Type II methemoglobinemia has been established in 10 to15% of cases for RCM 
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and is the more severe form of the disease in which the deficiencies of cb5r are present in 
the membrane-bound form of cb5r in somatic cells.  The symptoms of type II are 
expressed with severe developmental abnormalities including mental retardation, 
microcephaly, opisthotonus, strabismus, and generalized hypertonia often leading to 
premature death [45-47]. 
Cytochrome b5 reductase is encoded by the DIA1 gene.  It is because of this that it 
is believed that patients expressing type I methemoglobinemia are producing the 
abnormal gene product at a normal rate, but it is unstable.  Thus, only the mature red 
blood cells, which can not synthesize proteins, are affected.  In patients expressing type II 
methemoglobinemia, mutations in the DIA1 gene give rise to decreased expression or 
reduced catalytic activity of cytochrome b5 reductase and the deficiency is ubiquitous. 
Thus far, about 40 amino acid mutations have been identified within the DIA1 gene 
giving rise to either type I or type II methemoglobinemia [10, 31, 48-50]. 
 
The Ferredoxin: NADP+ Reductase Family of Flavoprotein Oxidoreductases. 
 Through a sequence alignment utilizing the X-ray crystal structure of spinach 
ferredoxin-NADP+ reductase [51], a family of flavin-dependent oxidoreductases have  
been identified which include: cytochrome b5 reductase, cytochrome P-450 reductase, 
methionine synthase reductase, ferredoxin:NADP+ reductase, as well as many others.  Of 
significant interest was the pattern of conserved residues that were detected within the  
flavin- and nucleotide- binding domains which were characteristic of the FNR family 
(Figure 10). These conserved sequences or “motifs” are essential for the proper 
characterization of FNR proteins that share a common evolution, structure, or catalytic 
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Figure 10. Alignment of Conserved Flavin-Binding and NADH-Binding Motifs from 
Various Enzymes Belonging to the “FNR Family” of Flavoprotein 
Transhydrogenases. Each of the published amino acid sequences was obtained from the 
GenBank protein database [52] with the corresponding accession number and reference. 
The superscripted numbers indicate the amino acid positions of the first and last residue 
of each motif within the full-length sequence of each protein. Abbreviations are: CB5R, 
cytochrome b5 reductase, NR, nitrate reductase, FNR, ferredoxin:NADP+ reductase, 
CPR, cytochrome P450 reductase, NOS, nitric oxide synthase, PDR, phthalate 
dioxygenase reductase, MSR, methionine synthase reductase, SR, sulfite reductase, FHG, 
flavohemoglobin, B5B5R, cytochrome b5-cytochrome b5 reductase fusion protein, ETP, 
electron transfer protein, NDR, naphthalene dioxygenase reductase, PH, phenol 
hydroxylase, NFR, NADPH:flavin reductase, CDPGR, CDP-glucose dehydratase 
reductase, CMR, p-cymene monooxygenase reductase, XMR, xylene monooxygenase 
reductase, NMR, nitrotoluene monooxygenase reductase, DQMR, dihydorquinoline 
monooxgenase reductase, MMOR, methane monooxygenase reductase, ADR, 
anthranilate dioxygenase reductase, TDR, toluate dioxygenase reductase, BDR, benzoate 
dioxygenase reductase, HBDR, hydroxybenzoate dioxygenase reductase, NQR1, Na+ 
translocating NADH:quinone reductase 1, UNK1, unknown M. loti gene product, UNK2, 
unknown Halobacterium sp. NRC-1 gene product, HYPR, hypothetical Xanthobacter 
reductase.    
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Enzyme 
 
Motif 1 Motif 2 Motif 3 
 
Motif 4 GenBank 
Accession/Ref 
CB5R 91RPYTPVS97 125GKMS128 181GTGIT-P186 274CGPPP-M279 NP_620232 / [8] 
NR 722RAYTPPS728 755GVMS758 805GTGIT-P810 898CGPPP-M903 P23312 / [53] 
FNR 139RLYSIAS145 176GVCS179 217GTGIA-P222 318CGLKG-M323 P10933 /  [54] 
CPR 454RYYSIAS460 488GVAT491 534GTGVA-P539 629CGDARNM635 P16435 /  [55] 
NOS 1178RYYSISS1184 1214GVCS1217 1255GTGIA-P1260 1354CGDVT-M1359 P29475 /  [56] 
PDR 51RNYSLSN57 83RGGS87 123GIGIT-P128 202CGPRPLM208 Q05182 /  [5] 
MSR 478RPYSCAS484 514GVCT517 573GTGIA-P578 677CGDKANM683 Q9UBK8 /  [57] 
SR 386RLYSIAS392 420GASS423 461GTGIA-P466 552CGDANRM558 P38038 /  [58] 
FHG 204RQYSLTR210 227GQVS230 268GVGQT-P273 362CGPVGFM368 P24232 /  [59] 
B5B5R 289KPYTPVS295 323GLFT326 364GTGFT-P369 458CGPTPFT464 NP_596918 /  [60] 
ETP 56RCYSITS62 80GRVS83 120GSGIA-P125 203CGPEPFM209 BAA12809 /  direct submission 
NDR 142RPYSMAG148 165GRVT168 206GTGLA-P211 295CGAPA-M300 AAD02134 /  [61] 
PH 149RAFSLAN155 173GAAT176 214GSGLSSP220 306CGPPP-M311 AAA25944 /  [62] 
NFR 58RPFSMAS64 77GASE80 123GTGFSYA129 212AGRFE-M217 AAN83224 /  [63] 
CDPGR 141RSYSIAN147 164GQMS167 204GTGFA-P209 292CGSPV-M297 P26395 /  [64] 
CMR 159RSYSFAN165 185GEFT188 225GSGLA-P230 315CGPPP-M320 AAB62300 /  [65] 
XMR 160RSYSFAT166 184GIFS187 224GTGLA-P229 315CGPPP-M320 AAB70826 /  direct submission 
NMR 161RSYSFSA167 185GVFS188 225GTGLA-P230 316CGPPP-M321 AAC38360 /  [66] 
DQMR 155RSYSPSS161 179GAMS182 221GTGLA-P226 310CGPQP-M315 CAA73201 /  [67] 
MMOR 159RSYSPAN165 183GRFS186 224GTGLA-P229 314CGPPG-M319 P22868 /  [68] 
ADR 154RSYSFAN160 178GVMS181 218GTGLS-A223 307CGPPP-M312 AAC34815 /  [69] 
TDR 153RAYSFSS159 176GLMS179 216GTGLA-P221 304CGPPP-M309 AAD31449 /  direct submission 
BDR 166RSYSFSS172 189GKMS192 229GTGIA-P234 317CGPVP-M322 P07771 /  [70] 
HBDR 152RAYSYSS158 175GKMS178 215GTGLA-P220 305CGPPP-M310 Q51603 /  [71] 
NQR1 222KAYSLAS228 259GVCS262 298GAGSSFG304 401CGPPLHN407 Q9Z723 /  [72] 
UNK1 168RLYLVST174 201GSSP204 383GIGIT-P388 471SGPQA-M476 NP_107088 /  [73] 
UNK2 51RYYTLSS57 102GEPS105 112GPGVG-P117 188CGAATDA194 NP_279534 /  [74] 
HYPR 142RAYSVAN148 166GAGT169 207GSGLA-P212 297AGPAP-M302 CAA09916 /  [75] 
Consensus RxYTSxxSN GxxST (FAD) 
RxxSN (FMN)
GxGxxP CGxxx-M  
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function.  The structural motif of members of the FNR family is that of a two-domain 
module with one binding the flavin and the other binding the pyridine nucleotide.  In  
regards to function, the FNR family is classified by the two electron reduction of a flavin 
prosthetic group (FAD/FMN) by a pyridine dinucleotide coenzyme (NAD(P)(H)), 
followed by the sequential transfer of electrons in one electron reactions with carriers. 
 An additional feature of the proteins found within the FNR superfamily is the 
varying levels of complexity based on the structural domains and modulation of electron 
transfer [2].  Cytochrome b5 reductase and FNR are examples of the simplest members of 
the FNR family in that they each consist of only two domains and reduce molecules 
which are able to bind and then rapidly disassociate following electron transfer.  In 
contrast, cytochrome P450 reductase, sulfite reductase-α, and PDR represent more 
complex enzymes.  Although the structures also consist of two domains, the one-electron 
acceptor molecule is actually fused to the two-domain core by a linker region.  Finally, 
the most complex members of the FNR family contain additional sequences and 
prosthetic groups which is indicative of more than three structural domains, these 
enzymes include: nitrate reductase and nitric oxide synthase [2].   
The conservation of the “RxYTSxxSN”, “GRxxST”, “GxGxxP”, and “CGxxx-M” 
sequence motifs found within the members of the FNR flavoprotein family, clearly 
demonstrates the importance of these motifs towards the interactions of flavin- cofactor 
and pyridine nucleotide binding and utilization. 
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Research Aims and Approaches 
 The general goal of this research was to gain further insight into the roles of the 
conserved motifs found within cytochrome b5 reductase that are involved in either FAD 
or NADH-binding.  Through the analyses of these motifs, naturally occurring 
methemoglobinemia variants which occur in relation to these motifs were also 
investigated.  To achieve this goal, variants were generated utilizing site-directed 
mutagenesis of an affinity-tagged R. norvegicus cytochrome b5 reductase construct [76].  
Each mutant enzyme generated was then subsequently characterized through biophysical, 
potentiometric, and enzymological techniques.   
 The initial specific aim was to further establish the role of the conserved 
“91RxYSTxxSN97” motif in regards to binding of the FAD- cofactor and overall 
cytochrome b5 reductase catalysis.  Previous studies had already established a role for the 
R91, P92, and Y93 amino acid residues [76, 77].  These authors concluded that none of 
the mentioned residues were “essential” for proper flavin incorporation but did in fact 
modulate the catalytic and thermodynamic properties within the active site of cytochrome 
b5 reductase.  In order to fully characterize the remaining residues of this motif, a series 
of variants were generated corresponding to amino acids that have been demonstrated to 
occur at the same residue positions within other members of the FNR family to include: 
T94H, T94G, T94P, P95G, P95I, V96S, and S97N.  Through the analysis of the crystal 
structure of cytochrome b5 reductase (PDB - 1IB0) we hypothesized that the introduction 
of a mutation to residue T94 would have the most significant impact due to the fact that 
the backbone nitrogen of this residue forms a hydrogen bond with the N5 atom of the 
FAD- cofactor isoalloxazine ring and is also positioned near the NADH-binding site.  A 
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second important feature of the T94 residue was demonstrated in the porcine cb5r 
structure where it was shown that the corresponding T66 residue was involved in the 
formation and stability of the NAD+-FAD complex [24].  
 The naturally occurring double mutant P92H and E255- allowed for further 
characterization of the “RxYSTxxSN” motif as well as examination of the effects of a 
methemoglobinemia double mutant occurring in both the FAD- and NADH-binding 
domains.  The E255- variant was previously detected [78] in the family with cyanosis 
first described in 1943 [43] who were found to be deficient in cytochrome b5 reductase 
[44].  In the P92H variant, homology modeling displayed that the side chain would be 
oriented towards the FAD isoalloxazine ring and the introduction of a histidine at this 
position would lead to a steric clash thereby resulting in the decrease of catalytic function 
of the enzyme.  E255 is positioned within the amino-terminus of an α-helix that is 
involved in properly positioning the carboxyl-terminal region of cb5r that contains the 
“CGxxxM” motif which has been demonstrated to be essential for NADH-binding.  
Deletion of this residue therefore would result in a decrease in substrate binding affinity 
as shown previously [79].  It can be hypothesized that the introduction of a double mutant 
occupying position in both the FAD- and NADH-binding lobes of cytochrome b5 
reductase would lead to the more severe type II RCM. 
 The second aim focused on the highly conserved FAD/FMN specificity motif “124 
G
RxxST127”, specifically the residues G124, K125, and M126.  The amino acid S127 has 
been previously characterized through the analysis of the naturally occurring type II 
RCM variant, S127P.  This mutation was the first RCM variant to be resolved by X-ray 
crystallography and demonstrated that the introduction of this mutation directly affects 
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NADH substrate binding due a phenomenon known as “flavin flexibility” where the 
FAD- cofactor of cytochrome b5 reductase is displaced into the NADH-binding cleft [80].  
Through further analysis of the crystal structure of cytochrome b5 reductase the critical 
importance of the “GRxxST” motif can been visualized.  This motif is located within the 
only α-helix of the FAD-binding lobe of cb5r and each residue of the motif forms either a 
hydrophobic or electrostatic interaction with the FAD prosthetic group.  Thus, it is 
important to fully develop an understanding of the molecular role of each residue of the 
“GRxxST” motif in regards to the flavin environment as well as proper cofactor binding 
and orientation. 
 The third aim of this research involved the investigation into the conserved 
“273CGxxxM278” motif which is located within the NADH-binding domain of cytochrome 
b5 reductase and is involved in the regulation of NADH-binding.  A different approach 
was used for the analysis of this motif.  Two methemoglobinemia variants have been 
previously described that are directly involved in the “CGxxxM” motif, the type II RCM 
variant M272- [81] and type I RCM variant P275L [78] and it is through these two 
mutations that the role of the motif was established.  Although M272 is not technically 
considered to be part of the “CGxxxM” it has been found to be highly conserved in 
higher eukaryotes.  The importance of studying the role of this residue was twofold, in 
that it directly precedes the C273 residue which has been found to be “essential” towards 
NADH-binding affinity and orientation [12] and the deletion of M272 has also been 
shown to give rise to type II RCM.  Upon the deletion of M272, a frame-shift is 
introduced to the motif that should cause a detrimental effect upon the affinity for the 
NADH substrate to the extent that it is capable of causing type II RCM.  Further analysis 
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of the molecular role of M272 involved the generation of variants of M272 based on 
amino acid residues that have been demonstrated to occur at the equivalent position 
within other members of the FNR superfamily. 
 Based on the crystal structure of cytochrome b5 reductase in complex with NAD+, 
a structural role for amino acid residue P275 was demonstrated [21].  It was shown that 
the conformation of the NAD+ was primarily determined by the proline side chain with 
the pyrophosphate chain packed against P275 and the NAD+ nicotinamide proximal 
ribose was packed parallel to the proline ring.  We predicted that the replacement of this 
proline side chain with a leucine would have a significant adverse effect upon the proper 
orientation and binding of the NADH substrate.  The characterization of the P275L 
variant would therefore provide insight into the role of the P275 residue in regards to 
NADH substrate binding and orientation as well as providing a molecular basis for 
disease. 
 The final specific aim was based upon the identification and characterization of a 
novel FAD-binding domain variant, G75S.  The G75S mutation was found in a patient 
who was compound heterozygous for the G75S mutation as well as the previously 
characterized V252M mutation [82-84] and exhibited a phenotype characteristic of type I 
methemoglobinemia.  It was hypothesized that possessing a mutation in both the FAD- 
and NADH-binding domains of cytochrome b5 reductase would result in the development 
of the more severe type II methemoglobinemia.  Although the patient was heterozygous 
for the double mutation, the G75S/V252M mutation was generated in order to investigate 
the synergistic effects of the double mutant on the enzyme’s structural and catalytic 
properties.  The generation of both the single and double mutants being associated with 
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the FAD and NADH-binding domains could therefore be utilized to provide further 
insight as an aid to determine the development of type I versus type II RCM status.            
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2. MATERIALS & METHODS 
 
MATERIALS 
Molecular Biology Reagents 
Restriction enzymes were purchased from New England Biolabs (Beverly, MA). Kits for 
plasmid preparation and agarose gel extraction were purchased from Qiagen Inc. 
(Valencia, CA).  Oligonucleotide primers were obtained from Integrated DNA 
Technologies (Coralville, IA). Native Pfu and Pfu Turbo Polymerases as well as 
Epicurian coli BL21(DE3)-RIL cells were obtained from Stratagene (La Jolla, CA).  The 
pET-23b vector was purchased from Novagen (Madison, WI).  T4 DNA ligase was 
purchased from Promega (Madison, WI). Rapid DNA ligation kits were purchased from 
Roche Scientific (Palo Alto, CA).  Triton X-100 and Hot Start Micro 50 PCR tubes were 
obtained from Molecular-Bio Products Inc. (San Diego, CA). DMSO and pCMB were 
obtained from Sigma Chemical Co. (St. Louis, MO).  The Molecular Biology Core 
Facility at the H. Lee Moffitt Cancer Center and Research Institute performed nucleotide 
sequencing. 
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Microbiology and Protein Purification Reagents 
Plastic and glassware were purchased from Fisher Scientific (Pittsburg, PA), 
VWR International (Suwannee, GA), and Midwest Scientific (St. Louis, MO).  Tryptone 
and yeast extract were obtained from EM Science (Gibbstown, NJ) and “Ultrol” grade 
MOPS buffer was purchased from Calbiochem (La Jolla, CA). IPTG and Ampicillin were 
obtained from Research Products International (Mt. Prospect, IL).  Ni-NTA agarose was 
purchased from Qiagen Inc. (Valencia, CA). PMSF was purchased from Sigma Chemical 
Co. (St. Louis, MO). 
 
Enzyme Assay and Spectroscopy Reagents 
Chemicals including NADH, NAD+, 5’-ADP-agarose, 2’5’-ADP, ADP-ribose, 
K3Fe(CN)6, glucose, dithionite, FAD, cytochrome c (Type VI from horse heart), bovine 
serum albumin, potassium phosphate, riboflavin, ferric citrate and trifluoroacetic acid 
were obtained from Sigma Chemical Co. (St. Louis, MO).  Tetrahydronicotinamide 
adenine dinucleotides (H4-NAD and H4-NADP) were synthesized according to the 
protocol described by Murataliev and Feyereisen [85] by bubbling molecular hydrogen 
through a stirred solution of 100 mM NAD+ or NADP+ contained in 50 mM Tris-HCl 
buffer, pH 8.0, in the presence of palladium catalyst (5 mg/mL).  Sinapinic acid (3,5-
dimethoxy-4-hydroxy cinnamic acid) was purchased from Aldrich Chemical Co. 
(Milwaukee, WI). 
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METHODS 
Protein Expression and Purification 
Expression of the wild-type and mutant cb5r or NCR variants was accomplished 
using E. coli BL21(DE3)-RIL cells harboring either the pH4CB5R [76], or mutant 
constructs. Cells were grown aerobically in TB media supplemented with riboflavin (100 
µM), ferric citrate (100 µM), and ampicillin (125 µM) overnight at 37 °C, and 
recombinant protein expression was induced by addition of IPTG (0.4 mM) followed by 
an additional 6-8 h incubation at 25 °C. The cells were pelleted by centrifugation 
(5000xg, 10 min.), resuspended in lysis buffer (50 mM Tris-HCl, containing 300 mm 
NaCl and 5 mM imidazole, pH 8.0) and disrupted by sonication in the presence of PMSF 
(1.2 mg/ml). Lysates were clarified by centrifugation (30,000xg, 30 min.) at 4oC followed 
by incubation with Ni-NTA agarose with gentle agitation (1 ml matrix/10 ml lysate) for 
up to 1h at 4°C. The His-tagged-(cb5r or NCR)-Ni-NTA matrix suspension was collected 
by centrifugation (1000xg, 5 min.), washed twice with 25 mM phosphate buffer, 
containing 300 mM NaCl and 5 mM imidazole, pH 8.0 and transferred to a 
chromatography column (2.5 x 10 cm).  Bound proteins were eluted with 25 mM 
phosphate buffer, containing 300 mM NaCl and 250 mM imidazole, pH 8.0. Fractions 
were pooled, assayed for NADH:FR activity and concentrated centrifugally using 10,000 
MWCO concentrators (Fischer Scientific, Pittsburg, PA).  Final purification was 
achieved by size-exclusion FPLC using either a Superdex 75 or Superdex 200 column (1 
x 30 cm) equilibrated with 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. 
Fractions exhibiting NADH:FR activity were pooled, concentrated, beaded and stored 
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under liquid N2 until required.  Wild-type NCR concentrations were estimated using 
ε413nm = 130 cm-1 mM-1 and wild-type cb5r concentrations were estimated using ε461nm = 
10.6 cm-1 mM-1. 
 The recombinant soluble, heme domain of rat cytochrome b5 was produced as 
described by Beck-von Bodman et al., [86] using an expression construct provided by Dr. 
Steven Sligar (University of Illinois, Urbana, IL). Briefly, E. coli BL21(DE3) cells 
harboring the pUC18 expression construct, which contained a codon-optimized gene 
encoding the soluble heme-containing domain of rat cb5, were grown overnight at 37°C 
in TB medium supplemented with ferric citrate (100 µM) and ampicillin (125 µM). 
Protein expression was induced at 25°C by addition of IPTG (0.4 mM), and the cells 
were harvested 8 hours later by centrifugation, yielding pink pellets. Lysis of the cells 
was achieved as described for cb5r. During fractionation of the cleared lysate, however, 
cb5 was precipitated by 95% (w/v) (NH4)2SO4. The pellet was resuspended in the 
minimum volume of low ionic strength phosphate buffer and dialyzed twice against a 
large volume the same buffer before separation on DE52 anion exchange 
chromatographic media.  Elution was achieved by a gradient of 0-1M NaCl before final 
purification by FPLC on a Superdex 75 10/30 HR column.  Red fractions containing cb5 
protein were pooled, concentrated, beaded, and stored under liquid N2. 
 SDS-polyacrylamide gel electrophoresis was performed as described by Laemmli 
[87] using 12.5% acrylamide/bis-acrylamide gels.  2-5 µg of protein was solubilzed in up 
to 30 µL of SDS loading buffer (10 mM Tris-HCl, pH 6.8, containing 1% SDS, 10% 
glycerol, 1 mM DTT, and 0.1% bromophenol blue) by boiling in water for 5 minutes 
before loading the gel.  Gels were run at 150 volts in SDS running buffer (25 mM Tris-
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HCl, pH 8.3, containing 192 mM glycine, 0.1% SDS) until the blue dye front traversed 
the gel. Gels were stained with Coomassie Brilliant Blue dye to visualize protein bands.   
 
Site-directed Mutagenesis  
The pH4CB5R [76] expression construct was specifically mutagenized using a 
modification of the Stratagene QuikChange™ (La Jolla, CA) protocol. 
Mutagenic Oligonucleotide Primer Design 
Complementary oligonucleotide primers (30-40 mers) containing the desired 
codon change as well as silent mutation (either inserting or deleting a restriction enzyme 
recognition sequence) were designed using the Primer Generator program 
(http://www.med.jhu.edu/medcenter/primer/primer.cgi) [88]. The sense strand annealing 
primers used in the construction of the various mutant proteins are listed in Table 1.  
Vector Polymerase Chain Reaction 
Vector PCR was performed using Pfu Turbo polymerase (1.25 units) in the presence of 
cloned Pfu buffer (20 mM Tris-HCl, pH 8.8 containing 2 mM MgSO4, 10 mM KCl, 10 
mM (NH4)2SO4, 0.1% Triton® X-100, and 0.1 mg/ml nuclease-free BSA) containing 10 
ng vector DNA (pH4CB5R or pH6NCR), 125 ng of each synthetic primer, 5% DMSO, 
and 200 µM dNTP’s with cycling parameters (20 cycles) of 1 min at 94 °C, 1 min at 55 
°C, 10 min at 68 °C.  DpnI restriction enzyme was added directly to the cooled PCR 
reaction tube following the PCR cycling reaction to cleave only the methylated template 
DNA.  This step greatly reduced the percentage of wild-type background transformants. 
Table 1.  Mutagenic Oligonucleotide Primers.   Nucleotides in bold encode the 
mutated bases generated to introduce the proper mutation.  Silent mutations in italics add 
(+) or eliminate (-) the indicated restriction site. 
 
 
   Mutation                               Primer Sequence (5’→ 3’)                         Restriction Site 
 
  G75S         CCT GGG CCT TCC TAT CAG TCA ACA CAT CTA CCT           +HincII 
  P92A    GGC AAC TTG GTC GCC TAC ACC CCT GTG TCT        -BsmFI 
  P92H    TGG GTG ATT CGT CAC TAC ACC CCT GTG TCT AGT    +HinFI 
  T94G    GTC ATT CGT CCC TAC GGC CCT GTG TCT AGT GAT     -MslI 
  T94H    GTC ATT CGT CCC TAC CAC CCT GTG TCT AGT GAT     -MslI 
  T94P    GTC ATT CGT CCC TAC CCC CCT GTG TCT AGT GAT     -MslI 
  P95A    CCC TAC ACC GCG GTG TCT AGT GAC GAT GAC AGG   +MaeIII 
  P95G    ATT CGT CCC TAG ACC GGT GTG TCT AGT GAT GAT    +BsaWI 
  P95H    GTC ATT CGT CCC TAC ACC CAC GTG TCT AGT GAT   +AflIII 
  P95I    ATT CGT CCC TAC ACC ATT GTT TCT AGT GAT GAT     -MslI 
  V96S    ATT CGT CCC TAC ACC CCT TCG TCT AGT GAT GAT     -MslI 
  S97N    CGT CCC TAC ACC CCA GTG AAT AGT GAT GAT GAC   +HincII 
  G124A   GTT TCC AGC CGG AGC GAA AAT GTC TCA GTA C       -BpmI 
  G124H   GTT TCC AGC TGG ACA CAA AAT GTC TCA GTA CC      -BpmI 
  G124K   GTT TCC AGC TGG AAA GAA AAT GTC TCA GTA CCT     -BpmI 
  G124R   GTT TCC AGC TGG ACG GAA AAT GTC TCA GTA CC      -BpmI 
  K125A   GCG GGA GGG GCA ATG TCT CAG TAC CTG            -BpmI 
  K125D   CCC AAG TTT CCA GCA GGC GAC ATG TCT CAG TAC     +NspI 
  K125E   CCA GCG GGA GGG GAA ATG TCT CAG TAC CTG         +NspI           
  M126C   GCT GGA GGG AAA TGT TCT CAG TAC CTG GAA AAC    +BsmAI           
  M126F   AAG TTT CCA GGG AGG GAA ATT CTC TCA GTA CCT     +ApoI          
  M126G   GCT GGA GGG AAA GGG TCT CAG TAC CTG GAA AAC     +BsaI 
  M126P   GCT GAA GGG AGG GAA ACC GTC TCA GTA CCT GGA    +BsmBI 
  M126S   GCT GGA GGG AAG TCG TCT CAG TAC CTG GAA AAC    +BsmBI 
  E255-   TTC GTG AAT GAG ATG ATC AGG GAC CAT CTT CCA   +HincII 
  V252M   GCC AAG GCT TCA TGA ATG AGG AGA TGA TCA GGG    +BspHI 
  M272-   GAG ACA CTG ATA CTG - - - TGT GGA CCC CCA CCG     NA* 
  M272A   GAG ACA CTG ATA CTG GCA TGT GGA CCC CCA CCG     +NspI 
  M272I   CTG ATA CTG ATC TGT GGA CCC                    +TfiI    
  M272L   CTG ATT CTG CTG TGT GGA CCC                    +TfiI    
  M272R   CTG ATT CTG AGG TGT GGA CCC                    +TfiI    
  P275L   CTG ATG TGT GGA CTC CCA CCG ATG ATC CAG         +PleI    
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PCR products were subsequently purified using the Qiagen PCR Cleanup Kit.  Products 
were eluted in 30µL of sterile elution buffer and stored at -20°C until ready for use. 
Preparation of Competent Cells and Linear DNA Transformation 
 Competent E. coli DH5α cells were prepared according to the protocol by 
Yuckenberg et al. [89] for storage at -70°C. In brief, an overnight culture of bacteria, 
grown in LB, was used to inoculate 250 mL of fresh LB medium.  The culture was 
incubated with shaking until an O.D.600nm of approximately 0.9 was reached.  Cells were 
then harvested by centrifugation at 0°C and washed in a solution of ice-cold 100 mM 
MgCl2. Cells were again harvested and resuspended in ice-cold 100 mM CaCl2, where 
they were then incubated on ice for 90 minutes.  Cells were  finally  harvested  and  
resuspended in  85 mM  CaCl2  containing  15% glycerol before being snap frozen in 
liquid N2 and stored at -80°C prior to use. This protocol was also used for the preparation 
of all other competent E. coli strains. 
Competent E. coli DH5α cells were transformed with linear DNA constructs 
according to the protocol provided with the Quikchange™ Mutagenesis Kit (Stratagene) 
Frozen cells were thawed slowly on ice and 50 µL aliquots were transferred to sterile 15 
mL polypropylene conical tubes maintained on ice. Up to 10 µL of the purified linear 
DNA construct was mixed carefully with the cells by swirling the pipette tip as the DNA 
was expelled.  The mixture was then incubated on ice for 20 minutes before being heat-
shocked at 42°C for 45 seconds and then returned to ice for 2 more minutes.  Finally, 1 
mL of SOB media was added and the cells were allowed to recover for 1 hour at 37°C 
with gentle shaking before being plated on the appropriate selection media. 
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Mutagenic Screen by DNA Restriction Digest   
Following overnight incubation at 37°C on ampicillin-containing SOB-agar plates,  
colonies were subcultured into 5 mL of liquid SOB media, containing ampicillin (125 
µM).  Clones were analyzed and screened for the silent mutations, introduced during 
mutagenesis, by restriction enzyme digestion using the appropriate enzymes listed in 
Table 3 and 4.  Each digest was separated using polyacrylamide gel electrophoresis or 
agarose gel electrophoresis and the restriction pattern visualized by EtBr staining of the 
gel. Figure 14 illustrates the result of a typical gel observed during screening of mutants. 
Mutant constructs exhibiting the predicted pattern that differentiated them from the wild-
type construct were verified by nucleotide sequencing in both the forward and reverse 
directions.  Positive constructs were subsequently used to transform competent E. coli 
BL21(DE3)-RIL cells to proliferate the generation of the mutant enzymes. 
 
Ultraviolet and Visible Absorbance Spectroscopy 
Absorbance spectra in the far (190-250 nm) and near UV (250-350 nm), visible 
(360-750 nm), and near IR (750-1000 nm) wavelength range were obtained for wild type 
and mutant enzymes using a Hewlett Packard (Agilent Technologies, Palo Alto, CA) 
8453 diode-array spectrophotometer utilizing microcuvettes of either 90 µL or 200 µL 
capacity and with 1 cm pathlength.  
 
Ultraviolet and Visible Circular Dichroism Spectroscopy 
 UV and visible CD spectra were obtained using a JASCO (Easton, MD) J710 
spectropolarimeter calibrated for both signal intensity and wavelength maxima using an 
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aqueous solution of d-10-camphosulfonic acid [90]. UV CD spectra were obtained in 10 
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0 using a cylindrical quartz cell 
of 0.1 cm path length (300 µl total volume) while visible CD spectra were obtained in 10 
mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0 using a 1 cm pathlength cell (90 µl 
total volume). All spectra were corrected for the appropriate buffer contributions and are 
expressed in terms of molar ellipticities (M-1 cm-1). 
 
Fluorescence Spectroscopy 
 Fluorescence spectra were obtained using a Shimadzu Scientific Inst. Inc. RF-
5301PC spectrofluorophotometer. Excitation and emission spectra were obtained using a 
slit width of 3 nm and emission and excitation wavelengths of 520 nm and 450 nm, 
respectively. Following acquisition of the wild type and mutant spectra, the enzymes 
samples were heated to 100oC for 30 min, centrifuged to remove protein aggregates and 
the corresponding spectra for the liberated FAD were subsequently recorded. All spectra 
were corrected for the appropriate buffer contribution.  
 
Steady-State Enzyme Activities  
NADH:FR and NADH:CR activities were determined at 25°C under conditions of 
constant ionic strength and pH in 116 mM MOPS buffer (µ = 0.05), containing 0.1 mM 
EDTA, pH 7.0, while NADH:BR activities were determined at 25°C under conditions of 
constant ionic strength and pH in 10mM potassium phosphate buffer (µ = 0.01), 
containing 0.1mM EDTA, pH 7.0.  NADH:FR activities were typically determined as the 
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decrease in absorbance at 340 nm in the presence of NAD(P)H (250 µM) and 
ferricyanide (500 µM). NADH:BR activity was determined as the increase in absorbance 
at 423 nm in the presence of NADH (250 µM) and rat cb5 (30 µM). All substrates were 
quantitated spectroscopically using the calculated molar extinction coefficients for 
NADH, H4NAD, NAD+, cb5, 2’-5’, and ADP-ribose (Siegel 1959, Beck von Bodman 
1986, The Merck Index 1989, Murataliev 2000). Activities are expressed as initial rates 
for the oxidation of NAD(P)H (µmol of NAD(P)H consumed/min/nmol FAD). Initial rate 
data at varying NAD(P)H, ferricyanide, or cb5 concentrations were analyzed using the 
software “ENZFIT” (Elsevier Biosoft, Ferguson, MO) to determine apparent kcat and Km 
values. 
 
Charge-transfer Complex Determination 
Reductive titrations were performed under anaerobic conditions as described by 
Foust [91]. Enzyme samples (50 µM FAD) in 116 mM MOPS buffer, containing 0.1 mM 
EDTA, pH 7.0, and NADH solutions (100 mM) were prepared by repeated evacuation 
and flushing with oxygen-free argon. Enzyme samples were titrated with NADH and 
monitored for increased absorbance in the near IR wavelength range from 700-900 nm. 
Titrations were determined to be saturating when the absorbance at 800 nm ceased to 
increase and no further bleaching of the flavin spectra occurred upon NAD(P)H addition. 
 
Spectral Binding Constant Determination by Differential Spectroscopy 
 
 Spectral binding constants, Ks, for various NADH analogs were determined by 
differential spectroscopic titrations as described by Sancho and Gomez-Moreno [92] and 
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Barber et al. [93]. A Shimadzu UV2501-PC was used to measure the difference spectra 
of samples in matched split-cell quartz cuvettes with 0.439 cm pathlength and 2.5 ml 
capacity.  Enzyme and NADH analogs were suspended in 10mM phosphate buffer, pH 
7.0, containing 0.1mM EDTA for all spectral determinations.  All analog concentrations 
were determined spectrophotometrically using previously published extinction 
coefficients. 
The reference cuvette contained 50 µM enzyme (as determined by FAD 
concentration) in the front compartment and analog-titrated buffer in the rear 
compartment. The sample cuvette contained analog-titrated enzyme (50 µM) in the front 
compartment and buffer in the rear compartment.  The appropriate buffer was added to 
the enzyme compartment of the reference cuvette to correct for the dilution caused by 
analog addition to the enzyme compartment of the sample cuvette.  Following sample 
addition, each compartment was stirred briefly to insure thorough mixing. Spectra were 
then recorded over the wavelength range from 300-800 nm depending on the titration. 
The magnitude of the absorbance change was determined for each spectrum via peak to 
trough subtraction in order to compensate for any baseline drift between spectra.  
Absorbance changes were plotted versus nucleotide concentration and the resulting plots 
were fit to the hyperbolic equation:  
∆Absorbance = ∆Absorbancemax*[nucleotide] / [Ks + (nucleotide)] 
 in order to determine the spectral binding constant (Ks), which was defined as the 
concentration of analog at which half maximal spectral perturbation was observed.  
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Thermal Stability Measurements 
 Thermal stabilities of wild type and mutant enzymes were determined as 
described by Trimboli et. al. [67] by monitoring both the release of the FAD prosthetic 
group, as indicated by the change in flavin fluorescence, and the loss of NADH:FR 
activity over the temperature range from 0-100°C.  
 
Determination of Flavin Midpoint Potential 
 Flavin midpoint potentials were determined by dye equilibration using the method 
of Massey [94]. Xanthine (30 µM) and xanthine oxidase (50 nM) were used to reduce a 
mixture of enzyme (40 µM FAD) and the indicator dye, phenosafranine (15 µM) in 100 
mM phosphate buffer containing 0.1 mM EDTA, first made anaerobic by repeated 
evacuation and flushing with oxygen-free argon. Benzyl viologen (6 µM) and methyl 
viologen (1 µM) were included to facilitate equilibration of the system. Visible 
absorbance spectra were collected over the course of each 3-hour equilibration. Flavin 
reduction was monitored at 410 nm while phenosafranine reduction was monitored at 530 
nm. E0’ values were calculated by graphical analysis of the plot [log (ox)/(red)]phenosafranine 
versus [log (ox)/(red)]FAD using the published midpoint potential of phenosafranine of –
252 mV [94]. 
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                                                       3.  RESULTS AND DISCUSSION 
 
Analysis of the conserved “RxYS/TxxS/N” FAD binding motif  
Multiple sequence alignments of the members of the flavoprotein 
transhydrogenases family have revealed four distinct regions, each containing a high 
level of sequence and structural conservation.  These regions are found within both the 
flavin- and pyridine nucleotide-binding regions of the ferrodoxin:NADP+ reductase 
(FNR, EC 1.18.1.2) superfamily (Figure 10) [5].  The first of these conserved sequences, 
corresponding to “RxYSTxxSN”, is a flavin-binding motif comprised of the residues 
91RPYTPVS97 in R. norvegicus cytochrome b5 reductase sequence.  It is considered to be 
one of the most highly conserved of the known flavin-binding motifs.  
Site-directed mutagenesis studies of R91, P92, and Y93 have demonstrated these 
residues to be non-essential for flavin cofactor incorporation.  However, amino acid 
residues R91 and Y93 do modulate the spectroscopic, catalytic, and thermodynamic 
properties of cb5r, and are critical in maintaining proper structure and orientation of the 
active site of the enzyme [76, 77].  Additionally, formation and stability of the NAD+-
FAD- semiquinone complex during NADH turnover has also recently been shown to be 
controlled by the fourth residue in the “RxYSTxxSN” motif, corresponding to T66 in 
porcine cytochrome b5 reductase, through the generation of the T66S and T66V variants 
[24].   
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 To further probe the structural and functional characteristics of this highly 
conserved flavin-binding motif, a series of variants were created through site-directed 
mutagenesis, utilizing the rat cytochrome b5 reductase expression system previously 
generated by Marohnic et al. [76].  The variants generated corresponded to alternate 
amino acid residues that occur at the same residue position within additional GenBank 
sequences of other members of the FNR superfamily and include: T94H, T94G, T94P, 
P95G, P95I, V96S, and S97N. 
 The fidelity of each variant was confirmed by nucleotide sequencing in both 
forward and reverse directions and the mutant proteins were then recombinantly 
expressed in BL21 (DE3)-RIL cells.  Purification to homogeneity was carried out through 
the utilization of a combination of Ni-NTA affinity and gel filtration chromatography for 
the mutant proteins and with the exception of T94G and T94P, all were expressed at 
levels comparable to that of the wild-type domain as observed by the appearance of  
single protein bands following SDS-PAGE analysis.  Neither the T94G nor T94P mutants 
yielded viable proteins for subsequent characterization, in each case the flavin cofactor 
failed to properly incorporate to yield a stable flavoprotein.  
UV/visible absorption spectra were obtained for oxidized samples of each of the 
purified variants together with wild-type cytochrome b5 reductase and are presented in 
Figure 11A.  The P95G, P95I, V96S, and S97N mutants each displayed spectra 
comparable to that of the wild-type domain, attributable to protein-bound flavin with an 
aromatic absorption maxima detected at 272 nm in the UV region of the spectrum  and a 
peak at 461 nm with a pronounced shoulder within the range of 485-500 nm in the visible 
region of the spectrum.  The T94H mutant however, produced visible absorption spectra 
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Figure 11.  Ultra-Violet, Visible, and Circular Dichroism Spectra of Wild Type, 
T94H, P95G, P95I, V96S, and S97N Proteins of Cytochrome b5 Reductase.  (A) 
Oxidized samples of wild-type and mutants cb5rs (20µM), (B) 7µM, and (C) 60µM FAD 
in 10mM phosphate with 0.1mM EDTA, pH 7.0 buffer.  The inset shows an expanded 
region of the visible spectrum where the flavin cofactor makes a major contribution.  
Individual spectra correspond to (____) H4cb5r; (____ ____) T94H; (__ __ __) P95G; (_ _ _ _) 
P95I; (. . . . .) V96S;  (__.__.__) S97N and free flavin (_____). 
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that was significantly altered with a red-shifted λmax of 467 nm compared to that of the 
wild-type cytochrome b5 reductase visible λmax of 461 nm.  Shifts within the visible 
absorption spectra of flavoproteins have previously been attributed to changes in the 
hydrophilicity of the flavin environment near the N(5) locus of the isoalloxazine ring 
[76].  The absorption ratios (A276/A461) for each viable mutant were within a range of 5.5 
to 5.9 which indicated a full flavin complement. 
 To examine the effects of each mutation upon the secondary structure of the 
protein, UV circular dichroism spectra were determined in the UV wavelength range (190 
– 300 nm).  As shown in Figure 11B, all of the mutants generated displayed line shape 
comparable to wild-type cytochrome b5 reductase with positive CD from 190-210 nm and 
negative spectra from 210-250 nm.  Although these results were in good agreement with 
the wild-type domain, both the T94H and V96S variants displayed a negative CD 
intensity greater than that of the wild-type protein at 222 nm.  The alteration displayed for 
the T94H and V96S UV CD spectra indicated an adverse structural change within the 
overall α-helical or β-sheet components of the two variants.  In order to examine the 
flavin environment of each variant, visible CD spectra were obtained as shown in Figure 
11C.  Representative spectra demonstrated that each variant retained a similar line shape 
as that of wild type cytochrome b5 reductase with positive maxima at 310 and 390 nm 
and negative maxima at 460 and 485 nm, respectfully.  However, both the T94H and 
P95G variants displayed an altered flavin environment within the region of 450 – 485 nm 
which is in agreement with the observation from the x-ray crystal structure, that T94 
forms a hydrogen bond with the isoalloxazine ring of the FAD- prosthetic group and the 
mutation of P95 to a glycine could lead to flexibility within the secondary structure 
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altering the FAD- cofactor conformation.  No significant changes were observed in the 
visible CD spectra for either the V96S or S97N variants demonstrating that neither 
residue is required for correct flavin orientation.   
 To establish if the alterations observed in the flavin environment from the UV/Vis 
and CD spectra affected the catalytic function of the enzyme, initial-rate kinetic 
parameters for NADH:FR and NADH:BR assays were determined for the wild-type 
cytochrome b5 reductase and for each purified variant.  The values obtained for the 
NADH:FR and NADH:BR assays are presented in Table 2.  NADH catalytic efficiencies 
(kcat/KmNADH) for all variants ranged between 22 and 62% compared to wild-type 
cytochrome b5 reductase, with T94H yielding the lowest catalytic efficiency.  
Interestingly, it was only the kcat for each of the variants that lead to the decrease 
observed in the overall catalytic efficiency, while the KmNADH of each mutant was either 
comparable to the wild-type domain or slightly enhanced as seen in the T94H variant 
indicating a higher affinity for the NADH substrate.  Similar results were observed in the 
NADH:BR assays in which the overall catalytic efficiency was decreased primarily due 
to the decreased rate of turnover (kcat) for each variant.  This was to be expected since the 
residues within the “RxYSTxxSN” motif are not involved in or located within close 
proximity to the amino acids that participate in cytochrome b5 reductase - cytochrome b5 
complex formation. 
 From the kinetic data obtained it was demonstrated that each of the variants 
generated displayed a KmNADH that was highly comparable to wild-type cytochrome b5 
reductase or, as mentioned previously, in the case of the T94H the affinity for substrate 
was enhanced almost 2-fold over the wild-type domain.  To further establish the binding 
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Table 2.  NADH:FR and NADH:BR Kinetic Constants of T94H, P95G, P95I, V96S, 
S97N, and Wild Type Cytochrome b5 Reductase. 
 
Mutant NADH:FR NADH:BR 
    kcat          KmNADH   KmFeCN6    kcat/KmNADH
  (s-1)       (µM)       (µM)      (s-1 M-1) 
   kcat          KmNADH   KmCyt b5    kcat/KmCytb5 
  (s-1)       (µM)       (µM)      (s-1 M-1) 
H4cb5r 
T94H 
P95G 
P95I 
V96S 
S97N 
800 ± 21      6 ± 1          8 ± 1      1.4 ± 0.3 x 108 
102 ± 21      4 ± 1          7 ± 1      2.8 ± 0.1 x 107 
326 ± 25      7 ± 1          8 ± 1      4.2 ± 0.2 x 107 
232 ± 10      6 ± 1          8 ± 1      4.0 ± 0.1 x 107 
637 ± 27      8 ± 1          7 ± 1      8.0 ± 0.6 x 107 
296 ± 5        5 ± 1          8 ± 1      5.7 ± 0.6 x 107
600 ± 10      2 ± 1         13 ± 1      4.7 ± 0.5 x 107 
  94 ± 2        2 ± 1        3 ± 0.3      3.0 ± 0.3 x 107 
244 ± 15      3 ± 1         11 ± 2      2.3 ± 0.5 x 107 
137 ± 6        3 ± 1         12 ± 1      1.2 ± 0.2 x 107 
465 ± 20      2 ± 1         16 ± 1      3.0 ± 0.4 x 107 
567 ± 36      3 ± 1         24 ± 1      2.4 ± 0.4 x 107
 
  
affinity of the substrate NADH and the product NAD+, spectroscopic binding constants 
were determined utilizing differential spectroscopy.  
As stated in “Methods and Materials”, the isoteric analog 1,4,5,6-tetrahydro-NAD 
(H4NAD) was utilized as an alternative substrate analog to evaluate the affinity for the 
physiological substrate NADH [85].  Differential spectroscopy was used to monitor 
complex formation during titrations with either H4NAD or the physiological product 
NAD+ as shown in Figure 12 and Figure 13.  Spectra obtained for each of the titrations 
carried out in the presence of H4NAD displayed a line shape comparable to wild-type 
cb5r with the exception of the P95I variant.  This indicated that for P95I, the isoteric 
substrate analog bound in an altered conformation due to the distorted environment of the 
FAD- prosthetic group as observed in the visible CD spectra.  Values observed for the 
spectroscopic binding constant (Ks) for each of the H4NAD titrations, shown in Table 3, 
demonstrated that the binding affinity for each of the variants was not significantly  
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Figure 12.  Spectroscopic Titrations of H4cb5r and the T94H, P95G, P95I, V96S, and 
S97N Variants in the Presence of H4NAD.  Titrations of all mutants (50mM) were 
performed in split cell optical cuvettes in 10mM phosphate buffer containing 0.1mM 
EDTA, pH 7.0 at 23 °C.  Difference spectra were recorded following the addition of 
solution containing H4NAD (30µM).  The inset panel corresponds to a plot of the 
magnitude of the spectral perturbations at the indicated wavelengths versus pyridine 
nucleotide concentration where a difference spectrum was observed.  Plots of the relative 
absorbance changes observed are as follows: (A) H4cb5r; (B) T94H; (C) P95G; (D) P95I; 
(E) V96S; and (F) S97N. 
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Figure 13.  Differential Spectroscopy of H4cb5r, T94H, P95G, P95I, V96S, and S97N 
cb5rs in the Presence of H4NAD.  Titrations of all mutants (50mM) were performed in 
split cell optical cuvettes in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at 
23 °C.  Difference spectra were recorded following the addition of solution containing 
NAD+ (30µM).  The inset panel corresponds to a plot of the magnitude of the spectral 
perturbations at the indicated wavelengths versus pyridine nucleotide concentration 
where a difference spectrum was observed.  Plots of the relative absorbance changes 
observed are as follows: (A) H4cb5r; (B) T94H; (C) P95G; (D) P95I; (E) V96S; and (F) 
S97N. 
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Table 3.  Spectral Binding Constants Obtained for Wild Type cb5r and the T94H, 
P95G, P95I, V96S, and S97N Variants. 
 
Mutant Ks H4NAD 
(µM) 
KsNAD+
(µM) 
KiNAD+
H4cb5r            45 ± 10        760 ± 30        675 ± 23 
T94H               122 ± 16          13 ± 2          23 ± 2 
P95G            53 ± 13        491 ± 15        360 ± 16 
P95I          116 ± 4        196 ± 14        225 ± 14 
V96S            62 ± 8      1503 ± 140             ND 
S97N          114 ± 11        775 ± 121             ND 
 
 
altered, with the P95G and V96S mutants yielding values comparable to wild-type 
cytochrome b5 reductase and the T94H, P95I, and S97N displaying Ks values ~ 2-fold 
greater than that of the wild-type domain values.   
These results indicated that the affinity for the substrate analog H4NAD is not 
significantly affected through the perturbations observed in the spectroscopic properties 
of the FAD prosthetic group.  Unlike the spectra seen in the H4NAD titrations, all of the 
generated variants retained a line shape for the NAD+ titrations compared to that of wild-
type cytochrome b5 reductase displaying positive maxima at 410 and 510 nm, and 
negative maxima at 430, 460, and 485 nm.  However, Ks values were markedly altered 
for the P95G, P95I, and T94H variants displaying an enhanced binding affinity for the 
NAD+ product with the T94H variant displaying a Ks value of 13 µM compared to that of 
the wild-type domain value of 800 µM (Table 3).  Values obtained for the V96S and 
S97N variants were ~ 2-fold greater than or comparable to wild-type cytochrome b5 
reductase, respectively.  These results are in good agreement with the kinetic values 
obtained in that the substrate H4NAD is still able to bind efficiently as is the product 
NAD+.  However, the enhanced binding affinity of NAD+ for the T94H, P95G, and P95I 
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variants combined with the reduced kcat kinetic values, indicated that the NAD+ is unable 
to dissociate from the NADH binding domain efficiently which has been demonstrated to 
be a critical step in the reaction mechanism of cytochrome b5 reductase [24]. 
 To further probe the properties of product inhibition, initial rate enzyme kinetics 
were performed, as described previously, in the presence of varying concentration of 
NAD+ to determine if the competitive inhibition properties of the NAD+ product was 
capable of giving rise to the alterations observed in the overall catalytic efficiencies and 
Ks values of the T94H, P95G, and P95I variants.  As shown in Figure 14, the 
Lineweaver-Burke plots obtained for wild-type cytochrome b5 reductase and the T94H, 
P95G, and P95I mutants all displayed a model of competitive inhibition represented by a 
single intercept at the y-axis showing no change in Vmax in the presence of varying 
concentrations of NAD+.  Ki values [x-intercept = -(Ki)] were established for the wild-
type cytochrome b5 reductase and corresponding variants through the secondary plot of 
the Km values for each assay against that of the concentration of the NAD+ inhibitor.  
Table 3 shows the Ki values obtained which corresponded to 675, 23, 360, and 225 µM 
for the wild-type domain, T94H, P95G, and P95I, respectively.  These results are in good 
agreement with the catalytic efficiencies and Ks values obtained and confirmed that 
NAD+ is not able to disassociate from the complex efficiently and thus acts as an 
inhibitor in the cytochrome b5 reductase reaction pathway.       
 Protein stability was evaluated by monitoring the thermal NADH:FR inactivation 
profile coupled with the increase in intrinsic flavin fluorescence and emission intensity of 
each of the variants which was compared to values obtained for wild-type cytochrome b5 
reductase.  The results obtained for the thermal denaturation profiles and change in  
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Figure 14.  Enzyme Inhibition Assessment with NAD+ for the T94H, P95G, and P95I 
Variants.  Panels A-D represent the Lineweaver-Burke plots obtained from the initial 
rate kinetic analyses in the presence of various concentrations of NAD+.  Concentrations 
of NAD+ correspond to (●) 0 µM; (■) 50 µM; (▲) 100 µM; (▼) 250 µM; (♦) 500 µM; 
and (+) 1000 µM for panel (A) [wild-type cb5r], (●) 0 µM; (■) 25 µM; (▲) 50 µM; (▼) 
100 µM; and (♦) 500 µM for panel (D) [P95I], and (●) 0 µM; (■) 25 µM; (▲) 50 µM; 
(▼) 100 µM; (♦) 250 µM; and (+) 500 µM for panels [B and C] [T94H and P95G], 
respectively.  Panel (E) represents a replot of the observed KmNADH determined from each 
Lineweaver-Burke plot in (A-D) versus the concentration of inhibitor (NAD+) where the 
inhibition constant (Ki) can be determined by the equation: x-intercept = -(Ki), and the y-
intercept = Km.  
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Figure 15.  Temperature Stability Profiles of cb5r and the T94H, P95G, P95I, V96S, 
and S97N Mutants.  Oxidized samples of T94H, P95G, P95I, V96S, S97N, and wild-
type H4cb5r (5 µM FAD) were incubated at the indicated temperatures, and aliquots were 
withdrawn and assayed for both residual NADH:FR activity (closed symbols) and 
intrinsic flavin fluorescence (open symbols) in 10 mM phosphate buffer, containing 0.1 
mM EDTA, pH 7.0 using excitation and emission wavelengths of 450 nm and 523 nm, 
respectively.  Points correspond to: (●,○) H4cb5r; (■, □) T94H; (▲, ∆) P95G; (▼, ) 
P95I; (♦, ◊) V96S; and (+) S97N.   
 
 
 
 
 
 
 
 49
 50
Table 4.  T50 Values of the Wild-Type Cytochrome b5 Reductase, T94H, P95G, P95I, 
V96S, and S97N Variants. 
 
 
Mutant T50
(°C) 
H4cb5r 56 
T94H 50 
P95G 43 
P95I 47 
V96S 50 
S97N 50 
 
    
intrinsic flavin fluorescence are shown in Figure 15.  T50 values (the temperature at which 
50% of maximum fluorescence and 50% retention of NADH:FR activity was detected) 
for each of the mutants indicated a decreased protein thermostability compared to the T50 
value of 56 °C for wild-type cytochrome b5 reductase.  Both the P95G and P95I variants 
showed the greatest decrease in thermostability with T50 values of 43 °C and 47 °C, 
respectively, while the remaining T94H, V96S, and S97N variants yielded a T50 value of 
50 °C.  These results indicated that any substitution of the P95 residue may lead to 
conformational changes in the protein’s secondary structure resulting in protein 
instability.      
 To examine the effects of potential structural changes on the properties of the 
flavin prosthetic group, oxidation-reduction potentials for the FAD cofactor were 
determined utilizing dye-equilibration titrations in the presence of phenosafranine (E°′ = -
252 mV) since the variants generated were based on residues within the “RxYSNxxST” 
motif and thus could affect the flavin reduction potentials due to their close proximity to 
the FAD- cofactor.  Flavin midpoint potentials (E°′, n = 2) for the FAD/FADH2 couple 
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were determined for the variants alone and in the presence of NAD+.  Spectra obtained 
during a representative titration of the T94H variant are shown in Figure 16.   The flavin 
redox potentials (n = 2) for the wild-type cytochrome b5 reductase and generated variants 
for the FAD/FADH2 couple were determined from the Nernst semi-log plots of the log 
([oxidized]/[reduced])FAD versus potential (mV) and are shown in Figure 16.  The 
standard midpoint potential values obtained are shown in Table 5.  For the standard flavin 
midpoint potentials in the absence and presence of NAD+, all potentials were nearly 
identical for the wild-type domain, P95G, and S97N variants, indicating that the 
introduction of structural alterations of these two variants did not have a dramatic effect 
on the flavin midpoint potential.  The V96S variant displayed a flavin midpoint potential 
comparable to the wild-type domain in the absence of NAD+ indicating that the mutation 
of V96S had no effect on the electron transfer potential.  Upon the addition of the product 
NAD+ however, a negative shift was observed yielding a midpoint potential -217 mV, 
comparable to the value obtained for the midpoint potential of free flavin (-220 mV) [95].  
Much the opposite was observed with the P95I variant, in that in the presence of NAD+ a 
midpoint potential of -193 mV was established which is in good agreement with the wild-
type cytochrome b5 reductase value of -190 mV.  In the absence of NAD+ the P95I 
mutant displayed a positive shift by 65 mV to -207 mV, a shift that, as mentioned, 
demonstrates a midpoint potential like that seen in the potential of free flavin.  T94H 
yielded the most significant results by displaying a midpoint potential of -219 mV both in 
the absence and presence of NAD+, indicating the introduction of a T94H variant causes 
a structural displacement of the flavin prosthetic group that leads to standard midpoint 
potential corresponding to that of free flavin. 
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Figure 16.  Potentiometric Titrations of the T94H, P95G, P95I, V96S, S97N, and 
Wild-Type Cytochrome b5 Reductases.  Reductive dye titrations were performed at 25 
°C as described in “Materials and Methods” using phenosafranine as the indicator dye in 
100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0.  Nernst plots in the absence 
(A) and presence (B) of 2 mM NAD+.  Plots correspond to (●) H4cb5r; (■) T94H; (▲) 
P95G; (▼) P95I; (♦) V96S; and (+) S97N.   
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Table 5.  Flavin Midpoint Potentials (E°′) Obtained for Wild-Type, T94H, P95G, 
P95I, V96S, and S97N cb5rs. 
 
E°′ FAD/FADH2
(mV) 
Slope 
(mV) 
E°′ FAD/FADH2
(mV) 
Slope 
(mV) 
Enzyme 
-NAD+ +NAD+
H4cb5r 
T94H 
P95G 
P95I 
V96S 
S97N 
-272                       -30 
-218                       -60 
-267                       -61 
-207                       -57 
-276                       -30 
-272                       -35 
-190                       -30 
-219                       -31 
-201                       -50 
-193                       -32 
-217                       -23 
-197                       -55 
 
  
Summary of Analysis of the conserved FAD binding motif 91RxYS/TxxS/N97
 Previous studies based on the crystal structure of NADH-cytochrome b5 reductase 
derived from pig liver microsomes described by Nishida et al. [39] revealed a highly 
conserved β-barrel structure for the binding motif of the flavin prosthetic group through 
the structural homology comparisons of the porcine cb5r, ferredoxin-NADP+ reductase 
(FNR) [96], phthalate dioxygenase reductase (PDR) [5] and the FAD- containing 
fragment of nitrate reductase [6].  Through these comparisons it was revealed that the 
overall barrel foldings are similar to each other and that three conserved residues, (R, Y, 
and S/T) were in a specific arrangement and necessary for correct flavin binding and 
orientation.  These three residues correspond to R91, Y93, and S127 within the rat model 
of cytochrome b5 reductase and provided the first insight into the highly conserved 
“91RxYSTxxSN97” flavin-binding motif.  Since the description of this motif, mutagenesis 
studies have been performed in order to elucidate the roles of these residues in 
maintaining proper flavin incorporation and overall function. Previous studies by 
Marohnic et al. [76] demonstrated that although R91 is not essential for flavin 
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incorporation, the removal of the positively charged side chain results in the phenomenon 
known as “flavin flexibility”.  In this case, production of the R91A and R91L variants 
resulted in the displacement of the ADP portion of the flavin prosthetic group into the 
ADP region of the NADH-binding site, thus acting as its own inhibitor.  Analysis of the 
P92 and Y93 variant indicated the  roles in which these residues modulated the flavin 
midpoint potential, spectroscopic properties of the protein-bound cofactor, and the 
catalytic efficiencies of cytochrome b5 reductase [77].  Mutagenic studies of the porcine 
T66V and T66S variants (corresponding to T94 in rat cytochrome b5 reductase) by 
Kimura et al. [24] established that this residue is involved in the stabilization of 
semiquinone intermediates within the reaction mechanism of cytochrome b5 reductase. 
 In order to fully elucidate the role of each residue, a series of variants were 
generated corresponding to naturally occurring substitutions observed within the FNR 
superfamily [5] that included T94G, T94H, T94P, P95G, P95I, V96S, and S97N.  The 
results presented here give further insight into the role of this motif towards correct 
orientation and binding of the FAD prosthetic group.  While the V96S and S97N variants 
gave results that were comparable to that of wild-type cytochrome b5 reductase, the 
T94H, P95G, and P95I variants all displayed significant deviations in the biophysical 
properties of the enzyme. 
 T94 has been considered to be a critical residue within the “91RxYSTxxSN97” motif 
due to its location within the FAD-binding lobe of cytochrome b5 reductase.  As shown in 
Figure 17,  T94 forms a backbone hydrogen bond to the N5 of the isoalloxazine ring of  
the FAD prosthetic group and is situated near the potential binding site of the 
nicotinamide ring of NADH [97, 98].  T94 also lies within 4.02Å of residue T184 of the 
 55
  
 
 
 
 
 
 
 
 
 
 
Figure 17.  Electrostatic Interaction of Amino Acid Residue T94 with the FAD 
Cofactor of Cytochrome b5 Reductase.  (A) Ligplot [99] of 1IB0.  C, O, N, S, and P 
atoms are represented as white, blue, red, yellow, and violet spheres, respectively, while 
covalent bonds are green sticks within FAD and blue sticks within amino acid residues of 
the FAD-binding lobe.  Hydrogen bonds are drawn as dashed lines with distances 
between atoms labeled.  Residues contributing to hydrophobic interactions are 
represented as arcs with rays and colored blue.  (B) Structural model of residue T94 and 
its orientation and hydrogen bonding interaction to FAD (atoms colored in CPK).   
 
 
 
 
 
 
 
 
 
 
A 
3.11 Å
T94
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NADH-binding lobe that forms essential hydrogen bond contacts from the OG1 atom of 
T184 to both the O4 and N5 of the isoalloxazine ring of the FAD- cofactor.   
The importance of the P95 residue has been demonstrated through the resolved 
crystal structure of cytochrome b5 reductase [21].  P95 is localized in a hydrophobic core 
of the FAD-binding domain, together with L72 and V105.  This triad is approximately 
6Å away from the active site making it a critical area in regards to enzyme function. 
  Homology modeling software (GENO3D) [100] was utilized to generate a 
structural model of the T94H, P95G, and P95I variants in order to compare the structural 
models with the results obtained Figure 18.  As described previously, various attempts 
were made to generate the T94G and T94P variants which resulted in limited success.  
The introduction of a glycine residue into a protein has been shown to “relax” the 
backbone secondary structure, thus the P95G variant may result in the perturbed flavin 
environment as observed in the visible CD spectra.  The introduction of a proline causes 
the opposite effect, introducing a “kink” into the backbone. Both of these mutations may 
lead to an altered conformation of the protein.  This demonstrates that the position of the 
T94 and P95 residues at the carboxy terminus of the Fβ4 strand and the hydrogen 
bonding of the T94 residue with the FAD isoalloxazine ring is necessary for correct 
flavin incorporation. 
 Although there is no side chain interaction involved with the T94 residue the 
introduction of a histidine imidizole group removes the polarity of the T94 hydroxyl 
group and replaces it with a positively charged, bulky side chain.  We predicted that the 
effects of this would have a significant effect on the environment of the flavin prosthetic 
group and results obtained from the red shift seen in the Uv/visible spectra and the  
P95 T94
V96
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Figure 18.  Structure of the Wild-type cb5r, T94H, P95G, and P95I Variants 
Generated in silica.  The models of wild-type cytochrome b5 reductase with T94, P95, 
and V96 and the T94H, P95G, and P95I mutants were generated using the modeling 
software GENO3D and SWISS-MODEL [100, 101].  Panel (A) is a structure of 1IB0 
[21] focused in on the region of the RxYSTxxSN motif, specifically on amino acid residues 
T94, P95 and V96, where the polypeptide backbone is cyan and the FAD cofactor and 
amino acid residues are colored by element (N=blue and O=Red).  Panel B is the 
GENO3D theoretical structure of the T94H variant, where the FAD cofactor is colored in 
yellow and T94H in green.  Panel C represents the P95G variant colored in orange, and 
Panel (D) represents the P95I variant colored in red.  
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perturbed visible CD spectral data clearly demonstrated this.  We proposed that the T94H 
variant generated a steric hindrance that affects the interaction of the T94 residue with the 
FAD isoalloxazine ring as well as the hydrogen bonding interaction of the T184 residue 
with the N5 atom of the FAD- prosthetic group isoalloxazine ring.  The alteration in the 
FAD environment was further confirmed by the results of the oxidation/reduction 
potential of the FAD/FADH2 couple which yielded a midpoint potential comparable to 
that of free flavin (-220 mV) in the absence and presence of NAD+ suggesting an 
unfavorable electron transfer efficiency.  
As mentioned previously, T94 and P95 are located near the potential binding site 
of the nicotinamide ring of NADH and the effects of the T94H, P95G, and P95I variants 
upon substrate binding yielded interesting results.  The spectra obtained for both the 
isoteric analog H4NAD and the product NAD+ displayed a line shape comparable to that 
of wild-type cytochrome b5 reductase indicating that no severe conformational changes 
occurred in the binding of either H4NAD or NAD+.  However, upon examination of the 
spectroscopic binding constants (Ks) for the T94H and P95I variants, the binding affinity 
for H4NAD had increased almost 3-fold compared to that of the wild-type domain 
showing a reduced binding affinity for the analog, whereas the Ks values obtained for the 
product NAD+ were significantly decreased for all three variant with the greatest impact 
observed of the T94H variant yielding a Ks value of 13 µM compared to that of 667 µM 
obtained for wild-type cytochrome b5 reductase.  Thus the spectral binding constants 
suggest that the NADH substrate binds with an altered efficiency compared to that of the 
wild-type domain yet the NAD+ product is not able to readily disassociate from the 
NADH-binding site and therefore acts as a potential inhibitor in the cytochrome b5 
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reductase reaction pathway.  The diaphorase activities associated with the T94H, P95G, 
and P95I variants were the first indication that this hypothesis was correct, in that the 
overall catalytic efficiency (kcat/Km) was only 22%, 32%, and 31%, respectively, that of 
wild-type cytochrome b5 reductase, yet this was only due to the poor rate of turnover 
(kcat) while the KmNADH was comparable to that of wild-type cytochrome b5 reductase for 
each mutant.  Competitive inhibition assays further confirmed this by determining initial 
rate enzyme kinetics in varying concentrations of NAD+.  Lineweaver-Burke plots 
generated from these assays revealed a model of competitive inhibition for the three 
variants as indicated by the increase in KmNADH with no change in the Vmax.  Ki values 
obtained from these assays were also in agreement, being significantly lower than that of 
wild-type.  These results are in good agreement with those in the previously reported 
T94V variant [24], in that the blue neutral semiquinone of FAD (FADH·) has a hydrogen 
atom on the N5 atom of  the isoalloxazine ring, and release of a proton from the N5 
position is required for conversion of the blue neutral semiquinone to the anionic red 
semiquinone [102] and the introduction of the T94H, P95G, and P95I variants would lead 
to a conformational change and hindrance towards the release of the proton from the N5 
position of the FADH· semiquinone thus causing a perturbed effect on the cytochrome b5 
reductase- cytochrome b5 electron transfer process.         
 
Type I recessive congenital methemoglobinemia associated with a double mutation, 
the novel P92H and previously described E255-, in the cytochrome b5 reductase gene 
 Recently, a family was identified where two siblings suffered from type I RCM 
suggesting that both parents were carriers.  Screening of the DIA1 gene for molecular 
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defects in the 2 year old sister detected a novel homozygous C to A mutation in exon 4 
and a heterozygous 3 bp in frame deletion of GAG in exon 9, causing a loss of glutamic 
acid at position 255.  Thus, one allele uniquely possessed a double mutation.  The exon 4 
mutation predicted a proline to histidine exchange at residue 92, corresponding to a P92H 
variant.  In addition, the same amino acid change at a nearby residue, corresponding to 
P95H, had previously been described in a patient with type II RCM [103].  The relative 
locations of both of these residues in the cb5r structure, with respect to the FAD 
prosthetic group and the complexed NAD+, together with indications of the degrees of 
conservation of these residues in different cb5r’s, is shown in Figure 19.  The E255- 
mutation has been previously detected [78] in the family first diagnosed with cyanosis 
described in 1943 [104], who were subsequently found by Gibson in 1948 to be deficient 
in cb5r [44].  Since half of the cb5r enzyme synthesized would have mutations in both the 
flavin- and substrate- binding domains, it would suggest a severe clinical phenotype type 
I. With this knowledge, utilizing the previously characterized heterologous rat expression 
system [105] could provide insight into the function of naturally occurring variants of 
cb5r [106] [79] [107], we prepared both the P92H and double P92H/E255- variants.  By 
performing initial-rate kinetic, thermostability, substrate affinity, and thermodynamic 
studies we were able to assess the impact of each mutation on the function of cb5r.  In 
addition, we also characterized the P95H variant and compared the results to the data 
previously generated for the E255- mutant [79]. 
 Sequencing of the DIA1 gene in a cyanotic patient detected a heterozygous 
deletion of GAG, bases 27,100 to 27,102 (NCBI accession number NT_011520) in exon 
9 resulting in the loss of E255 (Figure 20).  This mutation has been previously described  
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Figure 19. X-ray Crystallographic Structure of Cytochrome b5 Reductase. (A) A 
ribbon diagram of the structure of the rat cb5r diaphorase domain in complex with NAD+ 
(PDB=1IB0) is depicted showing the structural elements that comprise the FAD- and 
NADH-binding lobes and the connecting “hinge” region. The FAD prosthetic group and 
the bound NAD+ are shown in the “stick” representation with the individual atoms 
colored using the standard “CPK” coloring scheme. The positions of the three mutated 
residues, corresponding to P92, P95 and E255, are shown in “ball and stick” 
representation. (B) Graphical representation (sequence logo) of the amino acid residues 
present at positions 89 to 99 in the primary sequences of 56 cb5r sequences deposited in 
GenBank. A multiple sequences alignment was constructed using ClustalX [108], 
manually adjusted for maximum sequence conservation and used for the logo generation. 
The logo consists of stacks of symbols (one stack for each position in the sequence) with 
the overall height of the stack indicating the sequence conservation at that position and 
the height of the symbols within the stack indicating the relative frequency of each amino 
acid at that position [109]. (C) Graphical representation of the amino acid residues 
present at positions 251 to 259 in the primary sequences of 56 cb5r sequences deposited 
in GenBank. 
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as compound heterozygous with the G291D mutation in the original family with type I 
RCM disease [78] as described by Gibson [44].  In addition, a homozygous C to A 
change at base 16,076 (C16,076A) in exon 4 predicting an amino acid change of to 
histidine at codon 92 (Figure 20).  Uniquely, in this case one allele carried a double 
mutation.  The P92H mutation is located in the FAD- binding lobe of cb5r while the 
E255- mutation is present in the carboxy-terminal NADH-binding domain.  
Consequently, 50% of cb5r synthesized would have mutations in both the prosthetic 
group- and the substrate binding lobes of the enzyme.  To investigate how the double 
mutation would impact on the function of cb5r, the P92H and E255- variants were 
synthesized individually and as a P92H/E255- double mutant using a heterozygous 
expression system. 
 The plasmid encoding either the wild-type or the variant forms of the soluble, 
diaphorase domain of rat cb5r, corresponding to residues I33 to F300, was used to 
transform E. coli BL21 (DE3)-RIL cells.  The cells were disrupted by sonication and the 
five (P92A/H, P95A/H, and P92H/E255-) cb5r variants were purified to homogeneity by 
a combination of metal-affinity chromatography and gel filtration FPLC as previously 
described [21].  Evaluation of the expression yield of the various P92 and 95 variants 
indicated that all the proteins were efficiently expressed with yields comparable to those 
obtained for the wild-type domain.  All five cb5r variants were purified to homogeneity as 
evident by the presence of single protein bands following SDS-PAGE analysis of the 
final FPLC fractions as shown in (Figure 21), which also confirmed molecular masses 
(Mr) of approximately 32 kDa for all five variants, identical to the wild-type cb5r.   
  UV/visible absorbance spectra were obtained for oxidized samples of the five 
  
 
 
 
 
                                                                        
                                               
 
Figure 20. Detection of the G255- and P92H Mutations in the DIAI Gene. 
Sequencing of exon 9 of the DIA1 gene revealed a heterozygous deletion of GAG from 
bases 27,100 to 27,102 (NT_011520) in the child (A) as indicated by arrow in 
chromatogram, when compared to the wild type sequence (B). In addition, a homozygous 
base change of C to A at nucleotide 16,076 was detected in exon 4 in the child (C) 
indicated by arrow in chromatogram when compared to normal sequence (D). Bases are 
as follows:  G = black; A = green; T = red; C = blue. 
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Figure 21. SDS-PAGE Analysis of the Different P92, P95 and E255 cb5r Variants. 
Samples (2 µg protein) obtained following isolation of wild-type cb5r (A), the P92A (B), 
P92H (C), P95A (D), P85H (E) and the P92H/E255- double mutant (F) were analyzed 
using a 12.5 % polyacrylamide gel as described in “Methods”. The outer lanes 
correspond to protein molecular weight markers with the indicated molecular masses 
(kDa). 
 
 
 
purified P92 and P95 variants and were compared with the spectra obtained for the 
corresponding wild-type domain in (Figure 22A).  The P92A and H and the P95A and H 
cb5r variants exhibited spectra identical to that of the wild-type domain that were   
characterized by and absorption maximum detected at 273 nm in the UV range of the 
spectrum, and a peak at 461 nm with an associated pronounced shoulder in the range of 
485-500 nm in the visible region of the spectrum, the latter peak attributable to protein- 
bound flavin.  The A273 nm/461 nm absorbance ratios of the P92 and P95 variants were 
within the range of 5.5 ± 0.2 which was comparable to values previously obtained for 
wild-type rat cb5r of 5.6 ± 0.2 [77], indicating a full complement of the FAD prosthetic 
group.  
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Figure 22. UV/Visible Absorption and CD Spectra of cb5r and the Various P92, P95 
and E255 Mutants. (A) UV/visible absorption spectra were obtained for oxidized 
samples of cb5r and the various P92, P95 and E255 mutants at equivalent flavin 
concentrations (1.7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 
7.0. The inset shows an expanded region of the visible spectrum where the flavin 
prosthetic group makes a major contribution. Individual spectra correspond to P92A ( ----
- ); P92H ( ….. ); P95A ( -.-.- ); P95H ( - - -); P92H/E255- (-..-..-) and wild-type cb5r ( 
____ );. (B) UV CD spectra were recorded using enzyme samples (7 µM FAD) in 10 mM 
phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible CD spectra were 
recorded using enzyme samples (50 µM FAD) in 10 mM phosphate buffer, containing 
0.1 mM EDTA, pH 7.0. Line styles shown in “B” and “C” are the same as those depicted 
in “A”. 
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 To assess any alterations in the secondary structural content of the different P92 
and P95 cb5r variants, circular dichroism spectra were recorded in the UV wavelength 
range (190-300 nm).  As shown in Figure 22B, all five P92 and P95 variants exhibited 
positive CD spectra from 190-210 nm and negative CD spectra from 210-250 nm with 
the spectra retaining both positive and negative intensities very similar to that of the wild-
type domain.  The absence of any significant differences between the spectra of various 
mutants and the wild type domain suggested conservation of the secondary structure 
architecture and that none of the amino acid substitutions or deletions had any substantial 
effects on the folding of the protein.  Visible CD spectroscopy was utilized to examine 
the environment of the FAD prosthetic group.  As shown in Figure 22C, all five variants 
generated exhibited visible CD spectra that were virtually indistinguishable from that of 
wild-type cb5r, indicating that none of the amino acid substitutions or deletions had any 
significant effect on the conformation of the bound FAD prosthetic group. 
 To examine the influence of the various amino acid substitutions on the stability 
of the resulting proteins, thermal denaturation profiles were generated for the P92A and 
H, P95A and H and P92H/E255- variants by measuring both changes in the intrinsic 
flavin fluorescence emission intensity (λex = 450 nm, λem = 523 nm) and retention of 
NADH:FR activity following incubation of the protein at temperatures ranging from 0-
100 °C (Figure 23).  Changes in the intrinsic fluorescence of the cofactor or the retention 
of NADH:FR activity following thermal denaturation was an effective indicator of the 
stability of the core structure of the protein.  T50 values (the temperature at which 50% of 
maximum fluorescence and 50% retention of NADH:FR activity was detected) ranged  
from a low of 41 °C for the P92H/E255- mutant to a high of 57 °C for the P92A variant. 
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These values can be compared to a T50 of 56 °C obtained for wild-type cb5r. 
 Initial-rate kinetic analyses were performed for the P92 and P95 cb5r variants to 
evaluate the effects of the various residue substitutions and deletions on both NADH and 
cytochrome b5 utilization.  Values derived for the various kinetic constants for both the 
NADH:FR and NADH:BR activities are given in Table 6.  The single variants of  P92A 
and H and P95A and H demonstrated a minor reduction in the overall catalytic efficiency 
compared to that of wild-type cb5r for both the NADH:FR and NADH:BR assays 
whereas in the P92H/E255- variant the kcat (s-1) was decreased four fold for each assay 
and the Km for NADH was increased 33 fold.  These results for the P92H/E255- variant 
correlated with the previously published data on the E255- mutant [79] indicating that a 
deletion of residue E255 in the carboxy terminus of cb5r significantly affects NADH 
substrate utilization. 
 To compare the interaction of the different P92 and P95 cb5r variants with either 
H4NAD or NAD+, differential spectroscopy was utilized to monitor complex formation.  
Examples of alterations of the flavin visible absorbance difference spectrum following 
nucleotide binding are shown in Figure 24.  The formation of spectrally-detectable 
complexes was observed for the diaphorase domain during titrations of the majority of  
the mutants with both H4NAD and NAD+.  For H4NAD, the tetrahydronicotinamide 
derivative did not function as a hydride donor when substituted for NADH in either the 
NADH:FR or NADH:BR assays but provided a valuable tool for estimating the binding 
affinity for NADH.  The H4-nucleotide is a close isosteric analog and is assumed to 
involve the same contacts at the active site as NADH, but lacks the positive charge on 
nicotinamide ring that is present on NAD+.  The spectral changes observed following 
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Figure 23. Thermal Stability Profiles for the Various P92, P95 and E255 cb5r 
Mutants.  Oxidized samples of the various P92, P95 and E255 variants (5 µM FAD) 
together with wild-type cb5r in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 
7.0, were incubated at the indicated temperatures, aliquots withdrawn and assayed for 
both residual NADH:FR activity (closed symbols) and intrinsic flavin fluorescence (open 
symbols), the latter using excitation and emission wavelengths of 450 nm and 523 nm, 
respectively. The plots correspond to, P92A (+, +; T50=55+1 oC), P92H (▲, U; 
T50=45+1 oC), P95A (▼, V, T50=47+1 oC), P95H (, , T50=46+1 oC), P92H/E255- 
(, , T50=42+1 oC) and wild type cb5r (z, {; T50=55+1 oC). NADH:FR activities are 
relative to a sample of each protein maintained at 0 oC. Excitation and emission spectra 
were scaled relative to that of a sample of free FAD (5 µM) which was assigned a 
fluorescence intensity of 100 %. 
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Table 6. Kinetic Constants Obtained for the Different P92 and P95 cb5r Mutants. 
 
 
NADH:FR activity NADH:BR activity  
kcat KmNADH KmFeCN6 kcat/KmNADH kcat Kmb5 kcat/Kmb5
Mutant (s-1) (µM) (µM) (s-1 M-1) (s-1) (µM) (s-1 M-1) 
cb5r  800 + 21     6 + 1     8 + 1 1.4 + 0.3 x 108 600 + 16   13 + 3 4.9 + 1.3 x 107
P92A 
P92H 
P95A 
P95H 
P95H/E255 
 
 458 + 7 
 571 + 6 
 420 + 9 
 367 + 6 
 190 + 15 
    9 + 1 
  12 + 1 
  12 + 1 
  28 + 1 
293 + 44 
 
    8 ± 1 
    7 ± 1 
    8 ± 1 
    7 ± 1 
    7 ± 1 
 
5.0 + 0.5 x 107
4.6 + 0.2 x 107 
3.7 + 0.4 x 107 
1.3 + 0.1 x 107 
7.5 + 1.8 x 105 
 
404 + 7 
470 + 12 
375 + 7 
275 + 8 
112 + 6 
 
  14 ± 1 
  15 ± 1 
  14 ± 1 
  13 ± 1 
  15 ± 1 
 
2.9 + 0.3 x 107
2.7 + 0.2 x 107 
2.1 + 0.2 x 107 
1.6 + 0.2 x 107 
7.5 + 0.9 x 106 
 
 
H4NAD binding were identical to those previously detected for the corresponding 
titrations of the rat enzyme and yielded positive absorbance changes with maxima at 421, 
449, and 481 nm and negative absorbance changes at 396, 466, and 497 nm, respectively.   
The value obtained for the spectroscopic binding constant (Ks), shown in Table 7, was 
comparable to that obtained from wild-type cb5r and indicated that H4NAD bound to the 
domain twelve times stronger than NAD+.  For the binding of NAD+, differential flavin 
spectra were observed for all of the variants with the exception of the P92H/E255- double 
mutant, which showed no detectable spectral changes at NAD+ concentrations up to 5 
mM.  In contrast, the remaining mutants exhibited spectral changes that were similar to 
those of the wild-type domain, with positive absorbance maxima at 407 nm and 509 nm 
and negative absorbance maxima at 456 nm and 487 nm respectively.  The Ks values 
(NAD+ µM) were comparable to that obtained for the rat domain for each of the single 
mutants. 
 To examine whether the thermodynamic properties of the flavin prosthetic group 
were similar to those of the corresponding wild-type domain, potentiometric titrations  
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Figure 24. Flavin difference spectra observed following binding of pyridine 
nucleotides to the different P92, P95 and E255- cb5r variants. Difference spectra were 
obtained for the various P92, P95 and E255 cb5r mutants at equivalent flavin 
concentrations (50 µM FAD) in 20 mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0 
following titrations with either H4NAD (left panels) or NAD+ (right panels) as described 
in “Methods”. (A and E) P92H; (B and F) P95H; (C and G) P92H/E255-; (D and H) wild-
type cb5r. The insert panels correspond to plots of the magnitudes of the observed 
spectral perturbations (peak to trough measurements at the indicated wavelengths) versus 
ligand concentration. The corresponding Ks values are given in Table 7. 
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Table 7.  Spectral Binding Constants Obtained for Wild Type cb5r and the P92A, 
P92H, P95A, P95H, and P92H/E255- Variants. 
 
 
Mutant Ks H4NAD 
(µM) 
KsNAD+
(µM) 
H4cb5r                 45 ± 10 760 ± 30
P92A                 58 ± 5 800 ± 40
P92H                 93 ± 5 764 ± 44
P95A                54 ± 4 594 ± 39
P95H               115 ± 8 1873 ± 230
P92H/E255-                   ND ND 
 
 
were performed using the dye equilibration method for the different P92, P95 and E255 
cb5r variants in the presence of phenosafranine (E°’ = -252mV) as an indicator.  Spectra 
obtained during a representative titration of the P92A mutant are shown in Figure 25.  
Qualitative analysis of the individual spectra obtained from the various titrations 
indicated that the majority of phenosafranine was reduced prior to FAD reduction in the 
majority of the cb5r variants, suggesting that the flavin midpoint potential was more 
negative than that of phenosafranine.  In contrast, the titration spectra obtained for the 
P92H variant suggested that the enzyme-bound flavin was reduced in tandem with the 
dye, indicating a positive shift in the potential for the flavin prosthetic group in the P92H 
variant.  The flavin redox potentials (n=2) for the different cb5r variants were determined 
from the Nernst semi-log plots, shown in Figure 25.  The standard midpoint potentials 
obtained for the FAD/FADH2 couple in the native enzyme (E°’= -272±5 mV) was 
comparable to values obtained for the P92A, P95A and P95H variants.  Estimates of the 
flavin potential in the P92H/E255- double mutant could not be obtained owing to the 
significant instability of the enzyme. 
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Figure 25. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group 
in the Different P92, P95 and E255 cb5r Variants. Reductive dye-equilibration 
titrations of the different P92, P95, E255 mutants and wild-type cb5r (40 M FAD) were 
performed as described under “Methods” in 100 mM phosphate buffer, containing 0.1 
mM EDTA, pH 7.0 in the presence of phenosafranine (15 M, Eo’=-252 mV) [Marohnic 
et al, 2003]. Individual spectra were collected at 2-3 min intervals during the time course 
of the titrations. A. Selected spectra obtained during the dye-mediated redox titration of 
the P92A variant in the presence of phenosafranine are shown. B. The corresponding 
Nernst plots are shown for the titrations of the various mutants and correspond to P92A 
(, Eo’=-278+5 mV), P92H (S, Eo’=-240+5 mV), P95A (, Eo’=-265+5 mV), P95H 
(▼, Eo’=-265+5 mV), P92H/E255- (Eo’=ND) and wild-type cb5r (z, Eo’=-272+5 mV). 
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Summary of the RCM Variants Pro92His and E255- 
 Our comparative biophysical studies of the P92H, P95H, and the P92H/E255- 
double mutant have yielded results that could be accurately predicted from the knowledge 
of the detailed structural organization of the enzyme.  Residues P92 and P95 are both 
members of a conserved “RxYTSxxSN” flavin-binding sequence motif that has been 
identified in all cb5r sequences deposited to date in addition to the other members of the 
FNR superfamily of flavoprotein transhydrogenases.  While the side-chains of P92 and 
P95 do not contribute any direct contacts to the flavin prosthetic group, in contrast to the 
side-chains of other motif members, such as R91 and Y93 that provide direct hydrogen-
bonding interactions with oxygen atoms that are part of the flavin pyrophosphate and 
ribityl moieties, respectively, P92 is involved in a back-bone hydrogen bond between the 
carbonyl oxygen and the oxygen atom of the ribityl C2 and participates in providing a 
portion of the hydrophobic network that is also important for flavin binding. 
 A multiple sequence alignment revealed that while P92 is not conserved in all the 
known cb5r primary structures, serine [22] and alanine [103] residues are the only known 
substitutions, it is present in thirty-three of the fifty-seven various sequences that have 
been deposited in Genbank for that portion of the polypeptide chain.  However, in 
contrast, P95 is conserved together with the other motif members, Y93 and T94. 
 The results of homology modeling studies, shown in Figure 26, illustrate the 
effects of the P92H and P95H substitutions on the respective protein structures.  In 
contrast to the orientation of the side chain of  P92 in the native enzyme, where the 
proline side-chain is oriented parallel to the dimethylbenzyl moiety of the flavin 
isoalloxazine ring (Figure 26), in the P92H variant, modeling suggests that the imidizole 
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side chain would be oriented directly towards the dimethylbenzyl ring producing a steric 
clash that could be alleviated by a modest displacement of the isoalloxazine ring into the 
solvent cleft between the flavin- and NADH- binding lobes.  This displacement would be 
expected to result in a decrease in the efficiency of substrate utilization, as shown by the 
ten-fold decrease in the P92H specificity constant, while the increased exposure of the 
isoalloxazine ring to solvent would be expected to result in an increase in redox potential 
of the flavin prosthetic group, towards that exhibited by free flavin (E°’ =-219 mV) [111], 
as shown by the +32 mV increase for the mutant compared to wild-type cb5r. 
 The modeling studies suggest that substitution of histidine for proline at residue 
95 would be expected to have only a modest impact on the functional properties of the 
enzyme.  P95 is situated at the C-terminal end of  β-strand Fβ4 which is part of a six-
stranded antiparallel β-barrel that comprises the flavin binding lobe.  The proline amide 
nitrogen is located 6.1 Å distant from the N5 of the isoalloxazine ring and the side chain 
is oriented away from the flavin prosthetic group.  While the histidine substitution at 
residue 95 would not be expected to have any significant impact on the properties of the 
flavin, as confirmed by the absence of any changes in redox potential, the decrease in 
activity and increase in the Km for NADH may be due to small local changes in the 
folding of the polypeptide backbone. 
 In contrast to P92 and P95, which are part of a well established flavin-binding 
motif, E255 does not comprise part of a specific sequence motif of defined function and 
is located within a relatively non-conserved sequence region.  E255 is a solvent- 
accessible surface residue located at the amino terminus of a short α-helical segment (H7) 
that participates in correctly orienting the carboxyl-terminal portion of the protein that 
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Figure 26. Structural Models of the P92H and P95H cb5r Variants. A. The structures 
of the P92H and P95H variants were modeled using SWISS-MODEL [101] and are 
shown superimposed on the X-ray structure of wild-type cb5r (PDB=1IB0). The 
structures are shown as “ribbon” models with the P92H shown in blue, the P95H in red 
and the wild-type cb5r in yellow. Deviations (RMS) between the P92H and P95H models 
and the wild-type structure corresponded to 0.96 Ao and 0.97 Ao, respectively. The FAD 
prosthetic group and complexed NAD+ in the wild-type structure are shown in “stick” 
configuration with “CPK” coloring. B. An enlarged view of the superimposed structures 
in the region of the flavin prosthetic group showing the P92H and P95 substitutions. C. A 
portion of the superimposed P92H and wild-type structures showing a “ribbon” diagram 
of the region of the sequence between residues R91 and S97, corresponding to the 
“RxYTSxxSN” conserved motif, together with the sidechains of the wild-type proline, the 
mutant histidine and the FAD prosthetic group. D. As for “C”, except the sidechains of 
P95 and the histidine substitution are shown. 
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contains the “CGxxxM” motif and which is critical to NADH/NAD+-binding.  Thirty-two 
of the fifty-seven cb5r sequences deposited in Genbank share a glutamate at this position 
while another eighteen retain an aspartate residue.  The three base pair deletion of the 
codon corresponding to E255 would be anticipated to have a substantial impact on the 
interaction of cb5r with either NADH or NAD+, since the carboxy-terminal portion of the 
protein is primarily involved in interactions with the reducing substrate.  Removal of any 
residue prior to and in close proximity to the conserved “273CGxxxM278” motif, which 
provides a number of critical contacts for the reducing substrate, would significantly 
decrease substrate affinity, by as much as two-orders of magnitude, as has been 
previously shown [79] for the discrete E255- variant.  In addition, the resulting incorrect 
orientation of the bound substrate would reduce the catalytic efficiency by over 50%.  
Thus, combining the effects of P92H on the properties of the flavin prosthetic group with 
the results of the E255 deletion on substrate affinity and utilization would be anticipated 
to significantly impact enzyme functionality, as evident by the 103 decrease in the 
specificity constant (kcat/KmNADH) for the P92H/E255- double mutant. 
 
The role of the FAD/FMN specificity binding motif “124GRxxST127” 
Within the cb5r primary structure is a four residue sequence motif 124GRxxST127 
which, through the analysis of structural and sequence alignments within the flavoprotein 
transhydrogenase family, has demonstrated a high level of conservation.  A primary 
feature of this motif is the proposed regulation of FAD or FMN cofactor specificity [5].  
This specificity is  potentially regulated by residue 124 where, in the majority of FNR 
family members, including cytochrome b5 reductase, FAD is incorporated as the cofactor 
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and contains the motif “GxxST” whereas those members of the FNR family that utilize 
FMN, such as aniline dioxygen reductase, exhibit the “RxxST” motif.  This motif is 
located within the only α-helix in the flavin-binding domain of cytochrome b5 reductase 
known to be directly involved with correct binding and orientation of the flavin prosthetic 
group (Figure 27B).  In viewing the ligand binding plot for cytochrome b5 reductase and 
FAD- binding (Figure 27A)  the importance of each amino acid within the “GRxxST” motif 
is demonstrated with residue G124 having a hydrophobic interaction and residues K125, 
M126, and S127 all forming a backbone hydrogen bond with the pyrophosphate moiety 
of the FAD- prosthetic group.  Thus, it can be theorized that any mutations introduced 
into this motif could result in perturbations of the flavin environment and disruption of 
correct flavin binding and orientation.  This was previously demonstrated by Bewley et 
al. [80] in the type II methemoglobinemia variant S127P, which was the first RCM 
variant structure to be solved by X-ray crystallography and revealed that a mutation 
within the FAD-binding domain can lead to alterations in the NADH substrate binding 
behavior.  The X-ray structure of S127P revealed that the ADP moiety of the FAD- 
cofactor was displaced into the corresponding ADP substrate binding site, thus inhibiting 
efficient substrate binding.  This phenomenon has been referred to as “flavin flexibility”.      
A second observation in the S127P crystal structure related to the amino acid 
residue K125.  K125 has been demonstrated to be a critical residue within the GxxST 
motif in that the backbone nitrogen of K125 forms a hydrogen bond contact with the 
adenine moiety of FAD, through an ionic interaction K125 forms contacts in binding 
between the active sites of cytochrome b5 reductase and cytochrome b5 [112] , and K125 
comprises part of a 13 residue (F113 – K125) surface exposed loop region which is part 
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Figure 27. Structural Representation Displaying the 124GRxxST127 Motif by the FAD 
Cofactor Ligand Binding Plot and Secondary Structure of Wild-Type Cytochrome 
b5 Reductase.   (A) LIGPLOT [99] of 1IB0.  C, O, N, S, and P atoms are represented as 
white, blue, red, yellow, and violet spheres, respectively, while covalent bonds are green 
sticks within FAD and blue sticks within amino acid residues of the FAD-binding lobe.  
Hydrogen bonds are drawn as dashed lines with the distances between atoms labeled.  
Residues contributing to hydrophobic interactions are represented as arcs with rays and 
colored blue.  Panel (B) is a WirPlot rendering of rat cytochrome b5 reductase with 
corresponding labels for secondary structures pertaining to the NADH-binding domain 
(blue), the FAD-binding domain (red), and also the “hinge” region (green) for 
completion.  The location of the “124GRxxST127” motif is highlighted in red.    
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of the amino terminal flavin binding lobe which form a “lid” structure capping a portion 
of the cleft between the FAD- and NADH- binding domains.  In the crystal structure of 
the S127P variant this region underwent a conformational change and was displaced by 
6Å and led to perturbations in the adenine binding pocket and pyrophosphate binding site 
of the flavin prosthetic group demonstrating the importance of proper conformation of the 
“lid” structure. 
 Residue M126 of cytochrome b5 reductase forms a hydrogen bond with the 
backbone nitrogen and the O1P of the FMN pyrophosphate moiety of the FAD- cofactor.  
Previous clinical information diagnosed a patient possessing the mutation of M126V, 
corresponding to a A→G transversion of codon 126 (ATG→GTG), as a mutation capable 
of giving rise to type II methemoglobinemia.  However, this patient was compound 
heterozygous and a second mutation in the DIA1 gene revealed the presence of an 
intronic A→G (ISV4-2A→G) alteration which lead to the skipping of exon 5 [84].  
Biochemical characterization of the M126V variant by Davis [40] has recently 
established that the mutation introduced by M126V would only result in type I 
methemoglobinemia and the type II RCM observed in the patient was direct result of the 
intronic alteration leading to the skipping of exon 5 or a combination of the two 
mutations.  Through a direct hydrogen bond of the M126 nitrogen backbone with the 
pyrophosphate of the FMN moiety of the FAD- prosthetic group the M126 residue is 
believed to be a key residue in maintaining the integrity of the FAD binding pocket 
together with residues R91 and S127P [76].  The introduction of a valine substitution at 
residue 126 did not exemplify this.  However, both methionine and valine are non-polar 
and neutral amino acids, thus, the replacement of methionine to valine would be a 
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conservative mutation and more extensive and non-conservative mutations would need to 
be introduced in order to gain a full understanding of the role of the M126 residue and its 
interaction with the FAD- cofactor. 
 In order to fully elucidate the role of each residue in the “124GRxxST” motif, a 
different approach was directed towards each of the residues, based on their biochemical 
properties within cytochrome b5 reductase.  As mentioned, FAD/FMN specificity is  
proposed to be regulated by residue 124 through a G to R substitution.  To properly 
examine the effects of flavin binding and specificity on residue G124, a mutation of 
G124R was generated along with G124A, G124H and G124K, corresponding to a 
conservative uncharged control substitution and two other positively charged residues, 
respectively.  In the case of the K125 residue, specific  charge reversal variants, K125D 
and K125E, and a control mutation, K125A, were introduced to establish the effects of 
charge in relation to correct flavin binding and orientation as well as the ionic interaction 
of cytochrome b5 reductase - cytochrome b5 binding.  Finally, for the M126 residue, a 
series of variants were created which corresponded to amino acids that have been 
demonstrated to occur within other members of the FNR superfamily and included: 
M126C/F/G/P/S. 
 
Characterization of G124A/H/K/R and K125A/D/E                               
 Mutant constructs encoding for the variants G124A/H/K/R and K125A/D/E 
corresponding to the introduction of a positive charge at position 124 and charge reversal 
of residue 125, respectively, were generated through site-directed mutagenesis as 
described in “Methods and Materials” utilizing the original four-histidine tagged 
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cytochrome b5 reductase expression construct and the corresponding oligonucleotide 
primers listed in Table 1.  Nucleotide sequencing in both directions confirmed the correct 
sequence and proper introduction of each mutation, and each variant was further 
expressed in the E. coli strain BL21 (DE3)-RIL and purified to homogeneity via Ni-NTA 
agarose chromatography and size exclusion FPLC.  Expression yields for each of the 
variants were comparable to that of wild-type cytochrome b5 reductase and all were 
yellow in color indicating the stability of each mutant generated and stable incorporation 
of the flavin prosthetic group.  Purification to homogeneity was further confirmed by 
SDS-PAGE analysis as demonstrated by the appearance of single protein bands, which 
displayed molecular masses comparable to that of wild-type cytochrome b5 reductase (Mr 
= 31 kDa).   
UV/visible absorption spectra were obtained for oxidized samples of wild type 
cytochrome b5 reductase and each of the variants generated and are shown in Figure 28A.  
Each of the variants displayed an absorption spectra comparable to that of the wild-type 
domain by an aromatic absorption maxima at 272 nm in the UV region and peaks in the 
visible region at 386, 460, and a pronounced shoulder at 485 nm, all characteristic of 
simple flavoproteins.  This initial data suggested that none of the variants generated had 
any significant effects on the spectroscopic properties of the flavin prosthetic group.  In 
order to establish the effects of each mutation upon the secondary structure of the 
oxidized protein, far UV CD spectra were recorded in the range of 190–300 nm for each 
variant and wild-type cytochrome b5 reductase.  As shown in Figure 28B spectra of all of 
the G124 and K125 mutants correlated well to the wild-type domain by displaying 
positive CD maxima at 196 nm and negative maxima at 222 nm, indicating that the  
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Figure 28.  Ultra-Violet and Visible Absorbance, and Circular Dichroism of Wild-
Type, G124A, G124H, G124K, G124R, K125A, K125D, and K125E Cytochrome b5 
Reductases.  (A) Oxidized samples of wild-type and mutant cb5rs (10 µM), (B) (7 µM), 
and (C) (60 µM) FAD in 10 mM phosphate with 0.1 mM EDTA, pH 7.0 buffer.  The 
inset shows and expanded region of the visible spectrum where the flavin cofactor makes 
a significant contribution.  Individual spectra correspond to (____) H4cb5r; (____ ____) 
G124A; (__ __ __) G124H; (_ _ _ _) G124K; (. . . . .) G124R; (__.__.__) K125A; (__. .__. .__) 
K125D; and (______) K125E.  
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mutations introduced had no effect on the overall global folding of the protein.  In 
contrast, the visible CD spectra obtained displayed perturbations for each variant showing 
that the introduction of a positive charge at residue 124 and the charge reversal of K125 
resulted in alterations in the environment of the FAD- cofactor.  As illustrated in Figure 
28C, the spectra for the G124 variants each displayed an increased intensity within the 
region of 310-370 nm with the line shape of G124H and G124K showing a reversed 
polarity.  Each of the G124 variants also showed an alteration in the 460-485 nm region 
with a slight blue shift for each mutation indicating a change in the hydrophilicity of the 
flavin environment [77].  For the K125 variants, K125A only displayed a minor 
perturbance with a minor blue shift in the 450-485 nm region, whereas the K125D and 
K125E variants showed a significant alteration with a decreased intensity in the region of 
350-410 nm in addition to a minor alteration in line shape from 470-485 nm.  These 
findings are not unexpected since all of the mutations introduced are involved with either 
a hydrophobic or electrostatic interaction with the FAD cofactor. 
 To analyze the overall protein stability of each of the variants, thermal 
denaturation profiles were generated utilizing thermal NADH:FR profiling in tandem 
with the loss of  intrinsic flavin fluorescence emission quenching, following incubation of 
the proteins at temperatures ranging from 0-100 ºC.  Changes in the intrinsic fluorescence 
of the FAD prosthetic group monitored together with the retention of NADH:FR activity 
following thermal denaturation yielded a T50 value, the temperature at which there is 50% 
of maximum fluorescence or 50% retention of NADH:FR activity.  T50 values obtained 
are represented in Figure 29.  All G124 variants demonstrated decreased temperature 
stabilities with T50 values of 47, 49, and 50 ºC for the G124R, G124A/K, and G124H 
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variants, respectively, while each of the K125 mutations yielded T50 values of 53 and 56 
ºC for the K125E and K125A/D variants, comparable to the wild-type cytochrome b5 
reductase T50  of 55 ºC.  These results indicated that the introduction of a charge reversal 
mutation at residue K125 did not significantly affect the thermostability of the protein in 
regards to flavin binding, whereas the introduction of a positive charge at residue 124 
resulted in a lowered T50 value with G124R causing the most dramatic decrease to 47 ºC.  
Thus, the substitution of G124 with the positively charged arginine, lysine, and histidine 
has a more significant effect on the overall protein stability indicating the most altered 
flavin environment in regards to binding and orientation. 
 In order to determine how the G124 and K125 variants affected the overall 
catalytic efficiency, initial-rate kinetic analyses were performed as described in “Methods 
and Materials”.  Kinetic values obtained from these assays are reported in Table 9.  As 
expected, all of the generated variants resulted in a decreased specific activity when 
compared to wild-type cytochrome b5 reductase.  For the NADH:FR assays the catalytic 
efficiencies, kcat/KmNADH, for the G124A, G124H, G124K, and G124R variants were 
determined to be only 1.2 to 2.6% that of the catalytic efficiency of the wild-type domain.  
These results were due to both a dramatic increase in the KmNADH and decrease in the kcat, 
indicating that the introduction of a positive charge at position 124 leads to a decreased 
affinity for the NADH substrate resulting in decreased turnover, possibly due to the 
displacement of the FAD cofactor.  Likewise, the K125 charge reversal variants, K125D 
and K125E displayed a significant increase in the Km NADH, however, only a modest 
decrease in kcat was observed for each variant, showing that turnover was not significantly 
perturbed in these variants upon substrate binding.  Results for the NADH:BR assays also 
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Figure 29.  Temperature Stability of Wild-Type cb5r and the G124A, G124H, 
G124K, G124R, K125A, K125D, and K125E Mutants.  Oxidized samples of G124A, 
G124H, G124K, G124R, K125A, K125D, K125E, and wild-type H4cb5r (5 µM FAD) 
were incubated at the indicated temperatures, and aliquots were withdrawn and assayed 
for both residual NADH:FR activity (closed symbols) and intrinsic flavin fluorescence 
(open symbols) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0 using 
excitation and emission wavelengths of 450 nm and 523 nm, respectively.  Points 
correspond to: (●,○) H4cb5r; (■, □) G124A; (▲, ∆) G124H; (▼, ) G124K; (♦, ◊) 
G124R; (hexagon) K125A; (●●●●) K125D; and (+) K125E.   
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Table 8.  T50 Values of the Wild-Type Cytochrome b5 Reductase, G124A, G124H, 
G124K, G124R, K125A, K125D, and K125E Variants. 
 
 
Mutant T50
(°C) 
H4cb5r 55 
G124A 49 
G124H 50 
G124K 49 
G124R 47 
K125A 56 
K125D 56 
K125E 53 
 
 
 
 
 
Table 9.  NADH:FR and NADH:BR Kinetic Constants Obtained for G124A, 
G124H, G124K, G124R, K125A, K125D, K125E, and Wild-Type cb5rs. 
 
Mutant NADH:FR NADH:BR 
 kcat          KmNADH   KmFeCN6    kcat/KmNADH
(s-1)       (µM)       (µM)      (s-1 M-1) 
kcat          KmNADH  KmCyt b5      kcat/KmCytb5 
(s-1)       (µM)      (µM)        (s-1 M-1) 
H4cb5r 
G124A 
G124H 
G124K 
G124R 
K125A 
K125D 
K125E 
800 ± 21          6 ± 1        8 ± 1      1.4 ± 0.3 x 108 
355 ± 33      226 ± 30      7 ± 1      1.6 ± 0.4 x 106 
185 ± 4          55 ± 3        8 ± 1      3.4 ± 0.3 x 106 
145 ± 5          88 ± 6        8 ± 1      1.7 ± 0.2 x 106 
260 ± 10      115 ± 1        7 ± 1      2.3 ± 0.3 x 106 
871 ± 16        27 ± 1        8 ± 1      3.3 ± 0.3 x 107 
697 ± 16        20 ± 2        8 ± 1      3.4 ± 0.4 x 107 
658 ± 30      423 ± 1        8 ± 1      1.6 ± 0.2 x 106
600 ± 10      2 ± 1        13 ± 1        4.7 ± 0.5 x 107 
226 ± 12      4 ± 1        19 ± 0.3     1.2 ± 0.2 x 107 
160 ± 15      5 ± 1          9 ± 2        1.8 ± 0.4 x 107 
259 ± 22      3 ± 1        21 ± 3        1.2 ± 0.3 x 107 
321 ± 15      3 ± 1        18 ± 2        1.8 ± 0.3 x 107 
  55 ± 2        2 ± 1        15 ± 1        3.7 ± 0.5 x 106 
308 ± 12      4 ± 1        56 ± 9        5.6 ± 1.1 x 106 
   89 ± 9       5 ± 1        82 ± 12      1.1 ± 0.3 x 106
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correlated well to what we had hypothesized.  As mentioned, K125 is not only involved 
in a electrostatic interaction with the pyrophosphate moiety of the flavin prosthetic group 
but is also one of the critical positively-charged lysine residues that are involved in the 
charge pairing ionic interaction in cytochrome b5 reductase-cytochrome b5 complex 
formation.  The effects of the K125 charge reversal variants are reflected in the kcat/Km 
values retaining only 2, 8, and 12% of wild-type cb5r efficiency for the K125E, K125A, 
and K125D variants, respectively.  The results shown in the decreased catalytic 
efficiencies for the K125 variants are best reflected in the increased Kmcb5 leading to the 
significant decrease in kcat.  Correlating well with the values obtained for the NADH:FR 
activities, overall catalytic efficiencies ranged between 26 to 38% of wild-type 
cytochrome b5 reductase for each of the G124 variants which was only due to a decrease 
in the kcat values while the Km values for cytochrome b5 binding were unaffected.  This 
was to be expected since residue G124 is not involved in the cytochrome b5 reductase-
cytochrome b5 binding interaction so that the lowered catalytic efficiencies observed for 
the G124 variants was the direct result of the decreased affinity for NADH. 
 As demonstrated through the kinetic analyses, each of the G124 and K125 
variants displayed a decreased affinity for the NADH substrate.  Therefore, spectral 
binding constants were determined for each of the mutants utilizing differential 
spectroscopy in order to compare the affinities for both the substrate NADH and product 
NAD+.  As described in “Methods”, the NADH isosteric analog H4NAD was utilized to 
monitor complex formation and establish a spectral binding constant [85].  Differential 
spectroscopy was utilized to monitor complex formation during titrations with either 
H4NAD or NAD+ and is illustrated in Figure 30 and Figure 31.  The G124 variant 
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titrations performed in the presence of H4NAD yielded spectra with a line shape similar 
to that of wild-type cytochrome b5 reductase (Figure 30) with a negative maxima at 395 
nm and a shifted positive maxima at 495 nm compared to the wild-type spectra 
possessing positive maxima spectra at 410, 450, 480, and 515 nm and negative maxima at 
395 and 500 nm.  In contrast to the similar complex formation observed for the analog 
H4NAD, all titrations performed for the G124 variants in the presence of the product 
NAD+ produced a spectra more comparable to the spectral changes observed in the 
H4NAD titrations (Figure 31).  The values obtained for the respective binding constants 
(Ks) for all G124 variants are given in Table 10.  Interestingly, the Ks values obtained for 
the G124A, G124H, G124K, and G124R variants in the presence of H4NAD were 23, 14, 
46, and 31µM, respectively, compared to the wild-type cb5r value of 45µM, indicating a 
mode of binding comparable to or more efficient that the  wild-type domain.  Much of the 
same effect was witnessed in the titrations carried out in the presence of NAD+ with the 
G124 variants, yielding Ks values of 534, 436, 794, 651µM, respectively, all being lower 
or comparable to the wild-type value of 760µM.  With regard to the K125 charge reversal 
variants, both K125A and K125D displayed differential spectra for H4NAD comparable 
to that of wild-type cytochrome b5 reductase.  Titrations performed in the presence of 
H4NAD generated spectra with positive maxima at 410, 450, 480, and 515 nm, and 
negative maxima at 395 and 500 nm.  However, the K125E variant displayed only minor 
spectroscopic changes, suggesting an altered affinity for H4NAD.  This data was 
confirmed in the determination of the spectral binding constants for the K125A, K125D, 
and K125E variants yielding Ks values of 76, 65, and 380µM, respectively, demonstrating 
a slightly altered binding affinity for the K125A and K125D mutations while the 
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Figure 30.  Spectroscopic Titrations of H4cb5r, G124A, G124H, G124K, G124R, 
K125A, K125D, and K125E cb5rs with H4NAD.  Titrations of all mutants (50mM) were 
carried out as previously described in 10mM phosphate buffer containing 0.1mM EDTA, 
pH 7.0 at 23 °C.  Difference spectra were recorded following the addition of solution 
containing H4NAD (30µM).  The inset panel corresponds to a plot of the magnitude of 
the spectral perturbations at the indicated wavelengths versus pyridine nucleotide 
concentration where a difference spectrum was observed.  Plots of the relative 
absorbance changes observed are as follows: (A) H4cb5r; (B) G124A; (C) G124H; (D) 
G124K; (E) K125R; (F) K125A; (G) K125D; and (H) K125E. 
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Figure 31.  Spectroscopic Titrations of H4cb5r, G124A, G124H, G124K, G124R, 
K125A, K125D, and K125E cb5rs with NAD+.  Titrations of all mutants (50mM) were 
carried out as previously described in 10mM phosphate buffer containing 0.1mM EDTA, 
pH 7.0 at 23 °C.  Difference spectra were recorded following the addition of solution 
containing NAD+ (30µM).  The inset panel corresponds to a plot of the magnitude of the 
spectral perturbations at the indicated wavelengths versus pyridine nucleotide 
concentration where a difference spectrum was observed.  Plots of the relative 
absorbance changes observed are as follows: (A) H4cb5r; (B) G124A; (C) G124H; (D) 
G124K; (E) K125R; (F) K125A; (G) K125D; and (H) K125E. 
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Table 10.  Spectral Binding Constants Obtained for Wild Type cb5r and the G124A, 
G124H, G124K, G124R, K125A, K125D, and K125E Variants. 
 
 
Mutant Ks H4NAD 
(µM) 
KsNAD+
(µM) 
cb5r                   45 ± 10                760 ± 30 
G124A                  23 ± 2               534 ± 84 
G124H                  14 ± 2               436 ± 57 
G124K                  46 ± 7               994 ± 113
G124R                  31 ± 6               651 ± 121
K125A                  76 ± 11               451 ± 70 
K125D                  65 ± 8               820 ± 86 
K125E                380 ± 60             1182 ± 142
 
 
introduction of the K125E variant displayed a binding constant 8-fold greater than that of 
the wild-type domain.  Similar behavior was observed for the differential spectra 
generated in the titrations performed with the product NAD+.  Again, the K125A and 
K125D variants displayed differential spectra comparable to wild-type cytochrome b5 
reductase, with positive maxima at 410 and 510nm, and negative maxima 430, 460, and 
490nm.  This indicated that the K125A and K125D variants exhibited similar complex 
formation upon the binding of NAD+.  However, the differential spectra generated from 
the K125E variant with NAD+ displayed absorbance change magnitudes which were 
greatly reduced indicating a decreased binding affinity.  The Ks values reported in Table 
10 agreed well with the differential spectra obtained in that the kinetic binding constants 
increased on the order of 451, 820, and 1183µM for the K125A, K125D, and K125E 
variants, respectively, compared to the value of 760µM for wild-type cytochrome b5 
reductase.  
Based on the data and structural modeling of the G124 and K125 variants we  
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hypothesized that the mutations introduced would lead to alterations within the flavin 
environment of the enzyme.  To examine the effects of these predicted structural changes 
on the flavin prosthetic group of each variant, oxidation-reduction potentials for the FAD 
cofactor were determined utilizing the dye-equilibration potentiometric titration method 
for wild-type cytochrome b5 reductase and the G124 and K125 mutants in the presence of 
phenosafranine (E°′= -252 mV).  Flavin midpoint potentials (Eº′, n=2) for the 
FAD/FADH2 couple were determined both in the absence and presence of NAD+ from 
the linear Nernst plots of the log [FADox/FADred] versus the potential (mV) and are 
shown in Figure 32.  Values established for all redox potentials are shown in Table 11.  
Analysis of the midpoint potentials of the G124 variants in the absence of any pyridine 
nucleotide indicated that FAD reduction occurred after the reduction of phenosafranine 
which is represented by a positive shift in the midpoint potential values obtained 
corresponding to -252 mV for the G124K variant and -260 mV for the G124A, G124H, 
and G124R variants compared to the standard midpoint potential of -272 mV for 
cytochrome b5 reductase.  Correlating well with the standard redox potentials, midpoint 
titrations carried out in the presence of NAD+ all displayed a more negative shift in the 
redox behavior for each of the G124 variants yielding values of -222, -219, -209, and -
227 mV for the G124A, G124H, G124K, and G124R variants, respectively.  These values 
obtained in the presence of NAD+ are similar to the reported value of -220 mV for that of 
free flavin [95].  Another interesting aspect of the xanthine oxidase titrations for all of the 
G124 variants with NAD+ was observed in the analysis of the slopes of each Nenrst plot.  
The Nernst plot for cytochrome b5 reductase oxidation- reduction reaction in the presence 
of NAD+ yielded a slope of -30mV, representative of a n=2, two- electron reduction. 
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Figure 32.  Potentiometric Titrations of the G124A, G124H, G124K, G124R, K125A, 
K125D, K125E and Wild-Type Cytochrome b5 reductases.  Reductive dye titrations 
were performed at 25 °C as described in “Materials and Methods” using phenosafranine 
as the indicator dye in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0.  
Nernst plots in the absence (A) and presence (B) of 2 mM NAD+.  Plots correspond to (●) 
H4cb5r; (■) G124A; (▲) G124H; (▼) G124K; (♦) G124R; (hexagon) K125A; (. . . . .) 
K125D; and (+) K125E.   
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Table 11.  Flavin Midpoint Potentials (E°′)  Obtained for Wild-Type, G124A, 
G124H, G124K, G124R, K125A, K125D, and K125E cb5rs. 
 
 
E°′ FAD/FADH2
(mV) 
Slope 
(mV) 
E°′ FAD/FADH2
(mV) 
Slope 
(mV) 
Enzyme 
-NAD+ +NAD+
cb5r 
G124A 
G124H 
G124K 
G124R 
K125A 
K125D 
K125E 
-272                       -30 
-260                       -30 
-260                       -30 
-252                       -30 
-260                       -30 
-272                       -30 
-286                       -20 
-270                       -30 
-190                       -30 
-222                       -10 
-219                       -15 
-209                       -20 
-227                       -10 
-201                       -38 
-200                       -30 
-220                       -42 
 
 
However, the slopes obtained for the G124 variants all displayed a shift ranging between 
10 to 20mV slopes as shown in Figure 32.  The negative potential shifts displayed for the 
G124 mutants in the presence of NAD+, the alterations in the slopes, and negative 
potentials in the absence of product indicated that the introduction of a positive charge 
resulted in a structural displacement of the FAD cofactor leading to a destabilization of 
substrate binding and inhibition of efficient electron transfer from the NADH substrate to 
the flavin prosthetic group. 
In contrast to the results obtained for the G124 variants, the K125 mutations 
exhibited a different behavior.  In the absence of NAD+, the standard redox potentials and 
Nernst plot slopes obtained were all comparable to the wild-type domain with standard 
redox potential values of -272, -282, and -270mV for the K125A, K125D, and K125E 
variants, respectively, with slopes of 30mV.  In the presence of NAD+ however, both the 
K125A and K125D exhibited midpoint potentials with only a minor shift compared to the 
potential for wild-type cytochrome b5 reductase yielding potential values of -201 and -
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200 mV, respectively.  The slopes derived for each mutant were also comparable to the    
-30 mV slope of the wild type domain   A more dramatic shift was observed for the 
K125E variant with a midpoint potential of -220 mV which is in agreement of the Km 
value obtained in the NADH:FR assay for this variant indicating that the low affinity for 
NADH also had an effect on the efficiency of electron transfer represented by the 
midpoint potential in the presence of NAD+.  The alteration in the mode of electron 
transfer for K125E was also exemplified by a slope of -42 mV which is similar to that of 
an n=1 system represented by a slope of -60 mV.  These results provided evidence that 
the conformation change introduced into the flavin environment caused by the charge 
reversal variant K125E results in a decrease in the efficiency of electron transfer from the 
NADH substrate to the FAD cofactor. 
 
Characterization of the amino acid residue M126 
 In order to establish the molecular basis of the disease methemoglobinemia for the 
previously characterized RCM variant M126V [40], five more variants were generated to 
complement the M126V analysis.  The variants were chosen based on residues that 
naturally occur at position 126 in other members of the ferredoxin:NADP+ reductase 
superfamily and corresponded to M126C, M126F, M126G, M126P, and M126S.  It was 
hypothesized that alterations of the M126 residue would lead to a conformational 
disruption of the flavin environment due to the hydrogen bonding of the M126 backbone 
with the AMP phosphate moiety of the FAD cofactor, possibly resulting in the 
displacement of the flavin prosthetic group into the substrate binding cleft as observed in 
the type II methemoglobinemia variant S127P. 
 100
 The M126 variants were generated through site-directed mutagenesis of the rat 
H4CB5R expression construct as described in “Methods”.  Dideoxy sequencing in both 
directions confirmed the identity of each mutant construct.  The generated variants were 
subsequently expressed in the E. coli strain BL21 (DE3)-RILP and purified by Ni-NTA 
metal chelate chromatography and size exclusion gel filtration FPLC.  All five variants 
were purified to homogeneity as demonstrated by the appearance of single protein bands 
with a molecular mass of 31 kDa following SDS-PAGE (Figure 33) 
 Representative UV/visible absorption spectra were obtained for oxidized samples 
of wild-type cytochrome b5 reductase and each of the M126 variants (Figure 34A).  The 
spectra for each mutant was comparable to that of the wild-type domain with an aromatic 
absorption maxima at 270 nm in the UV region of the spectrum, and peaks at 385, 461, 
and a pronounced shoulder at 485-500 nm in the visible region all being signature peaks 
of protein-bound flavin.  Further examination of the global folding of the polypeptide 
backbone and the environment of flavin prosthetic group was carried out for each M126 
variant and wild-type cytochrome b5 reductase using UV and visible CD spectroscopy, 
respectively (Figure 34 B and Figure 34C).  All of the M126 variants displayed spectra in 
the UV range (Figure 34B) that were representative of the wild-type domain, displaying a 
positive CD maxima at 196 nm and negative maxima at 222 nm demonstrating that the α- 
helix and β-sheet architecture of the protein were not affected by the M126 mutations.  
Alternatively, in the visible range of the CD spectra, only the M126C variant retained  
visible CD spectra that was identical to wild-type cytochrome b5 reductase with positive 
CD maxima at 310 and 390 nm and negative maxima at 460 and 485 nm and followed an 
identical line shape.  Although the M126F variant displayed both negative and positive 
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Figure 33.  SDS Poly-Acrylamide Gel Electrophoresis of Wild-Type, M126C, 
M126F, M126G, M126P, M126S, and M126V Cytochrome b5 Reductases.  2µg each 
of purified enzyme samples were resolved on a 15% polyacrylamide gel.  M126V was 
utilized as a positive control in the M126 series of variants.  Lanes correspond to (S) 
protein molecular weight markers labeled accordingly (kDa); (A) H4cb5r; (B) M126C; 
(C) M126F; (D) M126G; (E) M126P; (F) M126S; (G) M126V. 
 
 
CD maxima comparable to the wild-type domain as well as a similar line shape a minor 
alteration in the flavin environment was observed with a blue-shift in the450-500 nm 
region.  A more significant perturbation in the flavin environment was observed for the 
M126S, M126G, and M126P mutants in that the intensity of the M126S and M126G 
spectra was diminished within the region of 400-500 nm while the M126P variant yielded 
a reversed polarity, as shown in Figure 34C.  Similar observations were witnessed in 
previous studies of the S127P [80] and R91 [76] variants where the AMP moiety of the 
FAD cofactor was displaced into the AMP pocket of the NADH-substrate binding site, a 
term referred to as “flavin flexibility”.  These results are not unexpected since M126 
occupies a positively charged FAD cofactor binding pocket with both the amino acid 
residues S127 and R91. 
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Figure 34.  Ultra-Violet and Visible Absorbance, and Circular Dichroism Spectra of 
Wild-Type, M126C, M126F, M126G, M126P, and M126S Cytochrome b5 
Reductases.  (A) Oxidized samples of wild-type and mutant cb5rs (10 µM), (B) (7 µM), 
and (C) (60 µM) FAD in 10 mM phosphate with 0.1 mM EDTA, pH 7.0 buffer.  The 
inset shows and expanded region of the visible spectrum where the flavin cofactor makes 
a significant contribution.  Individual spectra correspond to (____) H4cb5r; (____ ____) 
M126C; (__ __ __) M126F; (_ _ _ _) M126G; (. . . . .) M126P; and (__.__.__) M126S.  
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 To examine the effects of the M126 variants on catalytic function, initial rate 
kinetic analyses were carried out for NADH:FR and NADH:BR assays and correlated 
well with the data obtained from the circular dichroism spectra.  Values obtained for kcat 
and KmNADH are represented in Table 12.  NADH catalytic efficiencies, kcat/KmNADH, for 
the M126 variants decreased in the order of M126F>M126C>M126S>M126G>M126P 
with each retaining 24, 18, 7, 6 and <1%, respectively, of wild-type cytochrome b5 
reductase activity.  The effects of the perturbations upon the flavin environment seen in 
the visible CD spectra are represented well within the Km values established in the 
NADH:FR assays for the M126S, M126G, and M126P variants yielding KmNADH values 
of 62, 72, and 751 µM, respectively.  With respect to the NADH:BR assays, the catalytic 
efficiencies were all reduced in the order of WT 
cb5r>M126>M126F>M126S>M126G>M126P with only the kcat being affected with the 
exception of M126P having a Km 46µM compared to the wild-type value of 13µM.   
 Differential spectroscopy was utilized to determine if the effects observed in the 
spectral and kinetic analyses of the M126 variants were reflected in substrate utilization 
through monitoring complex formations during titrations with the NADH-substrate 
isoteric analog H4NAD or product NAD+ (shown in Figure 35 and Figure 36).  In the 
titrations performed with H4NAD the Ks values, shown in Table 13, all decreased on the 
order of WT cb5r>M126F>M126C>M126S>M126G.  A value for M126P was not able to 
be established and no spectroscopic changes were observed even upon the titration with 
1mM H4NAD.  In addition to the decreased affinity displayed in the Ks values, the 
M126C variant was the only mutation that retained the identical spectroscopic complex 
formation like that of wild-type cytochrome b5 reductase with a positive maxima at 410,       
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Table 12.  NADH:FR and NADH:BR Kinetic Constants Obtained for M126C, 
M126F, M126G, M126P, and M126S. 
 
Mutant NADH:FR NADH:BR 
 kcat          KmNADH   KmFeCN6    kcat/KmNADH
(s-1)       (µM)       (µM)      (s-1 M-1) 
kcat          KmNADH  KmCyt b5      kcat/KmCytb5
(s-1)       (µM)      (µM)        (s-1 M-1) 
H4cb5r 
M126C 
M126F 
M126G 
M126P 
M126S 
800 ± 21          6 ± 1        8 ± 1      1.4 ± 0.3 x 108 
641 ± 16        27 ± 2        7 ± 1      2.4 ± 0.3 x 107 
531 ± 13        18 ± 2        7 ± 1      3.1 ± 0.4 x 107 
550 ± 21        72 ± 6        7 ± 1      7.7 ± 0.9 x 106 
  46 ± 3        751 ± 66      8 ± 1      6.2 ± 0.9 x 104 
527 ± 13        62 ± 4        7 ± 1      8.6 ± 0.7 x 106
600 ± 10       2 ± 1       13 ± 1        4.7 ± 0.5 x 107 
444 ± 24       3 ± 1       15 ± 2        2.9 ± 0.5 x 107 
384 ± 26       3 ± 1       15 ± 2        2.7 ± 0.6 x 107 
443 ± 43       2 ± 1       26 ± 4        1.8 ± 0.5 x 107 
  54 ± 7         5 ± 1       46 ± 5        1.2 ± 0.3 x 106 
386 ± 37       4 ± 1       19 ± 1        2.1 ± 0.6 x 107
 
 
450, 480, and 515 nm, and negative maxima at 395 and 500 nm.  In contrast, the 
introduction of a phenylalanine mutation generated a spectra that corresponded to a 
complex formed in the titration performed in the presence of NAD+ with a positive 
maxima of 410 and 510 nm and negative maxima at 430, 460, and 485 nm.  Correlating 
with the perturbations observed in the decreased visible CD spectra of the flavin 
environment, spectral changes for the M126G and M126S variants demonstrated an 
altered complex formation with positive maxima at 400 and 500 nm and negative 
maxima begin represented by a negative maxima between 410 and 490 nm.  Unlike the 
altered complex formations observed for the titrations carried out in the presence of 
H4NAD, the spectral changes observed for the differential spectroscopy in the presence 
of NAD+ yielded positive maxima at 410 and 510 nm and negative maxima at 430, 460, 
and 485 nm, identical to that of wild-type cytochrome b5 reductase.  Values for the 
titrations carried out in the presence of NAD+ are listed in Table 13.  Ks values obtained  
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Figure 35.  Spectroscopic Titrations of H4cb5r, M126C, M126F, M126G, M126P, 
and M126S cb5rs with H4NAD.  Titrations of all mutants (50mM) were carried out as 
previously described in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at 23 
°C.  Difference spectra were recorded following the addition of solution containing 
H4NAD (30µM).  The inset panel corresponds to a plot of the magnitude of the spectral 
perturbations at the indicated wavelengths versus pyridine nucleotide concentration 
where a difference spectrum was observed.  Plots of the relative absorbance changes 
observed are as follows: (A) H4cb5r; (B) M126C; (C) M126F; (D) M126G; (E) M126P; 
and (F) M126S. 
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Figure 36.  Spectroscopic Titrations of H4cb5r, M126C, M126F, M126G, M126P, 
and M126S cb5rs with NAD+.  Titrations of all mutants (50mM) were carried out as 
previously described in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at 23 
°C.  Difference spectra were recorded following the addition of solution containing 
NAD+ (30µM).  The inset panel corresponds to a plot of the magnitude of the spectral 
perturbations at the indicated wavelengths versus pyridine nucleotide concentration 
where a difference spectrum was observed.  Plots of the relative absorbance changes 
observed are as follows: (A) H4cb5r; (B) M126C; (C) M126F; (D) M126G; (E) M126P; 
and (F) M126S. 
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with NAD+ correlated exactly with the Ks values for H4NAD with the spectroscopic 
binding constants showing a decreased affinity in the order of WT 
cb5r>M126F>M126C>M126S>M126S>M126G>M126P, with no appreciable value 
obtained again for the M126P variant even upon the addition of up to 5mM NAD+, a 
concentration ~8-fold greater than that for wild-type cytochrome b5 reductase. These 
results indicate that the conformational changes in the environment of the flavin 
prosthetic group result in a decreased affinity for both H4NAD and NAD+ providing 
evidence for a potential role for the M126 residue in catalysis. 
 Thermal denaturation profiles were also obtained for wild-type cytochrome b5 
reductase and the M126 variants and are shown in Figure 37.  The T50 values shown in 
Table 14 clearly demonstrate a direct correlation with the subsequent data shown thus far.  
The effect of the mutation upon the flavin environment with a decrease in catalytic 
efficiency, reduced substrate binding affinity, and perturbed visible CD spectra for the 
M126 variants is also reflected in a decreased thermostability when compared to the 
wild-type cytochrome b5 reductase T50 value of 55 ºC.  The M126 variant T50 values 
decreased in the order of 52, 51, 47, 45, and 44 ºC for the M126F, M126C, M126S, 
M126P, and M126G mutants, respectively.  The decrease in thermostability demonstrated 
that the degree at which there is a disruption in the environment of the flavin prosthetic 
group directly correlated to the stability of the protein. 
 Finally, to asses the effects of the conformational disruptions of the flavin 
environment upon the flavin reduction potential, oxidation-reduction potentials for the 
FAD prosthetic group were established using the dye equilibration method both in the 
presence and absence of NAD+ (shown in Figure 38).  The standard redox potential (Eº′) 
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Table 13.  Spectral Binding Constants Obtained for Wild Type cb5r and the M126C, 
M126F, M126G, M126P, and M126S Variants. 
 
Mutant Ks H4NAD 
(µM) 
KsNAD+
(µM) 
H4cb5r            45 ± 10         760 ± 30 
M126C          139 ± 13       1071 ± 32 
M126F            66 ± 1         781 ± 15 
M126G          242 ± 9       4216 ± 139 
M126P              ND             ND 
M126S          214 ± 6       2966 ± 109 
 
 
for the FAD/FADH2 couple was derived from the Nernst plot and values obtained are 
listed in Table 15.  Both the M126C and M126F variants exhibited a midpoint potential 
comparable to that of the wild-type domain (-272 mV) with values of -270 and -274 mV 
and a slope of -30 mV, representative of an n=2 reaction, respectively, and indicating that 
the substitution of cysteine or phenylalanine at position 126 had no significant effect on 
the standard redox potential.  However, the flavin redox behavior exhibited a more 
dramatic shift for the M126S, M126G, and M126P variants all yielding midpoint 
potentials of -258 mV although a slope of -30 mV was observed for each mutant.  This 
variation can be attributed to the alterations within the FAD cofactor environment 
observed in the preceding data.  Flavin midpoint potentials performed in the presence of 
NAD+ were all dissimilar compared to the value obtained for wild-type cytochrome b5 
reductase (-190 mV), yielding potentials of -206, -180, -198, -209, and -220 mV for the 
M126C, M126F, M126G, M126S, and M126P variants, respectively.  Each variant with 
the exception of the M126P mutant displayed potentials comparable to that of  
   
 
Temperature (OC)
0 10 20 30 40 50 60 70 80 90 100
%
 R
es
id
ua
l A
ct
iv
ity
 (N
A
D
H
:F
R
)
0
25
50
75
100
Fl
ou
re
sc
en
ce
 In
te
ns
ity
 %
0
25
50
75
100
 
 
 
Figure 37.  Temperature Stability of cb5r and the M126C, M126F, M126G, M126P, 
and M126S Mutants.  Oxidized samples of M126C, M126F, M126G, M126P, M126S, 
and wild-type H4cb5r (5 µM FAD) were incubated at the indicated temperatures, and 
aliquots were withdrawn and assayed for both residual NADH:FR activity (closed 
symbols) and intrinsic flavin fluorescence (open symbols) in 10 mM phosphate buffer, 
containing 0.1 mM EDTA, pH 7.0 using excitation and emission wavelengths of 450 nm 
and 523 nm, respectively.  Points correspond to: (●,○) H4cb5r; (■, □) M126C; (▲, ∆) 
M126F; (▼, ) M126G; (♦, ◊) M126P; and (+) M126S.   
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Table 14.  T50 Values of the Wild-Type Cytochrome b5 Reductase, M126C, M126F, 
M126G, M126P, and M126S Variants. 
 
Mutant T50 (º C) 
H4cb5r 55 
M126C 51 
M126F 52 
M126G 44 
M126P 45 
M126S 47 
 
 
cytochrome b5 reductase demonstrating the introduction of the nonpolar bulky side chain 
of proline resulted in a greater perturbation of the flavin environment.  Interestingly, the 
slope derived for each variant in the presence of NAD+ also differed when compared to 
the wild-type domain, producing slopes of -60 mV for the M126C, M126F, and M126G 
mutants and -42 and -45 mV for the M126P and M126S variants, respectively, which 
were indicative of an n=1 reaction.   
              
Summary of the “124GRxxST127” Motif                 
Overall, these results provide direct evidence to support the importance of the 
“124GRxxST127” motif for proper FAD cofactor incorporation and orientation.  Residues 
G124, K125, M126, and S127 are all located in the N-terminal portion of α-helix FαA, 
the only α-helix found within the FAD binding domain of cytochrome b5 reductase.  Each 
residue also forms a structural framework for the proper positioning of the flavin  
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Figure 38.  Potentiometric Titrations of the M126C, M126F, M126G, M126P, 
M126S, and Wild-Type Cytochrome b5 Reductases.  Reductive dye titrations were 
performed at 25 °C as described in “Materials and Methods” using phenosafranine as the 
indicator dye in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0.  Nernst 
plots in the absence (A) and presence (B) of 2 mM NAD+.  Plots correspond to (●) 
H4cb5r; (■) M126C; (▲)M126F; (▼) M126G; (♦) M126P;  and (+) M126S.   
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Table 15.  Flavin Midpoint Potentials (E°′) Obtained for M126C, M126F, M126G, 
M126P, M126S, and Wild-Type Cytochrome b5 Reductases. 
 
E°′ FAD/FADH2
(mV) 
Slope 
(mV) 
E°′ FAD/FADH2
(mV) 
Slope 
(mV) 
Enzyme 
-NAD+ +NAD+
H4cb5r 
M126C 
M126F 
M126G 
M126P 
M126S 
-272                       -30 
-270                       -30 
-274                       -30 
-258                       -30 
-258                       -30 
-258                       -30 
-190                       -30 
-206                       -60 
-190                       -60 
-198                       -60 
-209                       -42 
-220                       -45 
 
prosthetic group via a hydrophobic interaction with G124 and electrostatic interactions of 
the backbone nitrogen of K125, M126, and S127 with the AO2, O1P, and O2P of the  
FAD pyrophosphate moiety, respectively (shown in Figure 27A).  Of the four residues, 
S127 also possessed a side chain hydrogen bond with the FAD cofactor from the OG of 
S127 to the O2P pyrophosphate moiety of FAD.  Detailed analysis has demonstrated the 
importance of the S127 residue through the crystal structure of the type II RCM mutant 
S127P [80].  The introduction of a proline at position 127 leads to the displacement of the 
ADP moiety of the FAD cofactor into the corresponding ADP binding site of the NADH-
binding domain.  Through this displacement, the FAD- cofactor acts as an effective 
substrate inhibitor.  This suggested that any other mutations introduced into the GRxxST 
motif would also lead to an alteration in the flavin environment causing the displacement 
of the flavin prosthetic group and result in a significant decrease in the overall catalytic 
efficiency of the protein. 
 The initial evidence that suggested that each of the residues within the “GRxxST” 
motif was involved in maintaining proper flavin incorporation was obtained from the 
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circular dichroism studies.  Results from the spectra obtained in the far-UV region of the 
CD (190-300 nm) indicated that none of the mutations introduced had any significant 
effect on the overall global folding of the protein.  However, the spectra displayed in the 
near-visible region representing the environment of the flavin prosthetic group showed 
significant perturbations.  For the G124 and K125 variants, alterations were more 
prominent within the region of 300-400 nm and all displayed a blue-shift at 450-485 nm, 
representative of an alteration in the hydrophilicity of the flavin environment.  For the 
M126 variants, minor perturbations were observed as a blue-shift for the M126C and 
M126F mutants, whereas the M126S, M126G, and M126P variants all displayed a 
decrease in spectral intensity from the region of 400-500 nm which was in good 
agreement with the spectra previously published for the R91 and S127P variants [76, 80].  
This indicated that the mutations introduced at position 126 not only led to an alteration 
of the flavin environment but also to a possible displacement of the FAD- cofactor.  This 
can be attributed to the fact that, as mentioned, the M126 residue is located in the only α-
helical segment in the FAD- binding domain and it has been shown that the introduction 
of a glycine mutation into an α-helix can result in a change in the backbone structure 
through the removal of any side chain, while the introduction of a proline generates a 
kink in the backbone of an α-helix. 
 The perturbations observed in the visible CD spectra were all in good agreement 
with the results obtained for the kinetic and thermodynamic properties of the various 
mutants.  Comparisons of the overall catalytic efficiencies revealed that the decreased 
turnover was directly attributable to the reduced affinity, (Km), for the nucleotide NADH.  
This was in good agreement with the kinetic results obtained for the S127P variant which 
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displayed a Km value 9-fold greater than that of wild-type cytochrome b5 reductase.  As 
anticipated the results obtained from the NADH:BR assays demonstrated that the 
mutations introduced at the G124 and M126 residues had little to no effect on the Kmcb5, 
whereas the charge reversal variants K125D and K125E showed a significant decrease in 
their overall catalytic efficiency.  These results were in good agreement with previously 
published studies that had defined K125 as one of four positively-charged lysine residues 
that were involved in an ionic interaction with cytochrome b5 [112].   
 For the G124 variants, differential binding constants, (Ks), provided unexpected 
results in regards to substrate binding affinity based on the increased Km values obtained 
from the NADH:FR assay.  In the titrations performed with the substrate analog H4NAD, 
all differential spectra displayed a line shape similar to that of wild-type cytochrome b5 
reductase, however, spectral binding constants derived from each spectra were lower than 
that of  wild-type cytochrome b5 reductase showing an enhanced binding affinity for each 
G124 variant.  In the titrations that utilized NAD+, the spectral binding constants for the 
G124 mutants followed similar trends; in which all but G124K yielded  Ks values lower 
than that of the wild-type domain.  However, the differential spectra displayed for each 
variant were representative of the line shape observed in the presence of H4NAD.  These 
results indicated an altered mode of binding for the product, NAD+ that was a direct 
result of the perturbations generated by the G124 variants within the environment of the 
flavin prosthetic group.  It can also be concluded that the decrease in the Ks values is not 
indicative of enhanced binding of H4NAD and NAD+ but rather that, the disruptions of 
the flavin environment prevent efficient substrate disassociation.  The results for the 
differential spectroscopy were as expected for the K125 and M126 series of variants 
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where each displayed a decreased binding affinity which was in direct agreement with the 
Km values obtained for the activity assays. 
 The predicted alterations of the FAD environment were also evident by the 
perturbations detected in the oxidation-reduction potentials of the FAD/FADH2 couple 
both in the absence and presence of NAD+.  Each of the G124 variants displayed a 
positive shift in the flavin redox potential in the absence of NAD+ and a negative shift in 
the presence of NAD+.  A slope of -30 mV was also obtained for each of the G124 Nernst 
plots which was similar to that determined for the wild-type cytochrome b5 reductase 
oxidation-reduction potential, indicating a similar n=2 electron transfer process.  
However, the slopes derived from the Nernst plots in the presence of NAD+ were 
severely compromised for the G124 series yielding slope of -10, -12, -15, and -20 mV for 
the G124A, G124R, G124H, and G124K variants respectively.  In contrast, the midpoint 
potentials obtained for the K125A, K125D, and K125E variants were all comparable to 
that of wild-type cytochrome b5 reductase with the exception of K125E which yielded a 
midpoint potential of -200 mV in the presence of NAD+.  Finally, the results from the 
M126 series of mutants yielded oxidation-reduction potentials directly correlated with the 
kinetic and thermodynamic data already obtained for the M126 variants. The M126 
variants catalytic efficiencies, thermostability, visible-CD, and differential binding 
constants all decreased in the order of M126C and M126F being comparable to the wild-
type domain and then followed by M126S>M126G>M126P for each biophysical 
parameter.  This trend was also observed for the standard oxidation-reduction potentials 
of each mutant, with M126C and M126F generating potentials comparable to wild-type 
cytochrome b5 reductase and a positive shift observed in the titrations performed in the 
 116
absence of NAD+ for M126S, M126G, and M126P.  Data obtained for the M126G 
mutant did not conform to this pattern yielding a potential in the presence of NAD+ of -
198 mV while the M126S and M126P displayed potentials of -210 and -220 mV, 
respectively.  The midpoint potentials obtained were most likely a direct result of the 
perturbations of the flavin environment and reflect potential displacement of the adenine 
moiety of the flavin prosthetic group as suggested by the visible-CD spectra.  These 
observations, in conjunction with the poor substrate affinity, as demonstrated by the 
initial rate kinetic analyses, would result in a highly unfavorable electron transfer and 
flavin reduction process.          
           
Analysis of the effects of the RCM variant M272- and generated variants 
M272A/I/L/R on the CGxxxM motif. 
 Within the cb5r primary structure, several sequence motifs have been identified 
that are involved in either flavin binding (“91RxYTSxxSN97”) or FAD/FMN specificity 
(“124GRXXST127”) or function in modulating reduced pyridine nucleotide binding 
(“180GxGxxP185” and “273CGxxxM278”). The second of the conserved motifs that are 
involved in regulating pyridine nucleotide affinity, corresponds to a six amino acid 
“273CGpppM278” motif that comprises the residues C273 to M278 in the carboxyl-
terminal lobe of rat cb5r (Figure 40). Preceding this motif in the sequences of the majority 
of higher eukaryote cb5r’s is a conserved methionine residue, M272, that has been 
previously identified as absent in a patient with type II RCM [81]. 
 High resolution X-ray structures have been obtained for the soluble forms of rat 
[12], human [28], and pig [113] cb5r. Within the rat cb5r diaphorase domain (PDB 
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ID=1I7P), M272 has been shown to be located at the terminus of the strand Nβ4 together 
with the conserved “essential” cysteine residue, C273. This strand is part of a five-
stranded anti-parallel β-barrel structure which contains a canonical Rossman fold and 
comprises the pyridine nucleotide-binding lobe (residues K172 to F300) [12].  
Analysis of the structure of the diaphorase domain complexed with NAD+ (PDB 
ID=1IB0) has revealed that while M272 provides no direct electrostatic or hydrogen bond 
contacts with either the nicotinamide or ribose moieties of the bound NAD+, the 
subsequent residues, corresponding to C273 to M278, form a loop connecting Nβ4 with 
the final α helical ‘return’ in the NADH binding domain and provide an extensive 
framework of  hydrophobic contacts that are involved in binding the reducing substrate 
and specifically orienting the nicotinamide portion of the reduced pyridine nucleotide for 
subsequent efficient hydride transfer to the FAD prosthetic group. Within the “CGxxxM” 
motif, the conserved glycine, corresponding to G274, forms two critical hydrogen bonds.  
To probe the role of M272 in cb5r structure and function and to examine the effects of 
deleting this residue as previously identified in the type II methemoglobinemia variant, 
we utilized site-directed mutagenesis as a tool to either delete the methionine residue at 
position 272 in the rat cb5r diaphorase domain or substitute the methionine with the 
amino acid residues, A, I, L and R.  Residues that have been shown to commonly occur at 
the equivalent position within other members of the FNR superfamily.  Subsequently, we 
primarily examined the effects of these deletions and substitutions on the spectroscopic 
and thermodynamic properties of the FAD prosthetic group and the interactions the 
mutant with the physiological reductant, NADH. 
 Mutant constructs encoding the five different cb5r variants, M272-, A, I, L and R, 
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Figure 39. Multiple Sequence Alignment of cb5r Primary Structures. (A) Selected 
eukaryotic cb5r amino acid sequences were retrieved from GenBank, aligned using the 
ClustalX algorithm [108] and the alignment optimized for maximum sequence 
conservation. Only the portions of the sequences surrounding the conserved pyridine 
nucleotide-binding “273CGPPPM278” motif (underlined) are shown for clarity. Beginning 
and ending residue numbers within the translated GenBank sequences are indicated by 
superscripts while the methionine residue corresponding to M272 in R. norvegicus cb5r is 
shown in bold face. The consensus sequence is also shown below with identical residues 
indicated by “*” and similar residues indicated by “:”. 
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   SPECIES       SEQUENCE    
H. sapiens      267EPLVLMCGPPPMIQYAC283  
P. troglodytes    EPLVLMCGPPPMIQYAP  
M. mulatta        EPLVLMCGPPPMIQYAC  
M. fascicularis   EPLVLMCGPPPMIQYAC  
B. tauros         EPLVLMCGPPPMIQYAC  
S. scrufa         EPLVLMCGPPPMIQYAC  
C. familiaris   267EPLILMCGPPPMIQYAC283  
R. norvegicus   267ETLILMCGPPPMIQFAC283  
M. musculus       EPLILMCGPPPMIQFAC  
G. gallus         DVLILMCGPPPMIQYAC  
X. laevis         DVLILMCGPPPMVQYAI  
F. rubripes       DTLILMCGPPPMIQFAC  
T. nigroviridis   DTLILMCGPPPMIQFAC  
D. rerio          DSMILMCGPPPMIQFAC  
X. tropicalis     DVVVLMCGPPPMIQFAC  
M. domestica      DTMILMCGPPPMIQFAC  
C. briggsae       DSAVLMCGPPPMINFAC  
A. mellifera      DTMVLMCGPPPMINFAC  
A. gambiae        NSLVLMCGPPPMVNYAC  
L. major          KVMALMCGPPPMVQMAI  
C. neoformans     GHKVLMCGPPPMITAMK  
D. discoideum     QTMVIMCGPPMMNKAMT  
C. elegans        DSAVLLCGPPPMINFAC  
D. melanogaster   DTIVLLCGPPPMINFAC  
C. albicans       DTNLLLCGPPPMVSAMK  
D. hansenii       ATNLLLCGPPPMISAMK  
Y. lipolytica     NTKLLLCGPPPMISALK  
N. crassa         DVKILLCGPPPMISGLK  
E. gossypii       SAQLLLCGPPPMVSSAK  
M. alpina         DIKVLLCGPPPMVSAMS  
G. zeae           DSKVFLCGPPGMVNASK  
P. falciparum     DTLILLCGPPPMTSSIK  
C. glabrata       DVQLLVCGPPGMVSSVK  
K. lactis         GVQLLVCGPPPMVSSIK  
C. maxima         DALILVCGPPGMMKHIC  
T. brucei         KAILLVCGPPGFMKTIS  
S. pombe          ETKVLICGPTPMVNSLR  
S. japonicum      DTITLICGPPPFIEFAC  
S. cerevisiae     NVQILICGPPAMVASVR  
V. fordii         DIQILRCGPPPMNKAMA  
N. tabacum        DIQILRCGPPPMNKAMA  
A. thaliana       DIQILRCGPPPMNKAMA  
Z. mays           DIQILRCGPPPMNKAMA  
O. sativa         DIQILRCGPPPMNKAMA  
C. comosus        DIQILRCGPPPMNKAMA  
 A 
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Figure 40.  Graphical Sequence Alignment and Structural Representation of Amino 
Acid Residue M272.  (A) Graphical representation (sequence logo) of the amino acid 
residues present at positions 267 to 283 in the primary sequences of 55 cb5r sequences 
deposited in GenBank. The logo consists of stacks of symbols (one stack for each 
position in the sequence) with the overall height of the stack indicating the sequence 
conservation at that position and the height of the symbols within the stack indicating the 
relative frequency of each amino acid at that position. (B) Schematic diagram of a portion 
of the R. norvegicus cb5r X-ray structure (PDB=1IB0) showing the arrangements of the 
amino acids that comprise the sequence region containing the conserved “273CGxxxM278” 
motif and residue M272 that precedes the motif. Amino acid residues are shown in 
“stick” representation using the CPK color scheme while the appropriate portion of the 
peptide backbone, corresponding to residues I270 to C283, is displayed as a ribbon 
diagram. The location of the FAD prosthetic group and complexed NAD+ are also shown 
in “stick” representation using the CPK color scheme. 
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the latter corresponds to the most frequently encountered amino acid residues occurring 
at positions equivalent to M272 in the various cb5r sequences identified in GenBank and 
also within other members of the FNR superfamily of pyridine nucleotide-dependent 
flavoprotein transhydrogenases, were generated through directed mutagenesis of the 
original four-histidine tagged cb5r expression construct. Nucleotide sequencing 
confirmed the fidelity of each construct and each of the mutant proteins was subsequently 
expressed in the E. coli strain BL21(DE3)-RIL and purified to homogeneity by a 
combination of Ni-chelate chromatography and gel filtration FPLC. Evaluation of the 
expression yields of the various mutants indicated that the different M272 variants were 
expressed at levels comparable to that of the wild-type domain, with the exception of 
M272L which was obtained in significantly decreased yield (approximately 30% of wild-
type), suggesting decreased stability. All five M272 variants were purified to apparent 
homogeneity as evident by the presence of single protein bands following SDS-PAGE 
analysis of the different mutants as shown in Figure 41, which also indicated molecular 
masses comparable to that of the native enzyme (Mr approx. 32 kDa). 
 The oxidized forms of all five purified M272 variants were yellow in color 
indicating the incorporation of a flavin prosthetic group and confirming that M272 did 
not provide any backbone or side-chain contacts that were essential for protein folding 
and the stable incorporation of the flavin prosthetic group. 
 UV/visible absorbance spectra were obtained for oxidized samples of each mutant 
and wild-type cb5r and are compared in Figure 42A. The M272-, M272A, M272I, M272L 
and M272R variants each exhibited absorption spectra comparable to that of the wild- 
type enzyme with an aromatic absorption maximum detected at 272 nm in the UV region 
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Figure 41. SDS-PAGE Analysis of the Different M272 cb5r Variants. Samples  of the 
different M272 variants (2 µg each) and wild-type cb5r, obtained from the terminal FPLC 
purification step, were resolved on a 12.5% polyacrylamide gel : Lane A, wild-type cb5r; 
lane B, M272-; lane C, M272A; lane D, M272I; lane E, M272L; lane F, M272R.  The 
arrows indicate the positions of selected molecular weight markers with the indicated 
molecular masses (kDa).   
 
of the spectrum, and a peak at 461 nm with a associated pronounced shoulder in the range 
of 485-500 nm in the visible region of the spectrum, attributable to protein-bound flavin. 
None of the visible spectra of any of the M272 variants were blue- or red-shifted with 
respect that of the wild-type protein, as has been previously demonstrated for mutations 
of other residues, such as R91 and Y93 [77] [76], suggesting that none of the M272 
substitutions or its deletion had any significant influence on the spectroscopic properties 
of the FAD prosthetic group. Blue shifts in the visible absorbance spectra of flavoproteins 
have previously been attributed to changes in the hydrophilicity of the flavin environment 
near the N(5) locus of the isoalloxazine ring [114] [115] while red shifts have been 
observed for other mutants such as the previously characterized T94H. 
 To assess the secondary structural content of each of the M272 variants, CD  
spectra were recorded in the UV wavelength range (190-300 nm). As shown in Figure 
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Figure 42. UV/Visible Absorption and CD Spectra of cb5r and the Various M272 
Mutants. (A) UV/visible absorption spectra were obtained for oxidized samples of the 
various G272 mutants together with wild-type cb5r at equivalent flavin concentrations 
(1.7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. The inset 
shows an expanded region of the visible spectrum where the flavin prosthetic group 
makes a major contribution. (B) UV CD spectra were recorded using enzyme samples (7 
µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible 
CD spectra were recorded using enzyme samples (50 µM FAD) in 10 mM phosphate 
buffer, containing 0.1 mM EDTA, pH 7.0. Individual spectra correspond to; M272- (___ 
___ ___); M272A (__ __ __);  M272I (- - - -), M272L (. . . . .); M272R (__.__.__) and wild-type 
cb5r( _____ ). 
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42B, all of the cb5r variants exhibited positive CD from 190-210 nm and negative CD 
from 210-250 nm with all the spectra retaining both positive and negative intensities very 
similar to that of the wild-type domain. The absence of any significant differences 
between the UV CD spectra of the wild-type and mutant proteins suggested conservation 
of the overall secondary structure architecture and that none of the M272 residue 
substitutions or its deletion had any deleterious effects on the global folding of the 
diaphorase domain. 
 To examine the influence of the various M272 residue substitutions or deletion on 
the stabilities of the resulting proteins, thermal denaturation profiles were generated for 
the various mutant forms and compared with those obtained for wild-type cb5r and are 
shown in Figure 43. Alterations in both the intrinsic flavin fluorescence emission 
intensity (λem=523 nm) and retention of NADH:FR activity following incubation of the 
proteins at temperatures ranging from 0–100 °C were monitored. Changes in the intrinsic 
fluorescence of the cofactor or the retention of NADH:FR activity following thermal 
denaturation has been shown to be an effective indicator of the stability of the core 
structure of the protein. The various T50 values, the temperature at which 50% of 
maximum fluorescence or 50% retention of NADH:FR activity was detected, increased in 
the order M272R < M272A < M272- < WT < M272L < M272I, with all variants 
exhibiting T50 values in the range between 46 and 57 °C, which suggested that none of 
the substitutions had a dramatic effect on the thermal stability of flavin binding with the 
exception of the M272R variant. The M272I and L variants exhibited T50 values of 
approximately 57 °C, in good agreement with the value of 55 °C obtained for wild-type 
cb5r. The deletion (M272-) and A variants exhibited slightly decreased T50 values of 51 
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Figure 43. Thermal Stability Profiles for the Various M272 cb5r Mutants.  Oxidized 
samples of the various M272 variants together with wild-type cb5r (5 µM FAD) were 
incubated at the indicated temperatures and aliquots were withdrawn and assayed for both 
residual NADH:FR activity and intrinsic flavin fluorescence in 10 mM phosphate buffer, 
containing 0.1 mM EDTA, pH 7.0, the latter using excitation and emission wavelengths 
of 450 nm and 523 nm, respectively. The plots correspond to M272- (, ); M272A 
(U,▲); M272I (▼, V); M272L (, ); M272R (+, +) and wild type cb5r (z,{). 
NADH:FR activities were scaled relative to a sample of each protein that had been 
maintained at 0 oC while intrinsic flavin fluorescence was scaled to a sample of free FAD 
(5 µM) which was assigned a fluorescence intensity of 100%. 
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°C and 50 °C respectively, while the R mutation caused a decrease to 47 °C, indicating 
the most altered structure. These results suggested that the majority of the M272 
substitutions had only modest effects on the thermal stability of the different cb5r 
variants. 
 Initial-rate kinetic analyses were performed on all five cb5r M272 variants to 
evaluate the effects of the various residue substitutions on NADH utilization. Values 
derived for kcat and Km for both NADH:BR and NADH:FR activities of the various 
mutants are given in Table 16, together with the corresponding values obtained for wild-
type cb5r. 
With the exception of the M272L variant which retained 84% of wild-type activity with a 
corresponding two-fold decrease in affinity for NADH, the remaining four variants 
exhibited both substantially decreased NADH:FR activities together with either modest 
or substantial decreases NADH affinities with the M272- variant showing the most 
dramatic changes. NADH catalytic efficiencies, as indicated by kcat/KmNADH, were 
observed to decrease in the order WT > M272L = M272I > M272A > M272R > M272- 
with the latter variant retaining a level of NADH:FR efficiency that was five orders of 
magnitude less than that of the wild type protein. Of the five M272 variants, both the 
deletion mutant and the M272R variant were determined to have the lowest affinities for 
NADH.  
 To confirm that substitution or deletion of the M272 residue primarily affected 
the protein’s affinity for either the physiological reducing substrate NADH, or the 
product of the redox half-reaction, NAD+, we utilized differential spectroscopy of the 
flavin cofactor absorbance to determine spectroscopic binding constants, Ks, for the 
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Table 16.  Comparison of the Kinetic Constants Obtained for Wild-Type 
Cytochrome b5 Reductase, M272-, M272A, M272I, M272L, and M272R. 
 
Mutant NADH:FR NADH:BR 
 kcat          KmNADH   KmFeCN6    kcat/KmNADH
(s-1)       (µM)       (µM)      (s-1 M-1) 
kcat          KmNADH  KmCyt b5      kcat/KmCytb5
(s-1)       (µM)      (µM)        (s-1 M-1) 
H4cb5r 
M272- 
M272A 
M272I 
M272L 
M272R 
800 ± 21         6 ± 1         8 ± 1      1.4 ± 0.3 x 108 
         0.4 ± 0.1       70 ± 11       7 ± 1      5.9 ± 1.2 
x 103 
406 ± 11       11 ± 1         8 ± 1      3.7 ± 0.6 x 107 
503 ± 10         9 ± 1         8 ± 1      5.5 ± 0.6 x 107 
670 ± 5         12 ± 1         7 ± 1      5.5 ± 0.2 x 106 
478 ± 13         6 ± 1         8 ± 1      1.4 ± 0.3 x 106
600 ± 10       2 ± 1       13 ± 1        4.7 ± 0.5 x 107 
444 ± 24       3 ± 1       15 ± 2        2.9 ± 0.5 x 107 
384 ± 26       3 ± 1       15 ± 2        2.7 ± 0.6 x 107 
443 ± 43       2 ± 1       26 ± 4        1.8 ± 0.5 x 107 
  54 ± 7         5 ± 1       46 ± 5        1.2 ± 0.3 x 106 
386 ± 37       4 ± 1       19 ± 1        2.1 ± 0.6 x 107
 
 
NADH- analog, H4NAD and  NAD+ (Figure 44). Changes in the FAD absorption 
spectrum following binding of H4NAD to the respective proteins were observed for the 
M272L, M272I and M272A variants, however, no spectroscopic changes were detected 
for either the M272- or M272R variants, suggesting substantially altered affinities. For 
the M272L, I, and A variants, characteristic spectral changes were observed with 
lineshapes comparable to those recorded for the wild-type enzyme following complex 
formation with H4NAD.  
 Similar behavior was observed for the differential spectra obtained from the titrations of 
the various mutants with NAD+. While the M272A, I and L mutants generated spectra 
that were comparable both in lineshape and intensity to those obtained for wild-type cb5r, 
no differential spectra were obtained for either the M272- or M272R variants at 
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concentrations of NAD+ up to 10 mM, indicating either substantially decreased affinities 
for both mutants or an altered mode of NAD+ binding (Table 17). 
  
 
 
 
 
 
 
 
 
 
Figure 44. Flavin Difference Spectra Obtained Following Binding of Either H4NAD 
or NAD+ to the Various M272 cb5r Mutants. Difference spectra were obtained for the 
different M272 variants and wild-type cb5r at equivalent flavin concentrations (50 µM 
FAD) in 20 mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0 following titrations 
with either H4NAD (left panels) or NAD+ (right panels) as described in “Methods”. The 
insert panels correspond to plots of the magnitudes of the observed spectral perturbations 
(peak to trough measurements at the indicated wavelengths) versus ligand concentration. 
Plots of the relative absorbance changes observed are as follows: A and B: H4cb5r; C and 
D: M272A; E and F: M272I; G and H:  M272L; I and J: M272- (Titrations of M272R 
yielded spectra identical to those of M272-).  The corresponding Ks values are given in 
Table 17. 
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Table 17.  Spectral Binding Constants Obtained for Wild Type cb5r and the M272-, 
M272A, M272I, M272L, and M272R Variants. 
 
Mutant Ks H4NAD 
(µM) 
KsNAD+
(µM) 
H4cb5r           45 ± 10         760 ± 30 
M272-              ND             ND 
M272A           98 ± 11         891 ± 51 
M272I         204 ± 10       1078 ± 66 
M272L         106 ± 7       2293 ± 125 
M272R              ND             ND 
 
*ND indicates that either there was no detectable activity or no detectable spectroscopic change associated 
with the purified cb5r variant. 
 
 
To examine whether the substitution or deletion of residue M272 influenced 
NADH utilization through modulation of the flavin oxidation-reduction 
midpointpotential, potentiometric titrations were performed using the dye equilibration 
method for wild-type cb5r and the different M272 variants in the presence of 
phenosafranine (Eo’= -252 mV) as indicator dye. Flavin midpoint potentials (Eo’, n=2) 
were determined for the enzymes alone and in complex with NAD+. The spectra obtained 
during representative titrations of the M272A variant in the absence of NAD+ are shown 
in Fig. 6A. Qualitative analysis of the individual spectra obtained from the various 
titrations indicated that the majority of the phenosafranine was reduced prior to FAD 
reduction for the majority of the M272 variants and wild-type cb5r in the absence of any 
pyridine nucleotide, suggesting the flavin midpoint potentials were more negative than 
that of phenosafranine, for all the cb5r variants examined except for the M272- mutant. 
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For the M272- variant, the spectra indicated that both the protein and dye were 
effectively reduced  simultaneously, suggesting a significantly more positive potential for 
the FAD/FADH2 couple in this mutant than observed for wild-type cb5r or any of the 
other M272 mutants. 
In contrast to the results obtained for the different M272 variants in the absence of 
NAD+, titrations performed in the presence of NAD+ revealed very different redox 
behavior. Analysis of the spectra obtained for the M272A, I and L variants together with 
wild-type cb5r indicated that all four proteins were reduced well in advance of the 
phenosafranine dye, suggesting that complex formation significantly perturbed the flavin 
midpoint potentials to values more positive than that for phenosafranine for these three 
mutants. In contrast, the presence of NAD+ had a markedly decreased effect on the 
potential of the FAD/FADH2 couple in the M272R variant and effectively, no effect on 
the M272- mutant, suggesting little perturbation or modulation of the FAD redox 
potential in these two variants. 
The flavin redox potentials (n=2) for the different M272 variants and wild-type 
cb5r alone or as the enzyme-nucleotide complex were determined from the Nernst semi-
log plots shown in Figure 45. The standard midpoint potentials obtained for the 
FAD/FADH2 couple in both the wild-type enzyme (Eo’= -272 mV) and the M272A, I and 
L variants (Eo’= -271 mV to -275 mV) were approximately equivalent for all three 
proteins in the absence of any pyridine nucleotide, the values spanning a range of only 4 
mV. In contrast, the flavin midpoint potential in the M272- and M272R variants were 
determined to be 27 mV and 12 mV, respectively, more positive than the corresponding 
midpoint potential observed for the wild-type cb5r. 
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Figure 45. Comparison of the Oxidation-Reduction Midpoint Potentials for the FAD 
Prosthetic Group in the Different M272 Variants. Reductive dye-equilibration 
titrations of wild-type and the different M272 variants of cb5r (40 µM FAD) were 
performed as described under “Methods” in 100 mM phosphate buffer, containing 0.1 
mM EDTA, pH 7.0 in the presence of phenosafranine (15 µM, Eo’=-252 mV). Individual 
spectra were collected at 2-3 min intervals during the time course of the titrations. (A): 
Selected spectra obtained during the titration of the M272A mutant. (B): Nernst plots 
obtained for the FAD/FADH2 couple (n=2) are shown for the titrations of the various 
M272 cb5r mutants in the absence of NAD+ and correspond to: M272- (+, Eo’=-245+5 
mV), M272A (∆, Eo’=-271+5 mV), M272I (V, Eo’=-274+5 mV), M272L (□, Eo’=-
275+5 mV), M272R (◊, Eo’=-258+5 mV) and wild-type cb5r (○, Eo’=-272+5 mV).  (C) 
Nernst plots obtained for the FAD/FADH2 couple (n=2) are shown for the titrations of 
the various M272 cb5r mutants in the presence of NAD+ and correspond to: M272- (+, 
Eo’=-244+5 mV), M272A (▲, Eo’=-192+5 mV), M272I (▼, Eo’=-192+5 mV), M272L 
(■, Eo’=-191+5 mV), M272R (♦,Eo’=-220+5 mV) and wild-type cb5r (●, Eo’=-190+5 
mV). 
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 The decreased affinity for NAD+ that was determined for both the M272R and 
M272- mutants was also reflected in alterations in the shifts and slopes of the Nernst 
plots when compared to the wild-type domain. In contrast, while the presence of NAD+ 
resulted in no perturbation of the FAD/FADH2 redox potential or change in slope for the 
M272- mutant, for the M272R variant, the degree of perturbation was substantially 
decreased which was coupled with no apparent change in slope of the Nernst plot 
suggested that nucleotide binding did not result in any appreciable semiquinone 
formation. In the presence of NAD+, the redox potential of the FAD/FADH2 couple in the 
wild-type enzyme was positively-shifted by +77 mV (Eo’= -195+5 mV) which was 
comparable to the magnitude of the positive shifts observed for the potentials of the 
M272A, I and L variants.  In contrast, substantially small shifts were observed in the 
potentials of the FAD/FADH2 redox couple in both the M272R and M272- mutants, 
which corresponded to +37 mV and +1 mV, respectively.  
To assess the potential structural changes that would be anticipated to result from 
the deletion of the M272 residue, we utilized homology modeling to construct a model of 
the M272- variant using the experimental wild-type structures as templates. The 
superposition of the structures of the wild type enzyme and the M272- deletion mutant 
are shown in Figure 46. The modified loop containing the “CGxxxxM” NAD(P)H 
binding motif was strongly anchored by its connection to an interior β strand. In the wild 
type structure, M272 and C273 both occupy positions close to those expected for β strand 
extensions, but the final flanking β strand does not extend sufficiently far enough to reach 
these residues and they are slightly displaced relative to the neighboring interior strand 
residues, making any backbone hydrogen bonds very weak. The residue preceding M272 
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Figure 46.  Comparison of a Structural Model of the M272- Mutant and the Wild-
Type cb5r Diaphorase Domains. The X-ray structures obtained for the rat cb5r 
diaphorase domain in the absence (PDB ID = 1I7P) and complex with NAD+ (PDB ID = 
1IB0) were used as templates to generate a structural model for the M272- variant. (A) 
The overall backbone architecture of the wild-type (yellow) and M272- mutant (red) are 
superimposed and displayed as a cartoon ribbon model. The FAD prosthetic group is 
shown in “ball and stick” representation with individual atoms colored using the “CPK” 
convention. (B) An expanded portion of the PDB 1IB0 structure is displayed that shows 
the spatial relationship between the region of the polypeptide sequence corresponding to 
residues M272 to M278 and the bound NAD+. 
 
 
 
 
 
 
 
 
 
 A 
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is a full participant in interior sheet hydrogen bonding. Thus, the removal of residue 
M272 in the deletion mutant forces the subsequent cysteine residue (C273) to occupy the 
position comparable to that of M272 in the wild-type structure. Consequently, this 
deletion shortens the loop connecting the β strand with the following α-helical return. 
A primary consequence of this structural alteration is represented in figure 46 
where the displacement of the loop backbone is shown by the path of the green ribbon 
that corresponds to the mutant structure in comparison to the red ribbon that corresponds 
to the experimental wild-type structure. The wild type polypeptide makes five hydrogen 
bonds with NADH (a sixth is supplied by bound water); two of these would be disrupted 
by displacement of the loop, and the hydrophobic interactions between NAD+ and the 
proline residues would also be weakened. Possible secondary effects could also result 
from the structural alterations.  
To examine the predictions generated by the modeling studies of the M272- variant and 
the comparison with the experimental structures of the wild-type enzyme, we examined 
the binding of two NAD+ analogs, 5’-ADP-ribose and 5’-ADP, which correspond to 
successively truncated derivatives of NAD+, using differential spectroscopy. The 
structural model derived for the M272- variant indicated that if the loop region containing 
the “CGxxxxM” motif was displaced relative to its position in the wild-type structure, the 
major predicted impact would be to decrease the affinities for both 5’-ADP-ribose and 5’-
ADP, since the X-ray structure of wild-type cb5r in complex with NAD+ has revealed that 
the “CGxxxxM” motif is primarily involved in interactions with the adenosine portion of 
NAD+ where it contributes an extensive network of hydrophobic contacts. The 
differential spectra shown in Figure 47, revealed that while both NAD+ fragments form  
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Figure 47.  Difference Spectra and Spectral-Binding Constant Determination for 
Wild Type Cytochrome b5 Reductase and the M272- Variant with various Pyridine 
Nucleotide analogs.  Enzyme samples (50 µM FAD) in 10mM MOPS buffer, containing 
0.1 mM EDTA, pH 7.0 were titrated with the indicated pyridine nucleotides  {Panel A – 
wild-type cb5r + NAD+, Panel B – M272- + NAD+, Panel C - wild-type cb5r + ADP 
ribose, Panel D – M272- + ADP ribose, Panel E - wild-type cb5r + 5’ ADP, Panel F – 
M272- + 5’ ADP} as described in “Materials and Methods”.  The difference spectra 
obtained during the titrations are shown.  The inset panels correspond to a plot of the 
spectral perturbations (peak to trough subtraction) versus pyridine nucleotide 
concentration.      
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spectroscopically-detectable complexes with the M272-variant, suggesting either 
substantially-decreased affinities for both 5’-ADP-ribose and 5’-ADP or that both ligands 
were bound in very different conformations than their respective orientations in the wild-
type complexes, confirming the results that were predicted from the M272- modeling 
studies that suggested that the displacement of the hydrophobic “CGxxxxM” loop would 
have a substantial adverse impact on the affinity for NADH and the various analogs. 
 
Summary of the Recessive Congenital Methemoglobinemia Variant M272- 
 An extensive number of mutations have been identified in the DIA1 gene that 
codes for cb5r and result in RCM.  Previous studies of the majority of the known cb5r 
methemoglobinemia mutants that utilized a novel cb5/cb5r fusion protein have indicated 
that the M272- variant was the most compromised mutant in terms of specific activity 
[40].  Davis et al. have shown that using the NCR expression system, the M272- variant 
only retained <0.01% of the wild-type NADH:CR specific activity. 
 The model structure described in the preceding results section demonstrates that 
effects involving the “CGxxxM” motif are unavoidable in the M272- mutant. These 
effects could account for the substantially-weakened binding of NADH to the M272- 
mutant, when compared to the NADH-affinities of the other M272 variants, if the 
combination of hydrogen-bonding to the phosphate groups and hydrophobic interactions 
between NAD(H) and this motif are a significant factor in NADH binding.  
 In the wild type protein, the hydrophobic C273 side chain is positioned 
approximately 4.2 Å from the si-face of the FAD isoalloxazine ring system, and is in Van 
der Waals contact with the nicotinamide moiety of NAD+. This suggested the possibility 
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that C273 is involved in controlling the equilibrium between the unstacked configuration 
of bound NADH and the charge transfer complex. In the M272- deletion mutant, the 
cysteine side chain would be displaced into approximately the position of the M272 wild-
type side chain, and the next residue, G273, would be unable to compensate because it 
effectively lacks a side chain.  
Secondary effects could also play a role in the reduced affinity of the deletion 
mutant for NADH. Such effects could be propagated through small displacements in the 
neighboring loops which make up nearby sections of the NADH binding site. For 
example, a small reorientation of the α-helical region following the “MCGxxxM” motif 
could reduce the space available for binding the adenine moiety, forcing some 
reorganization of the loop containing F251, the stacking residue for adenine in the wild- 
type structure.  
The possible contribution of secondary effects of this kind could be investigated 
by measuring the affinity of phosphorylated adenenines for the site. In homologues such 
as cytochrome P450 reductase and Ferredoxin:NADP+ reductase, partial NADPH analogs 
such as 2’-AMP and 2’5’-ADP are inhibitors (and in some cases activators) because they 
compete with NADPH. The FAD and pyridine nucleotide binding sites in these enzymes 
have features which cb5r lacks, including a stacking residue supplied by the carboxyl-
terminal region for the FAD isoalloxazine and interdomain hydrogen bonds to the 
pyridine nucleotide. 
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Characterization of the type I Recessive Congenital Methemoglobinemia mutant 
P275L 
 Using the high-resolution x-ray structural model of the soluble rat cb5r diaphorase 
domain, [21] which has been solved in both the native state and complexed with NAD+ 
and shares 95% sequence conservation with the human variant, it was possible to make 
predictions regarding the effects of naturally occurring mutations on the function of cb5r.  
With the development of a heterologous expression system [21] [79] it was possible to 
confirm these predictions and to provide important insights into the structure-function 
relationships of variants with a view to dissecting the mechanisms involved in the 
development of both types of RCM.  For example, previous studies of the S127P type II 
variant using the rat model were the first to provide detailed structural evidence to 
explain the effects of this mutation in terms of perturbation of the conformation of the 
bound FAD prosthetic group substantially decreasing the enzyme’s catalytic efficiency 
[80].   
 We have identified an infant, cyanotic at birth, who was found to be compound 
heterozygous for a novel mutation, P275L, and the previously described G291D mutation 
[107] [85].  Expressing the G291D variant had indicated that the enzyme activity and 
thermostability of the cb5r variant were decreased [79], but it was unknown if the two 
mutations together would have a synergistic effect.  The rat model indicated that the P275 
residue was located in a highly conserved region that interacted with the NADH reducing 
substrate [21].  To understand how substitution of P275 would affect the function of cb5r, 
the P275L variant was generated using our heterologous expression system and enzyme   
activity, thermostability, and substrate affinity were determined. 
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 The propositus was the first live child of non-consanguineous parents of 
English/Scottish and Northern European with Cherokee Indian descent.  He was born at 
full term from spontaneous vaginal delivery to a 31-year-old mother with a history of 
depression, Crohn’s disease and anklyosing spondylitis.  Bextra for anklyosing 
spondylitis and Wellbutrin for depression were ceased when the mother became pregnant 
but she remained on Prozac for depression and Asacol for Crohn’s disease.  The 
pregnancy was otherwise unremarkable but a nuchal cord was present at delivery.  Apgar 
scores were recorded as 7 at 1 minute and 8 at 5 minutes.  At 14 hours of age, the infant 
was noted to be cyanotic even though his O2 saturations for hemoglobin were in the range 
of 90% and the methemoglobin level was found to be 13.2%.  The infant was 
administered a dose of intravenous methylene blue and the methemoglobin level 
promptly fell to 1.8%.  It slowly increased over the next two weeks to reach 10.2%.  
Several checks over the next few months indicated that he had a baseline methemoglobin 
level ranging between 10.2% and 11.2%.  Measurement of cb5r activity detected a level 
of 0.5 IU/g Hb (normal range 8.2-19.2 IU/g Hb) at two and seven weeks and on 
subsequent measurement at 14 months was 0.6 IU/g Hb.  Both parents were found to 
have normal cb5r activity with measurements of 13 and 18 IU/g Hb for the father and 
mother respectively.  Clinically, he had some mild perioral cyanosis but remains well at 
14 months without medication. 
The DIA1 gene of the cyanotic infant was sequenced and a novel C to T change in 
exon 9 (C27161T; NCBI accession number: NT_011520) and a G to A change, also in 
exon 9 (G27209A; NCBI accession number: NT_011520) were detected, as shown in 
Figure 48.  These nucleotide changes predicted P275L and G291D mutations.  
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Sequencing both phenotypically normal parents revealed that neither mutation had arisen 
de novo in the infant with the father and the mother being heterozygous for the P275L 
and G291D mutations, respectively.  The G291D variant has been described before [78] 
in the original family described by Gibson [44] and a second Northern Ireland family 
[107].  It is likely that the G291D variant had arisen independently in Northern Ireland 
and America, but performing haplotype studies may indicate if there is indeed a common 
origin for the G291D variant.  Both mutations are located in the NADH-binding lobe of 
cb5r and it is unknown if the two mutations together would have a synergistic effect.  
Using the rat model, it was possible to predict that since P275 is located in a conserved 
sequence motif corresponding to “273CGPPPM278” it is important for binding and correct 
positioning of the NADH reducing substrate, thus the P → L mutation would adversely 
affect functionality.  Thus, substitution of proline with leucine would be expected to 
result in the leucine side chain extending into the NADH-binding cavity thus sterically 
precluding NADH binding in the normal wild-type position.  A mutant construct 
encoding the P275L cb5r variant, which corresponded to the third residue in the 
conserved “CGPPPM” sequence motif, was generated using site-directed mutagenesis of 
the original four-histidine tagged cb5r construct.  Dideoxy sequencing confirmed that the 
fidelity of the construct and the mutant protein was subsequently expressed in the E. coli 
strain BL21(DE3)-RIL and  purified by metal-chelate affinity chromatography and gel 
filtration FPLC.  Evaluation of the expression yield of the P275L variant indicated an 
expression efficiency comparable to that of the wild-type cb5r domain, indicating the 
production of a stable protein product which could be purified to apparent homogeneity 
as indicated by the presence of a single protein band following  
   
 
27,153                                                   27,173                     27,998              27,218
C                                                     F
GTGTGGCCNCCCACCCATGAT
A                                                               D
GGACCACGTGGNCCACCCCAC
27,153                                                          27,173                      27,998                    27,218
B                                                               E
GTGTGGCCCCCCACCCATGAT GGACCACGTGGNCCACCCCAC
GTGTGGCCNCCCACCCATGAT GGACCACGTGGGCCACCCCAC
27,153                                                          27,173                         27,998                  27,218  
 
 
Figure 48. Detection of the C27161T and G27209A Mutations in the DIA1 Gene. 
Sequencing of exon 9 of the DIA1 gene detected two heterozygous base changes of C to 
T at nucleotide 27,161 (A) and G to A at nucleotide 27,209 (D) in the propositus as 
indicated by arrow in chromatogram. The father (B and E) was heterozygous for the 
G27209A change while the mother (C and F) was heterozygous for the C27161T 
mutation. Bases are as follows:  G = black; A = green; T = red; C = blue. 
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SDS-PAGE analysis (Figure 49).  The P275L cb5r  variant and the native enzyme were of 
comparable molecular mass, while MALDI-TOF analyses revealed the presence of a 
characteristic peak in the low mass region of the spectrum with a m/z of 792, indicative of 
the presence of FAD as the sole prosthetic group.  These findings suggested that residue 
P275 did not provide backbone or side-chain contacts that were essential for the stable 
incorporation of the FAD prosthetic group into cb5r. 
 UV/Visible absorbance spectra were obtained for both an oxidized sample of the 
P275L variant and wild-type cb5r as a control and are presented in Figure 50A.  The 
P275L variant exhibited a spectrum comparable to that of the wild-type enzyme with an 
aromatic maximum observed at 273 nm in the UV region of the spectrum, and a peak at 
461 nm with an associated pronounced shoulder in the range of 485-500 nm in the visible 
region of the spectrum, attributable to protein-bound flavin.   
 To compare the secondary structural content of the P275L variant with that of the  
wild-type protein, circular dichroism (CD) spectra were recorded in the UV wavelength 
range (190-300 nm).  As shown in Figure 50B, the P275L variant exhibited positive CD 
from 190 to 210 nm and the negative CD from 210 to 250 nm with the spectrum retaining 
both negative and positive intensities very similar to those of the wild-type domain.  The 
absence of any significant differences between the spectra of the mutant and wild-type 
protein suggested secondary structural conservation and that the P to L residue 
substitution had no deleterious effects on the folding of the diaphorase domain.  Similar 
results were observed for the corresponding visible CD spectra.  CD measurements were 
performed in the near UV/Visible range (300-600 nm) in order to probe the possible 
effects of the P275L mutation on both flavin conformation and polarity of the prosthetic 
25
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Figure 49. SDS-PAGE Analysis of the P275L cb5r Variant. Samples (2 µg protein) 
obtained following isolation of the P275L variant and wild-type cb5r were analyzed using 
a 15 % polyacrylamide gel as described in “Methods”. Individual lanes correspond to: S, 
protein molecular weight markers; A, P275L variant; B, wild-type cb5r. 
 
group microenvironment.  As shown in Figure 50C, the spectrum of the P275L mutant 
was unperturbed when compared to that of wild-type cb5r, exhibiting positive and 
negative maxima at approximately 400 and 460 nm, respectively, suggesting no 
significant change in either the polarity of the flavin environment or the conformation of 
the bound prosthetic group. 
To examine the influence of the P275L residue on the stability of the resulting 
protein, thermal denaturation profiles were generated for both the P275L and wild-type 
cb5r by measuring changes in both intrinsic flavin fluorescence emission (λex = 450 nm 
and λem = 523 nm) and retention of NADH:ferricyanide reductase (NADH:FR) activity 
following incubation of the proteins at temperatures ranging from 0 °C to 100 °C (Figure 
51).  Thetemperature (T50) at which 50% of maximum fluorescence was detected or 50% 
of the protein’s NADH:FR activity was retained, were effective indicators of the stability 
of the core structure of the protein.  The T50 value obtained for the P275L variant was 
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Figure 50. UV/Visible Absorption and CD Spectra of the P275L cb5r Mutants. (A) 
UV/visible absorption spectra were obtained for oxidized samples of the P275L mutant 
and wild-type cb5r, as a control, at equivalent flavin concentrations (10 µM FAD) in 10 
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. The inset shows an expanded 
region of the visible spectrum where the flavin prosthetic group makes a major 
contribution. (B) UV CD spectra were recorded using enzyme samples (7 µM FAD) in 10 
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible CD spectra were 
recorded using enzyme samples (50 µM FAD) in 10 mM phosphate buffer, containing 
0.1 mM EDTA, pH 7.0. Individual spectra correspond to P275L ( - - - ); wild-type cb5r    
( ___ ). 
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approximately 2 °C lower than that of wild-type cb5r, suggesting that the residue 
substitution had no significant effect on the thermal stability of the mutant protein. 
 To further confirm that the proline to leucine substitution had no substantial 
effects on the flavin environment, oxidation-reduction potentials were determined for the 
FAD/FADH2 couple (E°′, n = 2) in both the P275L variant and the wild-type cb5r using 
dye-equilibration potentiometery in the presence of phenosafranine as a redox indicator.  
Representative spectra obtained during the redox titration of the P275L mutant are shown 
in Figure 52A, and provide an example of the nature of the spectral changes observed 
during the dye-equilibration redox titrations while the corresponding Nernst plots 
obtained for both P275L and wild-type domain, both in the absence and presence of 
NAD+, are presented in Figure 52B.  The redox potential of the P275L variant was within 
10 mV of wild-type cb5r in the absence of NAD+, confirming that the mutation had little 
effect on the thermodynamic properties of the FAD prosthetic group.  However, in 
contrast, the redox potential obtained for the P275L variant in the presence of NAD+ was 
significantly more negative than that obtained for the wild-type domain in the presence of 
NAD+, indicating a decreased affinity of the mutant for binding the pyridine nucleotide. 
 As a measure of catalytic efficiency, both NADH:FR and NADH:BR activities 
were determined for the P275L variant and compared with that of wild-type cb5r.  Kinetic 
constants derived from these assays are reported in Table 18, and indicated that the 
P275L mutant exhibited a decreased NADH:FR turnover number compared to that of  
wild-type cb5r.Comparison of the specific activities of the mutant and wild-type cb5r 
indicated that the mutant retained 92% of wild-type NADH:FR activity.  However, the 
Michaelis constant (Km) for NADH utilization increased 437 fold, from 6 µM to 2.6 mM, 
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Figure 51. Temperature Stabilities of the P275L cb5r Mutant. Samples of the purified 
P275L mutant and wild-type cb5r (20 µM) were incubated in microfuge tubes as 
described in “Methods”. Flavin fluorescence emission spectra were determined at each 
temperature and the emission maxima at 524 nm plotted as a percentage of total 
fluorescence. Total flavin fluorescence was determined by measuring a similar dilution of 
the remaining stock solution following heating at 100 º C for 30 min. P275L (); wild-
type cb5r ({). Residual NADH:FR activities were determined at 340nm for each 
temperature as described in “Methods” and correspond to P275L () and wild-type cb5r 
(z). 
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Figure 52. Potentiometric Titrations of the P275L cb5r Mutant. Reductive dye-
equilibration titrations were performed at 25 oC as described under “Methods” using 
phenosafranine (Eo’=-252 mV) as the indicator in 100 mM phosphate buffer, containing 
0.1 mM EDTA, pH 7.0. (A) Representative spectra obtained during the titration of P275L 
in the absence of NAD+ are displayed. (B) The Nernst plots of log 
([oxidized]/[reduced])FAD versus potential correspond to P275L in the absence (, Eo’= -
264+5 mV) and presence (, Eo’=-212+5 mV), respectively of 2 mM NAD+. Also 
shown are the Nernst plots obtained for wild-type cb5r as a control in the absence (z, 
Eo’=-272+5 mV) and presence ({, Eo’=-192+5 mV), respectively, of 2 mM NAD+. 
Flavin reduction was monitored at 410 nm, an isosbestic wavelength for phenosafranine 
reduction and phenosafranine reduction was monitored at 530 nm, an isosbestic 
wavelength for flavin reduction. Flavin midpoint potentials for the FAD/FADH2 couple 
(n=2) were determined from the Nernst plots and yielded the indicated standard reduction 
potentials (Eo’). Only selected data points obtained from each of the titrations are shown 
for clarity. 
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indicating that the dominant effect of the mutation was a substantial decrease in the 
affinity for the reducing substrate.  In contrast, the Michaelis constant for the artificial 
electron acceptor ferricyanide was similar to that of wild-type cb5r, suggesting that the 
mutation did not affect the binding of this artificial oxidizing substrate.  The effect of the 
proline to leucine substitution on the overall NADH:FR catalytic efficiency of the 
enzyme, reflected in the kcat/KmNADH value, was to retain only 0.2% of wild-type 
NADH:FR catalytic efficiency.  These results suggested that the lower catalytic 
efficiency observed for the mutant was the result of the decreased affinity for NADH, 
rather than any decreased affinity for cb5. 
 Assays were also performed to ascertain if the proline to leucine substitution had 
any effect on the selectivity of the enzyme for either NADH or NADPH.  As shown in 
Table 18, the NADPH-dependent diaphorase activity decreased together with the affinity 
for NADPH.  However, the specificity constant, defined as the ratio of the catalytic 
efficiencies with NADPH and NADH, increased 5-fold when compared to the value 
obtained for the wild-type enzyme, indicating that P275 plays only a very modest role in 
regulating NADH/NADPH specificity. 
  To confirm the effects of the P275L substitution on the affinities for either 
NADH or NAD+, spectral binding constants (Ks) were determined using differential 
spectroscopy.  Representative spectra obtained from the P275L mutant and the wild-type 
enzyme with either H4NAD or NAD+ is shown in Figure 53.  While perturbations of the 
flavin visible absorbance spectrum were detected for the wild-type enzyme, no complex 
formation could be detected for the P275L variant with either compound, reflecting the 
substantially decreased affinity for either H4NAD or NAD+. 
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Table 18. Comparison of the Kinetic and Spectroscopic Binding Constants Obtained 
for the P275L Variant of cb5r. 
 
Mutant NADH:FR NADH:BR NADPH:FR Specificity 
Constant 
∆a
 kcat          KmNADH       kcat/KmNADH
(s-1)       (µM)          (s-1 M-1) 
kcat        KmCyt b5
(s-1)     (µM) 
kcat KmNADPH  kcat/KmNADPH 
(s-1)     (µM)          (s-1 M-1) 
 
P275L 
Wild Type 
733+7   2623+460     2.8+0.1x105
800+21  6+1         1.4+0.3x108
67+18     4+1 
600+17   12+1 
0.45     1123       4.0x102 
33      924       3.6x104
1.4x10-3 
2.7x10-4
 
 
Summary of they Type I RCM Variant P275L 
The identification of the novel P275L RCM variant represents the discovery of 
the eighth mutation in exon 9 of the DIA1 gene.  Five variants (V252M, R258W, P264L, 
P275L, and G291D) and a deletion mutant (E255-) [82-85, 106, 116] have been found to 
be associated with type I RCM while two other deletion mutants (M272- and F298-) [31, 
81] “273CGPPPM278” that is present in the majority of known cb5r sequences and is also 
found in other members of the ferredoxin:NADP+ reductase superfamily of flavoprotein 
transhydrogenases [5].  The X-ray structure of the rat cb5r diaphorase domain complexed 
with NAD+ (PDB code: 1IB0) has revealed that P275 is part of a solvent-accessible loop 
region located between sheet Nβ5 and helix Nα4 within the carboxy-terminal pyridine 
nucleotide-binding lobe [21].  Within this structure, NAD+ has been shown to bind in an 
extended conformation along a plateau that is formed by three proline residues, P275- 
P277.  The conformation of the bound NAD+ is shaped largely by P275 and bends around 
it with the pyrophosphate moiety packed against it and with the nicotinamide proximal 
ribose packed parallel to the proline ring (Figure 54B), suggesting that substitution of 
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Figure 53. Spectroscopic Titrations of the P275L Mutant with H4NAD and NAD+. 
Titrations of the P275L cb5r variant (50 µM FAD) were performed in split cell optical 
cuvettes in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0, at 23 º C. 
Difference spectra were recorded, following additions of a concentrated solution of either 
H4NAD (50 mM) or NAD+ (100 mM) to both sample and reference cuvettes, after the 
complete cessation of all absorbance changes. The inset panels correspond to plots of the 
magnitude of the spectral perturbations at the indicated wavelengths versus pyridine 
nucleotide concentration where a difference spectrum was observed. The plots of relative 
absorbance changes observed during the titrations are as follows: (A and B), P275L in the 
presence of H4NADH and NAD+. (C and D) wild-type cb5r in the presence of H4NADH 
and NAD+. 
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P275 would be anticipated to have profound effects on both binding and subsequent 
orientation of the nucleotide.  The results of the biophysical characterization of the P275L 
variant are in full agreement with this prediction.  The proline to leucine substitution was 
observed to have no detectable effects on either the spectroscopic or thermodynamic 
properties of the flavin prosthetic group in the absence of NAD+.  In addition, protein 
folding and stability were unaffected by the mutation.  In contrast, the proline to leucine 
substitution exhibited a profound effect on both the affinity of cb5r for the reducing 
substrate and its catalytic efficiency.  
Homology modeling of the P275L structure suggested that substitution of the 
hydrophobic leucine side chain would not be expected to perturb the overall folding and 
structural organization of the protein as shown in the overlay of the ribbon diagrams for 
the P275L and wild-type proteins in Figure 54A.  However, the linear isobutyl side chain 
would be anticipated to protrude into the NADH-binding site when compared to that of 
the wild-type proline structure, as shown in the electrostatic surface plots in Figure 54B 
and Figure 54C, resulting in steric hindrance and decreased binding affinity.  These 
predictions are in agreement with the results of both the initial-rate kinetic and pyridine 
nucleotide Ks analyses.  The absence of any spectral changes observed in either the 
H4NAD or NAD+ titrations, suggested that the Ks’s for these two compounds would be 
expected to be greater than approximately 1 and 5 mM , respectively, which are 
substantially greater than the values of 46 and 663 µM, respectively, obtained for the 
wild-type domain. 
 The molecular mechanisms responsible for the striking difference in phenotype 
between type I and type II RCM have not yet been satisfactorily explained.  Studies of 
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Figure 54.  Homology Model of the P275L cb5r Variant.  (A) Superposition of the rat 
cb5r X-ray structure (yellow; PDB code 1IB0) and the homology modeled P275L (red) 
structure.  Both structures are shown as ribbon diagrams that represent the regions of 
secondary structure.  The FAD prosthetic group, complexed NAD+, and residue P275, 
indicated by the arrow, are shown in “stick” representation using the CPK coloring 
scheme.  (B) Rendering of the sequence region, corresponding to I270 to F281, that 
surrounds residue P275.  The peptide backbone is drawn in ribbon configuration while 
the proline (gray) and leucine (magenta) side chains at position P275 in the position 275 
in the wild-type and mutant proteins are shown in “stick” representations.  Also shown is 
the complexed NAD+ in “stick” configuration with “CPK” coloring.  (C and D) 
Renderings of the sequence region, corresponding to I270 to F281, which surrounds 
residue P275.  The peptide backbone is shown in ribbon configuration while the proline 
(C) and leucine (D) side chains at position 275 in the wild-type and mutant proteins 
together with the complexed NAD+ are shown in an electrostatic surface representation 
with negatively and positively charged regions colored in red and blue, respectively.  
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naturally occurring mutations of cb5r using the heterologous expression system will 
permit accumulation of data on the structure-function relationships of the enzyme.  It is 
of interest that some mutations have been found in both types of disease, while the 
majority appear to be confined to one type.  The novel P275L is the fifth single amino 
acid substitution in the protein domain encoded by exon 9.  In general these mutations 
affect the affinity and activity of cb5r for NADH and may primarily or uniquely affect the 
heme iron reductase function of the enzyme.  However, cb5r has pleiotropic functions and 
mutations in the more 5′ regions of the gene may disrupt some of these thereby causing 
neurological impairment.         
 
Identification and characterization of the novel FAD-binding lobe G75S mutation in 
cytochrome b5 reductase: An aid to determine recessive congenital 
methemoglobinemia status in an infant. 
 Recently, we identified a four-month old infant with a novel G to A change in the 
last base of exon 3 in the DIA1 gene.  This resulted in the substitution of glycine with 
serine at residue 75 in the FAD-binding lobe of cytochrome b5 reductase.  The infant was 
compound heterozygous for the previously characterized V252M mutation [82-84] which 
is located in the C-terminal NADH-binding lobe of cytochrome b5 reductase.  Being 
compound heterozygous for mutations that would impair both the FAD and NADH 
function of cytochrome b5 reductase would suggest the more severe clinical form of 
RCM.  Thus, to provide insight at the molecular level and potentially to assist in the 
diagnosis of recessive congenital methemoglobinemia status, we generated and 
characterized the G75S, V252M and the corresponding double G75S/V252M cytochrome 
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b5 reductase variants using the rat heterologous expression system [79, 105].  The patient 
was compound heterozygous for the G75S and V252M cytochrome b5 variants and thus 
synthesized both individual variants.  However, while the homozygous double mutant did 
not occur in the patient, we were interested in generating the double mutant as an initial 
approach to investigate potential synergistic effects on either the structural or functional 
properties of the enzyme when both mutations occurred together in the same protein.  
Although the human erythrocytic form of cytochrome b5 reductase was recently 
described [20], the rat system is the only variant that has been used to characterize all the 
known methemoglobin amino acid mutations in terms of their effects on the expression, 
relative activities, and stability of the various proteins [79].  In addition, there is 95% 
sequence similarity between these two species with any non-conserved amino acid 
substitutions occurring in functionally insignificant regions of the protein. 
 The kinetic, protein stability, and cofactor oxidation-reduction potential 
properties were determined for all three variants and compared to the properties of wild 
type cytochrome b5 reductase and other methemoglobinemia-causing mutations, 
including E255-, G291D, and D239G [79, 105]. 
 The proposita was the second child of non-consanguineous parents of 
Mediterranean descent.  Cyanosis was noted at birth accompanied by reduced oxygen 
saturation determined by pulse oximetery but normal pO2 on arterial blood gas analysis 
and no evidence of cardiopulmonary abnormality.  Methemoglobinemia was detected at a 
level of 14.4%.  At the age of 4 months, the infant was referred for assessment of 
persistent methemoglobinemia.  Physical examination revealed no developmental delay 
or microcephaly.  Erythrocyte cytochrome b5 reductase activity was assayed 
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spectrophotometrically at 340 nm as the rate of oxidation of NADH in the presence of 
potassium ferricyanide as previously described [117].  Measuring cytochrome b5 
reductase activity indicated that the infant showed a marked reduction with an activity of 
only 0.5 U/gHb while both the father (4.9 U/gHb) and the mother (5.0 U/gHb) had ~50% 
of the residual enzyme activity as defined by the adult reference range of 7.2-13.9 U/gHb. 
 Sequencing of the DIA1 gene in the infant revealed a novel G to A change in the 
last base of exon 3 (G15,635A; genomic sequence NCBI NT_011520) and a G to A 
change in exon 9 (G 27,091A; genomic sequence NCBI NT_011520), resulting in amino 
acid exchanges of glycine to serine at residue 75 and valine to methionine at residue 252, 
respectively (Figure 55).  Screening the parents indicated that the father was 
heterozygous for the G75S variant, and the mother was heterozygous for V252M.  The 
G75S mutation is located in the amino-terminal FAD-binding lobe of cytochrome b5 
reductase, as shown in Figure 56, while the V252M mutation is present in the carboxy-
terminal NADH-binding domain.  Thus, the infant was compound heterozygous for 
mutations in both the prosthetic group and substrate binding lobes of cytochrome b5 
reductase.  In contrast to the G75S mutation, the V252M variant has been previously 
described either in the homozygous state in both types I and II patients [82, 84] or in 
combination with the I215T mutation [83], which is also located in the NADH-binding 
lobe.  To determine how these two radically different mutations would affect the function 
of cytochrome b5 reductase, both the G75S and V252M variants and the corresponding 
double mutant were generated using our heterologous expression system. 
 E. coli BL21 RIL cells harboring the expression plasmids for either rat G75S, 
V252M or G75S/V252M cytochrome b5 reductase variants were grown, disrupted and the 
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three mutant proteins were purified using a combination of Ni-NTA agarose affinity and 
gel filtration chromotographies as previously described [76].  Qualitative analysis 
indicated that all three mutants were obtained in substantial quantities and were expressed 
with efficiencies comparable to that of wild-type cytochrome b5 reductase.  All three 
proteins were yellow in color indicating flavin incorporation and were purified to 
apparent homogeneity as indicated by the appearance of single protein bands following 
SDS-PAGE analysis as shown in Figure 57.  The three cytochrome b5 reductase variants 
exhibited molecular masses of approximately 32 kDa confirming the production of full 
length proteins. 
 Spectroscopic analysis, including UV/visible absorption and CD spectra, revealed 
that G75S, V252M, and G75S/V252M variants retained identical spectroscopic 
properties to those of the wild-type protein with UV/visible absorption maxima at 276, 
386, and 461 nm, respectively, that indicated a full complement of FAD incorporation 
and that the flavin was present in an environment spectroscopically indistinguishable 
from that of the native domain (Figure 58A).  UV and CD spectra indicated an absence of 
any significant change in protein architecture suggesting comparable protein folding 
(Figure 58B and Figure 58C).  Thus, neither the G75S nor V252M, or a combination of 
both mutations did not appear to adversely affect the global folding of the respective 
proteins while the substantial similarities in the visible CD spectra indicated that the 
flavin prosthetic groups were in a similar environment in all the proteins examined.   
 In contrast, both NADH:FR and NADH:BR activity assays revealed that 
theG75S, V252M and G75S/V252M double mutant exhibited substantially decreased 
activity, as shown by the kinetic constants given in Table 19.  The G75S variant 
  
Figure 55.  Detection of the G15,635A and G27,091A Mutation in the DIA1 Gene.  
Sequencing of exon 3 of the DIA1 gene revealed a heterozygous change of G to A at 
nucleotide 15,635 in the father (A) and daughter (C) indicated by an arrow in the 
chromatogram on the negative strand, when compared to normal sequence of the mother 
(B).  Sequencing of exon 9 of the DIA1 gene detected a heterozygous base change of G to 
A at nucleotide 27,091 in the mother (E) and daughter (F) indicated by an arrow in the 
chromatogram when compared to the normal sequence of the father (D).  Bases are as 
follows: G – Black; A – green; T – red; C – blue. 
 
 
exhibited a specific activity or catalytic constant, kcat, corresponding to approximately 
17% of the wild-type domain activity, while the affinity for the reduced pyridine 
dinucleotide was only slightly decreased as indicated by the 1.5 fold increase in the 
Michaelis Constant (Km) for NADH, indicting that the G75S variant primarily exhibited a 
defect in the rate of hydride transfer rather than substantially impaired NADH binding.  
Overall, the G75S variant retained only 11% of the catalytic efficiency, as indicated by 
thespecificity constant (kcat/KmNADH), of native cytochrome b5 reductase.  These results 
could be contrasted with those obtained for the V252M variant which exhibited only a 
modest decrease in specific activity, corresponding to an approximate 20% reduction, 
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Figure 56.  X-Ray Crystallographic Structure of Cytochrome b5 Reductase.  A 
ribbon diagram of the structure of the R. norvegicus cytochrome b5 reductase diaphorase 
domain (PDB = 1IB0) complexed with NAD+ is depicted showing the structural elements 
that comprise the FAD- and NADH-binding lobes and the “hinge” interconnecting 
region.  The FAD-binding lobe is depicted in blue, the NADH-binding lobe is depicted in 
red with the “hinge” region depicted in green.  The FAD-prosthetic group and the bound 
NAD+ molecule are shown in “ball and stick” representation using the Corey-Pauling-
Koltun convection.  Te two residues that have been identified in the methemoglobinemia 
mutants, G75 and V252 are also shown in “ball and stick” representation. 
 
 
 162
 
 
Figure 57.  SDS-PAGE Analysis of Wild Type Cytochrome b5 Reductase and the 
G75S, V252M, and G75S/V252M Variants.  Purified proteins (2 µg each protein) 
obtained from the final FPLC purification step of all three mutants together with a sample 
of wild-type cytochrome b5 reductase were resolved on a 12.5% polyacrylamide gel.  
Lane A, wild-type cytochrome b5 reductase; Lane B, G75S; Lane C, V252M; Lane D, 
G75S/V252M; Lane S, molecular weight standards.  The positions of selected molecular 
weight markers are indicated by molecular masses (kDa). 
 
 
however, as anticipated for a mutation in the NADH-binding lobe, the affinity (Km) for 
NADH was decreased approximately 9-fold, indicating that the V252M retained only 9% 
of the catalytic efficiency of wild-type cytochrome b5 reductase.  The results obtained for 
the G75S/V252M double mutant were intermediate between those of the two single 
mutants suggesting the effects of the two individual mutations were not synergistic.  
Comparison of the kcat and Km values obtained for all three mutants revealed that while 
the primary effect of the G75S mutation was to decrease the catalytic efficiency of the 
enzyme, in contrast, the V252M mutation primarily decreased the affinity for the 
reducing substrate NADH, which resulted in approximately equivalent specificity 
constants for both mutants.  It should be noted that the values obtained for the specificity 
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Figure 58.  Comparison of the UV/Visible Spectroscopic Properties of Wild-Type 
Cytochrome b5 Reductase  and the G75S, V252M, and G75S/V252M Variants.  
Oxidized samples of G75S, V252M, G75S/V252M, and wild-type cytochrome b5 
reductase (10-60 µM FAD) were analyzed using ultra violet/visible absorbance (A) and 
circular dichrosim (B and C) spectroscopies, respectively, in 10 mM phosphate buffer, 
containing 0.1 mM EDTA, pH 7.0.  Individual spectra correspond to G75S (____ ____), 
V252M (__ __ __), G75S/V252M (……), and wild-type cytochrome b5 reductase (______).  
The insert shows expanded portions of the visible regions of the spectra. 
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Table 19.  Comparison of the Kinetic Constants Obtained for the G75S, V252M, 
G75S/V252M and Wild-Type Cytochrome b5 Reductases. 
 
Mutant NADH:FR NADH:BR 
 kcat          KmNADH   KmFeCN6    kcat/KmNADH
(s-1)       (µM)       (µM)      (s-1 M-1) 
kcat          KmNADH  KmCyt b5      kcat/KmCytb5
(s-1)       (µM)      (µM)        (s-1 M-1) 
H4cb5r 
G75S 
V252M 
G75S/V252M 
 800 ± 21        6 ± 1          7 ± 1      1.4 ± 0.3 x 108 
 133 ± 26        9 ± 1          7 ± 1      1.5 ± 0.1 x 107 
 633 ± 14      52 ± 5          7 ± 1      1.2 ± 0.2 x 107 
 187 ± 17      17 ± 1          8 ± 1      1.1 ± 0.1 x 107
600 ± 10      2 ± 1       13 ± 1        4.7 ± 0.5 x 107 
   60 ± 3       4 ± 1       14 ± 3        1.5 ± 0.1 x 107 
 285 ± 14     3 ± 1       13 ± 2        1.2 ± 0.2 x 107 
    85 ± 3      3 ± 1       14 ± 3        1.1 ± 0.1 x 107
 
 
constants of all three mutants were an order of magnitude lower than the corresponding 
value obtained for the wild-type enzyme, reflecting the significant effect of the mutations 
of the catalytic functionality of the enzyme. 
 The modest increase in the Km for NADH observed for the G75S variant was 
confirmed upon the measurement of the spectral binding constants (Ks) [77] for both 
H4NAD and NAD+.  In contrast to the results previously obtained for the wild-type 
domain which have yielded Ks values of 45±10 and 760±30 µM for H4NAD and NAD+, 
respectively, identical experiments performed with the G75S variant, yielded Ks values of 
59 µM and 85 µM, respectively, confirming the modest decrease in affinity for the 
reduced form of the pyridine nucleotide (Figure 59).  However, the significantly 
decreased Ks value obtained for NAD+ indicated that the mutant exhibited a substantially 
greater affinity for the reaction product, which would be expected to result in decreased 
enzyme activity owing to a decreased rate of product disassociation.  In contrast, values 
obtained for both H4NAD and NAD+ were significantly elevated for the V252M mutant, 
confirming the results obtained for the activity assays. 
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 To assess the impact of the G75S and V252M substitutions on protein folding, 
thermal stability studies were performed monitoring both the loss of NADH:FR activity 
and the increase in intrinsic flavin fluorescence for both the single and double mutants.  
Both parameters are indicative of relative protein unfolding and can be effectively used to 
monitor alterations in protein stability.  As shown in Figure 60, the G75S, V252M and 
G75S/V252M variants exhibited T50 values of approximately 48 °C, 53 °C, and 45 °C, 
respectively, which may be compared to the value of 57 °C the wild-type domain, 
suggesting that both the glycine to serine and valine to methionine substitutions resulted 
in significant changes in the stability of the mutant proteins when compared to native 
cytochrome b5 reductase.  Oxidation-reduction potential measurements for the 
FAD/FADH2 couple (n = 2), were determined using the xanthine/xanthine oxidase dye 
equilibration method utilizing phenosafranine (E°′ = -252 mV) as the indicator dye.  
While we were unable to determine the redox potential for the flavin prosthetic group in 
either the G75S or the G75S/V252M variants owing to substantial protein instability and 
aggregation during the titration experiments, a value for the V252M mutant was obtained 
reflecting the stability of this variant.  The spectral changes accompanying reduction of 
the V252M variant during the course of the dye mediated titration were directly 
comparable to those previously published for the wild-type cytochrome b5 reductase 
suggesting very similar flavin redox potentials for the two proteins.  The corresponding 
Nernst plots, shown in Figure 61, which relate to the concentrations of the oxidized and 
reduced forms of the flavin cofactor to the observed solution potential [77], revealed that 
the flavin midpoint potential for the FAD/FADH2 couple (n = 2) in the V252M variant 
was -276 mV, which was essentially unchanged from the midpoint potential of -274 mV 
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Figure 59.  Flavin Difference Spectra Obtained Following Binding of Either H4NAD 
or NAD+ to Wild-Type Cytochrome b5 Reductase or the Various G75S and V252M 
Mutants.  Difference Spectra were obtained for both wild-type cytochrome b5 reductase 
(A and B) and the G75S (C and D), V252M (E and F), and G75S/V252M (G and H) 
variants at equivalent flavin concentrations (50 µM FAD) in 20 mM MOPS buffer, 
containing 0.1 mM EDTA, pH 7.0 following titrations with either H4NAD (left panels) or 
NAD+ (right panels) as described in “Materials and Methods”.  The insert panels 
correspond to plots of the magnitudes of the observed spectral perturbations (peak to 
trough measurements at the indicated wavelengths) versus ligand concentration.  The 
corresponding Ks values are given in Table 20. 
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Table 20.  Spectral Binding Constants Obtained for Wild Type cb5r and the G75S, 
V252M, G75S/V252M Variants. 
 
Mutant Ks H4NAD 
(µM)  
KsNAD+
(µM) 
H4cb5r               45 ± 10           760 ± 30 
G75S               59 ± 4             85 ± 6 
V252M             428 ± 55      14,001 ± 2251 
G75S/V252M             134 ± 7           956 ± 83 
 
 
obtained for the wild-type cytochrome b5 reductase.  However, in the presence of NAD+ 
or NADP+, the redox potential of the FAD/FADH2 couple was shifted to -232 mV and -
190 mV, respectively, which reflected and confirmed the decreased affinity of the 
V252M mutant for NAD+ compared to the native enzyme. 
 
Summary of the novel FAD-binding lobe G75S mutation in cytochrome b5 reductase 
 The G75S and V252M mutation identified in exons 3 and 9 respectively represent 
radical amino acid substitutions in distinctly different regions of the polypeptide chain 
that are primarily responsible for either FAD or NADH binding, respectively.  
Identification of the G75S variant represents the discovery of a new mutation in the DIA1 
gene, the V252M variant has been previously reported [82-84] in both type I and type II 
individuals, but biophysical studies on a recombinant form of the V252M variant have 
not been previously described.  To understand the effect of these mutations on the 
function of cytochrome b5 reductase and the development of recessive congenital 
methemoglobinemia, we generated and characterized the G75S variant together with the 
V252M and the G75S/V252M double mutant using a rat cytochrome b5 reductase 
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Figure 60.  Comparison of the Thermostability Properties of Wild-Type 
Cytochrome b5 Reductase and the G75S, V252M, G75S/V252M Variants.  Oxidized 
samples of G75S, V252M, G75S/V252M and wild-type cytochrome b5 reductase (5 µM 
FAD) were incubated at the indicated temperatures, and aliquots were withdrawn and 
assayed for both residual NADH:FR activity (open symbols) and intrinsic flavin 
fluorescence (closed symbols) in 10 mM phosphate buffer, containing 0.1 mM EDTA, 
pH 7.0 using excitation and emission wavelengths of 450 nm and 523 nm, respectively.  
The plots correspond to (●,○) H4cb5r; (■, □) G75S; (▲, ∆) V252M; and (♦, ◊) 
G75S/V252M. 
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 Fig. 61.  Comparison of the thermodynamic properties of wild-type cytochrome 
b5reductase and the V252M variant. Reductive dye-equilibration titrations of both 
wild-type and the various of cytochrome b5 reductase mutants (40 µM FAD) were 
performed as described under “Materials and Methods” in 100 mM phosphate buffer, 
containing 0.1 mM EDTA, pH 7.0 in the presence of phenosafranine (15 µM, Eo′ = −252 
mV) as indicator dye. Individual absorption spectra were collected at 2- to 3-min 
intervals during the time course of the titration and the corresponding Nernst plot 
obtained for the FAD/FADH2 couple (n = 2) is shown for the titration of the V252M 
variant (O, Eo′ = −276 mV). Also shown is the corresponding plot for wild-type 
cytochrome b5 reductase ( , Eo′ = −272 mV). Redox potentials are given with respect to 
the Standard Hydrogen Electrode and are considered accurate to ±5 mV.  
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heterologous expression system.  The double mutant does not represent the situation in 
the patient, but we were curious to examine the impact of both mutations on the protein 
structure of cytochrome b5 reductase.  Although the G75S mutation is located in the 
FAD-binding lobe, it did not affect the global folding of the protein or the incorporation 
of the flavin cofactor.  Instead the G75S mutation caused reduced protein stability and 
impaired NADH activity, thus resulting in type I recessive congenital 
methemoglobinemia. 
 The G75S variant is the fourth example of an amino acid substitution that results 
in a mutation (GGC to AGC) in exon 3, which codes for a portion, comprising residues 
I52 to G75, of the amino-terminal FAD-binding lobe of cytochrome b5 reductase.  Other 
mutations previously identified within the FAD-binding lobe include R58Q, P65L and 
L72P [31, 48, 82, 118].  All three mutations in exon 3 give rise to the type I form of RCM 
which is the more benign form of the disease. 
 The x-ray structure of the soluble domain of rat cytochrome b5 reductase [21], 
both in the absence and presence of NAD+, indicated that residue G75 is situated at the 
apex of a broad loop structure that precedes the Fβ3 strand which comprises part of a 
FAD-binding six stranded, anti-parallel β-barrel structure.  Inspection of the rat 
cytochrome b5 reductase structure revealed that while G75 makes no direct contacts with 
either the FAD prosthetic group or the bound NAD+ nucleotide, the residue is situated at 
a relatively solvent-accessible cleft within the structure and is contacted by a number of 
bound water molecules.  A multiple sequence alignment, shown in Figure 62, has 
revealed that G75 is part of a highly conserved region of the amino acid sequence that 
corresponded to residues “70LGLPxGxH77” that is present in the majority of cytochrome 
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b5 reductase sequences identified so far and also includes H77 which provides 
hydrophobic interactions with the flavin isoalloxazine ring.  In addition, modeling studies 
of the interaction of human cytochrome b5 reductase with cytochrome b5 have suggested 
that the conserved histidine 77 is hydrogen bonded to the b5 propionate group in the 
cytochrome b5 reductase- cytochrome b5 complex [20]. 
 Homology modeling of the G75S variant suggested that substitution of the more 
bulky serine side chain for the glycine hydrogen atom would be expected to result in 
steric constraints which would require displacement of the Nβ7 strand that forms the 
initial part of the “linker” or “hinge” region that joins the FAD- and NADH-binding 
lobes.  Perturbation of the organization of this “linker” region would be anticipated to 
result in decreased diaphorase activity owing to a change in registration between the two 
structural lobes as previously reported for other “linker” domain RCM mutants, such as 
P144L [82], P144S [119], and L148P [48].  In addition, alterations in the organization of 
the two lobes would be expected to decrease the stability of the protein which has also 
been previously documented for the P144L and L148P variants [105].  The relative 
importance of a glycine residue at position 75 in the primary structure is also reinforced 
by its conservation in the majority of the other protein sequences that form part of the 
ferredoxin:NADP+ reductase (FNR) super-family of flavoprotein transhydrogenases, 
including FNR, phthalate dioxygenase reductase and assimilatory NADH:nitrate 
reductase [5].   
In contrast to the G75S mutation, the V252M substitution was determined to have a 
markedly less severe impact on either the structure or function of cytochrome b5 
reductase.  Unlike G75, residue V252 is not situated in a region of particularly well 
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conserved primary sequence and can be found to occur as valine, isoleucine or proline 
residues in cytochrome b5 reductase homologues, although the marked preference 
appears to be for the presence of an alipathic hydrocarbon side chain at this position in 
this sequence, as shown in Figure 62. 
 Within the rat cytochrome b5 reductase structure, V252 is part of a surface-
accessible loop region located midway between strand Nβ4 and helix Nα3 [21].  While 
V252 makes no direct backbone or side chain contacts with either the FAD- or bound 
NAD+, this loop region forms part of the NAD+ binding site and aids in correctly 
orienting the side chain of F251 over the adenine moiety of the substrate.  Carbon CG2 of 
the isopropyl side chain of V252 is only 5.3 Å away from the adenine O2 atom of the 
NAD+.  In addition, the V252 amide nitrogen atom participates in a water-mediated 
hydrogen bond to the NAD+ AO2* atom.  Thus, substitution of V252 by the considerably 
more bulky side-chain of methionine would be unlikely to have any dramatic effects on 
either the properties of the FAD prosthetic group or the specific activity of the protein but 
could decrease the affinity for NADH due to potential steric interactions which would 
disrupt the structure of the loop region and decrease the interaction with the adenine 
moiety.  This prediction is in good agreement with the results obtained from the 
NADH:FR activity studies which indicated a nearly 10-fold increase in the Km for 
NADH. 
 Previously, we have identified other mutations in the carboxy-terminal 
NADH-binding lobe of cytochrome b5 reductase, including D239G, E255-, and G291D 
[78, 105, 107], whose biochemical properties can be compared with those of the V252M 
variant.  The V252M variant was found to retain the spectroscopic properties typical of  
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Fig. 62.  Multiple Sequence Alignment of Selected Cytochrome b5 Reductase 
Primary Structures. Published amino acid sequences for cytochrome b5 reductases from 
various species were obtained from GenBank using the corresponding accession 
numbers, aligned using the CLUSTAL X algorithm [108] and the alignment manually 
adjusted for maximum sequence conservation. Only portions of the sequences 
surrounding the residues equivalent to G75 and V252 in H. sapiens cytochrome b5 
reductase are shown with the conserved “G” and “V/I” residues underlined. Superscripts 
indicate the positions of the starting residues for the two sequence portions within the 
respective primary sequence. Shown below the alignment is a “sequence logo” [109] that 
consists of stacks of symbols (one stack for each position in the sequence) with the 
overall height of the stack indicating the sequence conservation at that position and the 
height of the symbols within the stack indicating the relative frequency of each amino 
acid at that position. 
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the wild-type protein and to exhibit a full complement of FAD incorporation with the 
flavin prosthetic group present in an environment spectroscopically indistinguishable 
from that of the native domain.  This was similar to the spectroscopic properties and FAD 
complement of the other NADH-binding lobe variants [105, 107].  In contrast, 
NADH:FR activity assays revealed the V252M mutant retained substantial diaphorase 
activity, as indicated by a specific  activity corresponding to 80% of the wild-type 
domain, similar to D239G at 94%, while the E255- and G291D variants only retained 
38% and 58% of wild-type activity, respectively. 
 There was reduced affinity towards the NADH substrate but no change in cofactor 
selectivity as with D239G [107] and no significant change in the thermostability of the 
V252M variant when compared to wild-type cytochrome b5 reductase.  Thus, loss of the 
non-polar side chain at residue 252 does not affect thermostability or enzyme activity but 
reduces affinity towards the NADH substrate, indicating the key role that this region of 
the primary structure plays in substrate affinity.  It is interesting to note that a change in 
the Km for NADH alone is sufficient to cause the development of type I RCM.  Since the 
NADH cofactor is required for the reduction of soluble cytochrome b5 and in turn 
methemoglobin reduction. 
 In summary, characterization of the individual G75S and V252M cytochrome b5 
reductase variants together with the G75S/V252M double mutant indicated decreased 
catalytic activity rather than total loss of enzyme function as predicted by the suggested 
type I recessive congenital methemoglobinemia phenotype of the infant.  In addition, the 
results for the G75S/V252M double mutant were intermediate between those of the two 
individual variants suggesting that the effects of the two individual mutations were not 
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synergistic.  All three cytochrome b5 reductase variants displayed an approximately 10-
fold decrease in catalytic efficiency combined with decreased protein stability, albeit 
slight for V252M, which would be expected to manifest as potentially increased 
methemoglobin concentrations.  In conclusion, these studies provide insight into the 
development of type I as opposed to type II disease and may be a potential diagnostic tool 
in young infants to aid in defining recessive congenital methemoglobin status.           
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4.  CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The studies presented here were intended to provide additional structural and 
functional insight into the highly conserved motifs found within cytochrome b5 reductase, 
and other members of the FNR superfamily, in respect to FAD-binding and NADH-
binding as well as their catalytic function.  This was accomplished through two alternate 
approaches.  The first approach involved the generation of variants of the amino acid 
residues found within the conserved motifs based on alternative residues observed to 
occur at the same position in other members of the FNR family as well as within other 
species, charge reversal mutants, and the introduction of a positive charge as in the case 
of the G124 variants.  The second approach incorporated the analyses of naturally 
occurring recessive congenital methemoglobinemia mutants that are located within, or in 
close proximity to, the conserved motifs.  Through this method of characterization we 
were able to establish a role for each of the previously uncharacterized amino acid 
residues found in the FAD- and NADH-binding motifs as well as determine the 
molecular basis for disease for each of the RCM variants. 
 Previous studies based on the “RxYSTxxSN” motif had established it as being 
highly conserved within the β-barrel structure in the FNR superfamily of enzymes [39].  
Work by Kirksey et al. determined that in monoamine oxidase B the equivalent arginine 
residue beginning the motif possessed a necessary charge for proper incorporation of the 
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FAD- cofactor [120].  More recently, a role for the R91, P92, and Y93 has been 
established [76, 77].  It was demonstrated that these residues were not in fact “essential” 
for flavin incorporation, yet R91 and Y93 were both required for the modulation of the 
biophysical and catalytic properties of cytochrome b5 reductase as well as maintaining the 
proper active site structure.  The work presented here determined a role for the remainder 
of the motif to include: T94, P95, V96, and S97.  While the V96S and S97N variants 
yielded results that were comparable to wild-type cytochrome b5 reductase, indicating 
that these residues were not essential for proper flavin incorporation or catalysis,  the 
introduction of a T94H variant involved the removal of the polarity of a hydroxyl group 
and caused a significant perturbation with respect to the environment of the flavin 
prosthetic group.  The introduction of the imidizole side chain resulted in a steric 
hindrance effect directly affecting the interaction of the T94 residue with that of the FAD 
isoalloxazine ring and displacing it away from the FAD binding site.  This was further 
confirmed in the analyses of the spectroscopic binding constants, where the T94H variant 
displayed a greater affinity for the product NAD+ but a reduced affinity for the H4NAD 
substrate analog.  Inhibition studies concluded that upon substrate binding the NAD+ 
product was not able to disassociate efficiently from the NADH-binding site which may 
be due to the displacement of the flavin.  Similar, yet not as dramatic, effects were 
observed for the P95I and P95G variants.  Interestingly, we were never able to generate a 
stable protein for either the T94G or T94P variants.  We believe that this is due in part to 
the fact that the introduction of a glycine leads to a relaxation in the secondary structure 
of the protein and the introduction of a proline causes a kink in the backbone structure.  
Due to its highly conserved position these dramatic alteration to the T94 residue would 
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lead to the generation of an unstable form of the protein that was unable to properly 
incorporate the flavin prosthetic group.  
 Further analysis of the “RxYSTxxSN” motif was accomplished through the 
characterization of the naturally occurring RCM double mutant P92H/E255-.  The 
examination of this variant not only afforded an opportunity to determine the properties 
of a RCM mutant occurring within a highly conserved motif but also allowed us to 
investigate the effects of a mutation found in both the FAD-binding and NADH-binding 
domains of cytochrome b5 reductase.  The substitution of a proline by a histidine at 
residue position 92 leads to the introduction of an imidizole side chain that would result 
in a steric hindrance with the isoalloxazine ring of the flavin prosthetic group.  The 
results of this steric hindrance lead to a significant decrease in the efficiency of substrate 
utilization as well as a dramatic perturbation of the environment of the flavin causing a 
partial displacement of the cofactor as observed in the potentiometric titration with a 
positive shift towards that of free flavin.  The E255- variant has been previously 
characterized and has been demonstrated to have a profound effect on the NADH-binding 
motif “CGxxxM” that results in a decrease in substrate affinity and a reduction of the 
catalytic efficiency of over 50% [79].  Thus, the combination of the P92H and E255- 
variants in the double mutant combined the effects of the P92H on the FAD-binding 
domain and the E255- on the NADH-binding domain resulting in a 103 decrease in the 
overall catalytic efficiency. 
The analysis of the crystal structure of cytochrome b5 reductase exposed the 
critical importance of the “GRxxST” motif which has been proposed to be involved in the 
regulation of FAD or FMN specificity [5].  Each of the four residues found within this 
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motif are shown to be directly involved in proper FAD-binding and orientation through 
hydrophobic or electrostatic interactions.  Additionally, the residues of this motif are 
located within the only α-helical segment found within the FAD-binding lobe of 
cytochrome b5 reductase.  Therefore, any mutations of the residues of this motif would 
have a significant impact on the environment of the flavin prosthetic group.  This was 
previously demonstrated through the characterization of the type II RCM variant S127P 
[80], in which the ADP moiety of the flavin prosthetic group was displaced into the 
NADH-binding domain, thereby acting as its own inhibitor.  This work represented the 
first application of site-directed mutagenesis to the G124, K125, and M126 residues 
found within the cytochrome b5 reductase “GxxST” motif to gain insight into the roles of 
each of these residues in regulating flavin binding and orientation.  Significant 
perturbations were first observed in the visible CD spectra for each of the variants.  The 
most dramatic effect was determined for the M126 variants which displayed spectra 
comparable to that of the previously described S127P variant, indicating that, much like 
the S127P mutation, alterations of the M126 residue also lead to the displacement of the 
ADP moiety of the FAD- cofactor.  The perturbations were also found to effect a 
decrease in the overall catalytic efficiency for all of the variants in regards to both 
turnover and substrate binding.  Interestingly, in establishing the differential binding 
constants for the “GxxST” variants, the introduction of a positive charge at position 124 
displayed an enhanced affinity for both H4NAD and NAD+ yet showed an altered 
conformation of binding for the NAD+ product.  This indicated, that much like that of the 
T94H variant, the substrate is not able to bind as efficiently yet is not able to disassociate 
due to the perturbation of the flavin prosthetic group caused by the introduction of a 
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positive charge on residue G124.  Finally, evidence suggests that the disruption of the 
flavin environment leading to a displacement of the FAD- cofactor were supported by the 
shifts observed in the values of the midpoint potentials obtained in the presence of NAD+ 
which all displayed a negative shift towards that of the potential of free flavin.  The 
results from the kinetic, thermodynamic, and spectral data clearly demonstrate that any 
alterations introduced into the “GxxST” motif of cytochrome b5 reductase lead to a partial 
displacement of the flavin prosthetic group resulting in a reduction in the overall catalytic 
efficiency and electron transfer. 
The characterization of the naturally-occurring RCM variants M272- and P275L 
allowed for the determination of the importance of the conserved NADH-binding motif 
“CGxxxM” motif as well as establishing a molecular basis for disease for each of the 
variants.  The M272 residue has no direct interaction with the NADH substrate yet it 
directly precedes the highly conserved residue C273, which has been determined to be an 
“essential” residue within the “CGxxxM” motif.  The deletion of residue M272 has also 
been shown to give rise to type II RCM [81] and initial kinetic analyses has demonstrated 
that this mutation has the lowest catalytic efficiency observed thus far for any 
methemoglobinemia variant [40].  The deletion of this residue results in a frame-shift of 
the entire nucleotide binding motif which displayed a significant decrease in the substrate 
binding affinity as well as a reduction in the catalytic efficiency.  As demonstrated in the 
determination of the spectral binding constants, no spectroscopic changes were observed 
for the M272- variant even at very high concentrations of substrate.  Interestingly, the 
same effects were witnessed for the M272R mutation.  The introduction of the arginine 
side chain was hypothesized to protrude towards the C273 residue resulting in a 
 184
disruption of the essential contacts that C273 makes with the NADH substrate leading to 
the decreased substrate binding affinity.  The effects upon substrate affinity as well as the 
modulation of electron transfer by the M272- and M272R variants was observed in the 
potentiometric titrations performed in the presence of NAD+.   For the wild-type 
cytochrome b5 reductase a shift of +77 mV was observed for the FAD/FADH2 couple in 
the presence of NAD+, however, this shift was significantly decreased for the M272- and 
M272R variants, further confirming that substrate binding had been severely 
compromised.   
Residue P275 is a critical residue found within the “CGxxxM” motif that 
functions in proper NADH-binding and orientation of the pyridine nucleotide.  Through 
analysis of the crystal structure of cytochrome b5 reductase in complex with NAD+ it was 
observed that the bound NAD+ conforms itself and actually bends around the P275 
residue.  The mutation of the proline to that of a leucine, as determined in a patient 
exhibiting a type I RCM phenotype, demonstrated the critical role that this amino acid 
residue plays.  The initial rate kinetic analyses provided the first evidence of the effects of 
the introduction of a leucine at position 275.  Surprisingly, the P275L variant displayed 
an activity that was comparable to that of wild-type cytochrome b5 reductase, however, 
the Km for NADH utilization was increased 437 fold compared to that of wild-type cb5r, 
indicating a dramatic decrease in the affinity for the NADH substrate.  To further confirm 
the reduced affinity for NADH, spectral binding constants were determined for both the 
analog H4NAD and the reaction product NAD+.  In this experiment, no complex 
formation could be detected even upon the addition of concentrations of substrate that 
were 10-fold greater than that required for saturation of the wild-type enzyme.  
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Additionally in the potentiometric titrations, the redox potential in the absence of NAD+ 
was comparable to the value obtained for wild-type cytochrome b5 reductase, indicating 
that the P275L variant had no effect on the FAD- cofactor.  However, upon the addition 
of NAD+ the potential was significantly more negative, confirming that the replacement 
of the proline residue with a leucine does in fact lead to a decreased affinity for the 
NADH substrate that is capable of giving rise to type I RCM.  It is evident from these 
results that any alterations in the highly conserved “CGxxxM” motif can significantly 
affect the overall catalytic efficiency of cytochrome b5 reductase and the correct 
maintenance of the motif is imperative in proper NADH substrate binding and 
orientation. 
Finally, the characterization of the naturally occurring double mutant 
G75S/V252M again allowed us to examine the effects of a RCM mutation that occurs in 
both the FAD-binding and NADH-binding domains and use this information as a 
potential aid to determine the methemoglobinemia status (type I or type II) upon the first 
onset of the disease.  Although the patient was actually heterozygous for the double 
mutation, we decided to generate the double mutant as a homozygote in order to examine 
the possible synergistic effects.  Previous studies have described the V252M as giving 
rise to type I RCM [40, 84].  It was then our prediction that the G75S variant would also 
be capable of demonstrating characteristics of that of type I RCM, yet the combination of 
the two mutations affecting both the NADH-binding and FAD-binding domains would 
give rise to the more severe type II RCM.  However, although both the single and the 
double mutants displayed a decrease in catalytic efficiency, the double mutant actually 
yielded results that were intermediate between that of the two single mutants.  This 
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information can therefore provide valuable insight towards the early diagnosis of RCM 
type I versus type II status in an infant. 
This data provides valuable insight into the structural and functional properties of 
the highly conserved motifs of cytochrome b5 reductase that are involved in FAD- or 
NADH-binding and orientation as well as a determination of the molecular basis of the 
disease recessive congenital methemoglobinemia.  These results support logical 
conclusions based on the kinetic, spectral, thermodynamic, and molecular modeling 
properties of each of the generated variants.  However, in order to complete this work and 
support our conclusions, crystal structures of the variants, both in the absence and 
presence of NAD+ should be obtained.  This would provide the most concrete evidence to 
support the conclusions presented in this work.  The evaluation of the naturally occurring 
methemoglobinemia variants M272- and P275L provided us with a clear definition of the 
importance of the “CGxxxM” motif in regards to NADH substrate binding and 
orientation.  In order to fully elucidate the role of each residue though, a project is already 
underway that will involve alanine scanning of the entire motif.  The data presented here 
in this research provided a broad analysis of the motif whereas the alanine scanning data 
will provide information on the structural and catalytic role of each individual residue.    
Additional work could also be carried out involving the “GRxxST” motif.  The 
generation of the G124, K125, and M126 variants established the critical role that each 
residue plays towards the proper incorporation of the cb5r flavin prosthetic group.  To 
gain a broader understanding of the roles of these residues, a series of double and triple 
mutants could be generated and only the most interesting variants selected for further 
characterization.  As previously mentioned, the GR124 residue not only forms a 
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hydrophobic interaction with the FAD- cofactor of cb5r but also has been proposed to 
regulate FAD/FMN specificity within members of the FNR superfamily.  To investigate 
this, flavin analog substitution could be performed utilizing the G124R variant.  From 
this a Ks for FAD, FMN, and various other analogs could be determined.                                                   
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